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ABSTRACT 
 
 
Protein-protein interactions (PPIs) play key regulatory roles in biological 
systems, and some of these are interesting drug targets.  Consequently, it is important to 
develop generally applicable methods to identify small molecules that disrupt or disturb 
PPIs.  One emerging approach is to use novel small molecule scaffolds to mimic protein-
protein interfaces.  To identify good mimics for PPI targets, a novel computational 
approach Exploring Key Orientations (EKO) has been developed.  This thesis is focused 
on the design, synthesis, EKO analysis and biological applications of two interface 
mimic scaffolds. 
The first mimic, an oligo-piperidine-piperidinone (OPP) scaffold was designed 
and synthesized to target extended interface regions. Derivatives of this scaffold have 
been efficiently prepared in a divergent-convergent method.  Conformational studies 
revealed that the OPP scaffold could exist in an extended helical conformation and it 
was a good mimic of ideal α-helix in solid state.  Further investigations by molecular 
modeling indicated this scaffold could be a multi-faceted mimic for several secondary 
structure motifs in solution.  An interesting protein target called antithrombin was 
discovered with EKO database mining analysis for the OPP scaffold.  In biological 
studies, derivatives of OPP were found to interfere with oligomerization of antithrombin 
in a side-chain and concentration dependent manner.   
  iii 
As an orthogonal interface mimic, a new constrained cyclic peptide-organic 
hybrid was also explored to target compact PPI interface regions.  An anthranilic acid 
was incorporated in the scaffold as a turn-inducing motif.  Extensive conformational 
analyses by 1D and 2D NMR, CD, and molecular modeling were performed and the 
results showed that the cyclic peptide scaffold could mimic multiple turn structures. 
Moreover, these new turn mimics were conformationally homogeneous in solution and 
their conformations had a strong and predictable correlation with side-chain 
stereochemistries. 
The scaffolds described in this thesis represent suitable scaffolds to target 
protein-protein interactions. Compared with traditional methods, interface mimicry 
approach together with EKO analysis can significantly facilitate the discovery of small 
molecules for protein-protein interactions. 
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CHAPTER I  
INTRODUCTION*  
 
1.1 Protein-protein Interactions as Drug Targets 
Protein-protein interactions (PPIs) are widely involved in cell-signaling, gene 
expression regulation, immune response initiation and many processes of cell 
metabolism.1,2 Since many of these interactions play critical regulatory roles in 
biological processes such as cell proliferation and apoptosis, it is of great significance to 
study these interactions to have a better understanding of the biological systems. 
Specifically, a lot of these interactions are related to many diseases such as cancer, 
Alzheimer’s disease, diabetes and high cholesterol.3-5  Therefore, studies towards 
selective modulation of the function of protein-protein interactions at the molecular level 
may lead to breakthrough therapeutics for some of the most challenging diseases.6-8  
Some of the most widely studied PPIs are highly pharmaceutically interesting such as 
p53/MDM29 and Bak/Bcl2 interactions,10 which are related to cell apoptosis and thus 
potential cancer targets.1,11,12  Consequently, it is highly desirable to develop generally 
applicable methods to identify molecular entities that are able to disrupt PPIs.   
  
                                                
*Reprinted in part with permission from “Extended Piperidine-piperidinone Protein 
Interface Mimics”, Dongyue Xin, Arjun Raghuraman and Kevin Burgess, J. Org. Chem. 
2015, 80, 4450-4458. Copyright 2015 American Chemical Society and from “Small 
Molecule Probes That Perturb a Protein-protein Interface in Antithrombin”, Dongyue 
Xin, Andreas Holzenburg and Kevin Burgess, Chem. Sci. 2014, 5, 4914-4921. Copyright 
2014 The Royal Society of Chemistry. 
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1.2 Current Methods to Target Protein-protein Interactions 
Protein-protein interactions can be targeted by monoclonal antibodies or small 
molecules.  Significant theoretical and experimental techniques have been developed in 
the past two decades to increase the success rate and reduce the cost to identify novel 
molecules for selected PPIs.  However, compared with enzymatic targets, it is still much 
more challenging to develop therapeutics for PPI targets.1 
Monoclonal antibodies (mAbs) are well suited in targeting certain types of PPIs, 
especially the ligand-cell surface receptor interactions such as EGF/EGFR13,14 and 
PD1/PDL115,16 and this led to some revolutionary treatments for certain types of cancer.  
However, antibodies also have some limitations in biomedicine. MAbs are 
macromolecular proteins, so most are generally not cell permeable and thus their current 
applications are mainly limited to cell surface receptors.  Furthermore, mAbs do not tend 
to penetrate into solid tumors17,18,19,20  because they are too big to leave blood vessels 
and efficiently diffuse into tissue.  MAbs that do diffuse into tissue tend to be trapped by 
antigens located on the perivascular tumor cells, preventing permeation into the tumor 
mass,21 ie there is an “antigen barrier”,22-24 even around micrometastases.22  Moreover, 
slow clearance of mAbs from the body results in high normal tissue exposure25-27 hence 
most mAb molecules in a dose accumulate in the excretory organs (intact mAbs in the 
liver, fragments in the kidneys) and do not reach their targets.28,29  MAbs also can be 
immunogenic, even when they are humanized or human;30 this can cause 
hypersensitivity, neutralizing effects, and changeable pharmacokinetic properties.29  
These limitations should be considered alongside problems with non-specific 
  3 
conjugation chemistry leading to reduced product homogeneity,31 cost, and 
stability/shelf life issues.  Despite these factors, interest in mAb has surged because it is 
comparatively easy to raise antibodies to cell surface receptors.32 
The most frequently used method to find small molecules for PPI targets is high 
throughput screening (HTS), which is widely applied in the development of inhibitors 
for enzymes.33  However, HTS for PPI targets usually gives disappointing hit-rates.  It 
has been suggested that one reason is that the compound collections screened do not 
have appropriate chemotypes.1  Besides HTS, there are only a few methods suitable to 
develop small molecules for PPI targets.  Fragment-based approaches using NMR or X-
ray supported by modeling, and “tethering”, are exciting but the process of joining small 
pharmacophores into a small molecule that retains the correct shape is difficult and not 
always attainable.34,35,36  Some other methods such as the anchor approach37,38 provides 
only partial solution for specific PPIs.  In addition, in many cases, the lack of small and 
well-characterized binding pockets makes it difficult to use normal docking programs for 
virtual screening.1 
One generally accepted approach specifically targeting PPIs is using secondary 
structure mimics.8,39,40  Peptides corresponding to the interface regions are usually poor 
starting points because PPIs usually involve discontinuous amino-acid residues and 
peptides are vulnerable to proteases and have other undesirable pharmacological 
properties.1,40  To overcome these problems, several semi-rigid molecular scaffolds that 
can present side chains corresponding to interface residues have been developed.  
Pioneering work by Hamilton41-43 and others42,44,45 featured biphenyl, terphenyl and 
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related scaffolds to form what we call minimalist peptidomimetics.46,47  These 
compounds do not have polyamide backbones, are impervious to proteases, and can be 
cell permeable. 
 
1.3 Minimalist Mimics 
Minimalist mimics of peptides and proteins are organic scaffolds that: (i) access 
fewer conformations than peptides (ie are “semi-rigid”); and, (ii) display three or more 
amino acid side-chains.  Motivation for studies of minimalist mimics stem from their 
potential to perturb protein-protein interactions (PPIs).  Non-covalent interaction 
energies at protein interfaces tend to be dominated by side-chain to side-chain 
interactions.48,49  A minimalist mimic that presents side-chains in orientations 
corresponding to one PPI component, called here the protein-ligand, has the potential to 
displace that ligand and bind to the other partner in the PPI, the protein-receptor. (Figure 
1.1) 
 
 
Figure 1.1.  Mimicking side-chain orientations at PPI interfaces with minimalist mimics. 
minimalist 
mimic
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Figure 1.2.  Recent examples of minimalist mimics. 
 
Figure 1.2 shows illustrative minimalist mimics (a,45,50,51 b,52 c,53 d,54 e,55 f56), 
reported since this area was reviewed in 2011.47  For any particular PPI, a minimalist 
mimic scaffold only has potential if it is synthetically accessible with amino acid side-
chains corresponding to the protein-ligand at the interface region.  The main 
shortcoming of designing generic secondary structure mimics, is that secondary 
N
N
O
R1
O
R2 O
N
N
R3
O
CONH2R4
N N
N
N
N
N
N
N
H
N
H
N
R2
N
H
N
H
R3
R1
X
Y
N
H
OO
R3
O
N
H
R2
O R
1
R4
a
Arora
b
Lim
c
Fletcher
helical mimics
OMe
N
H
N
H
N
H
O
O
O
N
NO
N
N
N
O
N
N
N
O N
R1
R2
R3
sheet mimics
e
Hamilton
NO
N
N
O
N
N
O N
R1
R2
R3
d f
  6 
structures at PPI interfaces are usually distorted, and many interfaces do not involve 
secondary structures at all.  This makes it difficult to decide where to overlay the mimic 
on the interface region, and therefore what amino acids side-chains should be 
incorporated. 
If the appropriate region of overlay can be determined, the scaffold has to be 
made presenting those particular side-chains.  Mimic a, has been formed from amino 
acids, and is attractive in this regard. Sheet mimics d – f have only so-far been prepared 
with methyl side-chains, but there is potential to construct d and e from a variety of 
amino alcohols. Preparation of mimics b, c, and f with a variety of genetically encoded 
amino acid side-chains would be more challenging. 
In our view, the hidden potential of so-called minimalist mimics is they also 
populate conformations other than the targeted secondary structure.46,47,57 (Figure 1.3)  
This led us to appreciate that minimalist mimics in some situations can resemble regions 
of a PPI interface but not any particular secondary structure. This was enlightening 
because it forced us to realize that mimicry of secondary structures is not the real issue 
in designing small molecules to perturb PPIs. 
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Figure 1.3.  Equilibrating conformers of Hamilton’s terphenyl minimalist mimic in 
solution. 
 
1.4 Exploring Key Orientations (EKO) and Exploring Key Orientations on 
Secondary Structures (EKOS)  
To fully explore the potential of a small molecular scaffold in targeting PPI 
interface motifs, we developed the Exploring Key Orientations (EKO) strategy.  Briefly, 
in EKO each set of three residues on a protein at a crystallographically characterized PPI 
interface is categorized in terms of six Cartesian coordinates corresponding to the three 
sets of Cα and Cβ atoms. (Figure 1.4)  Similarly, each kinetically and 
thermodynamically accessible conformation of a minimalist mimic of a PPI interface, an 
interface mimic, can be characterized in the same way, regardless of whether it 
resembles a secondary structure or not. 
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Figure 1.4.  Identification of good interface mimics with Exploring Key Orientations. 
 
EKO (Exploring Key Orientations)58 and EKOS (Exploring Key Orientations on 
Secondary structures, described in Chapter VI)57 are strategies to facilitate correlations 
of accessible solution state conformations of certain chemotypes with protein-protein 
interaction (PPI) interfaces, and with secondary structures, respectively.  Specifically, 
EKO and EKOS are designed to work with chemotypes that involve semi-rigid organic 
scaffolds with three amino acid side-chains.  EKO is designed to identify chemotypes of 
this kind that perturb PPIs.  It involves molecular dynamics to generate a comprehensive 
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to match these with side-chain orientations found at PPI interfaces.  The implication is 
that if the scaffold can present side-chains in the same orientation as an interface region 
involving one protein in a PPI, then it might be able to displace that protein, or at least 
perturb the interface. 
 
1.5 Conclusion 
Developing general and novel methods to find small molecules to target PPIs can 
be challenging but at the same time highly rewarding due to the importance of PPIs in 
biological systems. Minimalist mimics represent one of the new approaches and some 
interesting bioactive small molecules for PPIs have been discovered in this way. The 
novel computational approaches EKO and EKOS can provide useful theoretical 
predictions to complement the application of minimalist mimics. These computational 
models take advantage of the naturally existing binding pockets at the PPI interface 
regions and further development of these methods may lead to a general solution to the 
problem of finding suitable small molecule scaffolds for particular PPIs.  
My PhD study is focused on the design and synthesis of several novel small 
molecule scaffolds as minimalist mimics for PPI targets. These small molecules are 
proven to be suitable scaffolds in the EKO and EKOS analysis and some of these 
molecules are biological active for selected PPI targets.  
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CHAPTER II 
OLIGO-PIPERIDINE-PIPERIDINONES AS MULTI-FACETED SECONDARY 
STRUCTURE MIMICS* 
 
2.1 Introduction 
Minimalist mimics of secondary structures display amino acid side-chains on 
backbones more rigid than, and structurally different to, polypeptide chains.42,47,59 
Mimics that can be made conveniently with a variety of amino acid side-chains tend to 
be the most valuable, hence modular syntheses involving amino acid-derived starting 
materials are ideal.45,60,61 Besides these synthetic considerations, it is also important to 
gain an understanding of how well ideal secondary structures can be represented by the 
best-fitting accessible conformer from the mimic’s conformational ensemble. Such 
analyses indicate how a minimalist mimic can optimally fit on one secondary structure 
relative to another, and which side-chain spacings are best represented. This is valuable 
information because otherwise, for example, it is unclear which of the so-called ideal α-
helical mimics actually fit better on other secondary structures, and which ones best 
present a given side-chain combination (eg i, i+3, i+4 or i, i+4, i+5).57 
                                                
*Reprinted in part with permission from “A Multi-faceted Secondary Structure Mimic 
Based on Piperidine-piperidinones”, Dongyue Xin, Lisa M. Perez, Thomas R. Ioerger 
and Kevin Burgess, Angew. Chem. Int. Ed. 2014, 53, 3594-3598. Copyright 2014 
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim and from “Extended Piperidine-
piperidinone Protein Interface Mimics”, Dongyue Xin, Arjun Raghuraman and Kevin 
Burgess, J. Org. Chem. 2015, 80, 4450-4458. Copyright 2015 American Chemical 
Society.  
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The minimalist mimic oligo-pyrrolidine-pyrrolidinone (A, in Figure 2.1) was 
previously developed in Dr. Burgess’s research group.58,62,63 Conformational studies 
indicated that this scaffold exists in an extended conformation and it is able to mimic the 
β-strand and β-sheet regions of PPIs. Previous studies showed that this scaffold could be 
used to mimic the β-strand at the dimerization interface of HIV-1 protease.58  
Derivatives of scaffold A were shown to effectively promote the dissociation of HIV-1 
dimer and inhibit its enzymatic activity.58  
Scaffold A is a novel and bioactive minimalist mimic, but it also has some 
limitations.  Firstly, accessibility of scaffold A is limited by the difficulties in its 
synthesis.  A vulnerability in syntheses of substrates A is the enolizable, and therefore 
stereochemically delicate, CH.63 The epimerization of the chiral centers on the scaffold 
will lead to ambiguity in its chemical structure and its potential interaction with PPI 
targets.  Another problem in syntheses of scaffolds A is that fragments bearing bulkier 
amino acid side-chains tend to retard coupling reactions.  Therefore, bulky amino acid 
side chains such as valine and threonine cannot be successfully incorporated into the 
scaffold.  Besides, scaffold A is mainly designed to mimic the β-strand and β-sheet 
regions of PPIs, so it has limited application in PPI targets featuring helical secondary 
structures at the interface regions.  Therefore, the design of novel oligomic mimic 
scaffolds that are synthetically accessible and conformationally distinctive from scaffold 
A is highly desirable.  This chapter will discuss the design, synthesis and conformational 
studies for oligo-piperidine-piperidinone scaffold (1, Figure 2.1) as a novel oligomeric 
minimalist mimic.64-66 
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Figure 2.1.  A comparison between oligo-pyrrolidine-pyrrolidinone and oligo-
piperidine-piperidinone.  Oligo-pyrrolidine-pyrrolidinone A can snake between various 
S- and crescent-shaped conformers, whereas all the inter-ring σ-rotations in 1 together 
represent only one significant degree of freedom making the scaffold overall more 
linear.  
 
2.2 The Design and Syntheses of Novel Oligo-Piperidine-Piperidinones as 
Secondary Structure Mimics 
To solve some of the problems faced by scaffold A and target different extended 
PPI regions, the oligo-piperidine-piperidinone minimalist mimic 1 was designed.  An 
attribute of scaffolds 1 is that they are based on β-amino acids where a methylene group 
insulates the chiral center from stereomutation.  In addition, in comparison with scaffold 
A, we postulated this steric effect would be less pronounced in construction of 1 where 
the side-chains are one methylene removed from the electrophilic coupling site.  
Therefore, mimic 1 is more synthetically accessible than A. 
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Minimalist mimics 1 can prepared from amino acid-derived starting materials 
with a modular synthesis procedure.  Syntheses of molecules 1 began with preparation of 
β-substituted β-amino acid derivatives 2 using a novel combination of literature 
procedures67,68 that allowed us to obtain multi-gram amounts, without chromatography 
in most cases (Scheme 2.1).  These amino acids 2 were reacted with Meldrum’s acid, a 
known reaction for α-amino acids,69 to form six-membered homologs of tetramic acids 
(Scheme 2.2).  Removal of the Boc-protecting group gave the piperidinediones 3 that 
were converted to the vinylic chlorides 4.  Those analogs with threonine side-chains 
have an inherent marker for loss of stereochemical fidelity; as anticipated, no 
epimerization was observed, at least in the syntheses of the compounds containing Thr.  
Throughout this thesis, compounds are numbered according to the scaffold with lower 
case one-letter codes relating their side-chains to the parent amino acids (eg f for Phe, s 
for Ser, s’ for the –CH2OtBu, t for -CH(OH)Me, and t’ for -CH(OBn)Me; named from 
N- to C-terminus just as in peptides). 
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Scheme 2.1.  Syntheses of the β-amino acid derivatives. 
 
 
 
Scheme 2.2.  Syntheses of the electrophilic N-caps 4. 
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Nitriles 5, intermediates in the syntheses of the β-amino acids 2, were 
simultaneously N-deprotected and hydrolyzed, then reductively coupled with the known, 
and commercially available, synthons B70 or C71 to give the amines 6 (Scheme 2.3).  
Reaction of these β-amino esters with Bestmann’s ylide72 gave the protected 
intermediates 7.  Compounds 5 to 7 were isolated, without chromatography, on 
multigram scales.  N-Deprotection of the intermediates 7 gave the nucleophiles 8.  
Amines 8 were then condensed with the electrophiles 4 to give the scaffolds 9 bearing 
two side-chains.  As anticipated, this process seems largely unaffected by steric demands 
of the side-chains since the coupling yields were uniformly high. 
In a divergent step, intermediates 7 were C-deprotected, then converted to the 
vinylogous chlorides 10.  Convergence was then possible via coupling of the 
nucleophiles 8 with the electrophiles 10 to give the extended systems 11 that were then 
N-deprotected and capped with the electrophiles 4.  
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Scheme 2.3.  Syntheses of the target materials 1. 
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The syntheses of mimics 1 may seem complicated, but they are driven by the 
simple modularity concept expressed in Figure 2.2.  Overall, the divergent-convergent 
syntheses of compounds 1 pivot around synthons 7; these were converted to nucleo- and 
electrophiles that were joined to elongate the scaffold.  Fragments 8 and 10 in Scheme 
2.3 are similar to C- and N-protected amino acids in peptide syntheses.  
 
 
 
Figure 2.2.  N-Capping, N-protected, and C-protected synthons like 4, 10, and 8, are 
pivotal in divergent-convergent routes to scaffolds 1. 
 
Scheme 2.4 illustrates how iterative couplings under elevated temperature and 
mildly basic conditions were suitable for synthesis of 14fffff with five repeating units 
derived from Phe.66  The synthesis indicates that the coupling reactions are efficient 
enough to enable the synthesis of long oligomers.  Figure 2.3 shows the MALDI MS of 
this product has a single ion at the predicted m/z of 1507.8 for M+H (plus 1529.8 for 
M+Na, and 1545.8 for M+K).  This product is considerably less polar than typical 
peptides, being soluble in dichloromethane, methanol, and DMSO.  
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Scheme 2.4.  Synthesis of the piperidinones-piperidine mimic 14fffff with ten linked 
rings. 
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Figure 2.3.  HRMS (MALDI+) spectrum of DDDDD-14fffff. 
 
2.3 Conformational Studies of Mimic 1 
No spectroscopic technique can characterize conformational ensembles of small 
molecules like 1 or A in solution because they equilibrate between hundreds solution 
states that have significantly different side-chain orientations.  Techniques like CD and 
NOESY/ROESY NMR give a conformational average, that does not correspond to any 
real state.45  An X-ray structure shows whatever mimic conformation happened to 
crystallize, where part of the shape is governed by crystal packing forces.  Those 
packing forces are significant enough that some solid-state conformations may not be 
preferred in solution.  Indeed, a solid state mimic conformation that does not resemble 
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the target secondary structure has been reported by Hamilton et al,55 and this type of 
occurrence should not be surprising because crystal packing forces are relatively large.  
Three intermediates (9gg, 11af, 1faf) were isolated65 and crystallized in the 
course of the synthetic studies described above.  Representations from X-ray crystal 
structures of those compounds are shown in Figure 2.4. 
 
 
Figure 2.4.  X-ray crystal structures of scaffolds 9gg, 11af and 1faf.  The N- to C-
dimension of 14fffff was estimated to be around 36 Å.  
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Solid state structures of 9gg, 11af, and 1faf reveal these molecules crystallize as 
conformers that have different dihedral angles for the linkages marked with red arrows 
in Figure 2.4.  Rotation around bonds associated with these red arrows has a profound 
effect on the side-chain orientations.  This supports the assertion that minimalist mimics 
have the potential to adopt conformers that can overlay on more than one ideal 
secondary structure or interface region.  Compounds 9gg, 11af, and 1faf have 3, 4, and 5 
piperidinone/piperidine rings, and they measure (N- to C-termini) 11.2, 15.1, and 17.5 Å, 
respectively.  Those dimensions correspond to 3.73, 3.77, and 3.50 Å respectively per 
piperidinone or piperidine ring, and the difference between these figures (0.27 Å) 
reflects the extent of kinking or curvature in the overall conformation.  None of these 
solid state conformations overlay very well on ideal secondary structures, but within this 
series 9gg and 11af are the most extended (cf sheet structures), and 1faf is most helical.  
Compound DDDDD-14fffff was not crystalized, but the solid state data suggests this 
compound might have N- to C-dimensions of (10 x 3.50) to (10 x 3.77), or around 36 Å 
in the solid state. 
A problem that has not been addressed in studies of minimalist mimics is how to 
evaluate the relevance of a solid-state structure to a conformational ensemble in solution.  
Here we suggest EKOS (described in Chapter VI) can be used to determine if a solid-
state conformation from an X-ray structure is present in the simulated conformational 
ensemble and, if it is, provide an estimate of the energy difference between the simulated 
solution-state conformer closest to the solid-state structure and the lowest energy one 
overall.  EKOS also makes it possible to overlay the single conformer represented in a 
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solid-state structure on all ideal secondary structures to find the one it best matches and 
the preferred side-chain combination.  This information is generated free from the bias 
of the researcher(s) who may have designed the scaffold to mimic a particular secondary 
structure and side-chain conformation. 
An example of the use of EKOS as described above is as follows.  Figure 2.5a 
shows data for a solid-state structure of DLD-1faf. That structure overlaid on an ideal α-
helix with an RMSD (root-mean-square deviation) of 1.5 Å (based on the six Cα + Cβ 
coordinates of the side-chains; Figure 2.5b).  To estimate the energy of the conformer 
represented by the X-ray structure, but in solution, the EKOS was used to systematically 
overlay the simulated conformational ensemble on the X-ray structure to find the 
conformer with the best fit.  In fact, that conformer (matched to 0.46 Å RMSD; Figure 
2.5c) had a simulated energy of 0.91 kcal•mol-1 relative to the lowest one generated, ie it 
is predicted to be significantly populated in solution.  The simulated conformer that 
overlaid most closely on the ideal α-helix did so with a similar RMSD and energy (0.50 
Å, 0.84 kcal•mol-1, Figure 2.5d).  Overall, these data indicate there is a conformer in the 
simulated ensemble that represents an ideal a-helix better than the one that crystallized.  
Moreover, the simulated solution-state conformers closest to the solid state structure and 
to an ideal a-helix seem to have about the same relative energies.  The conformer from 
the X-ray and the most α-helical one from the simulation both had the same side-chain 
correspondence: i, i+5, i+10. 
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Figure 2.5.  Analysis of the X-Ray crystal structure of DLD-1faf. a X-Ray crystal 
structure of DLD-1faf.  That structure is shown overlaid upon: b an ideal α-helix; and, c 
the simulated conformer best matching the X-ray structure.  d The simulated conformer 
best matching an ideal α-helix is overlaid on an ideal α-helix.  e Two copies of the X-ray 
structure overlapping on the C- and N-termini illustrates the helical structure is 
anticipated to repeat every 3 nm and 5 residues. 
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Figure 2.5.  Continued. 
 
Figure 2.5e shows copies of the X-ray structure arranged such that the C-terminal 
piperidinone of one is superimposed on the N-terminal piperidinone of the other.  This 
illustrates how the solid-state conformer is anticipated to coil in a helical way, repeating 
every 5 residues and 3 nm.  Parenthetically, Whitesides and co-workers communicated 
repeated reductive couplings of unfunctionalized 4-piperidinones to give “linker rods”.73  
A “rod” with four piperidine repeats, was 1.6 nm long in the solid state (X-ray), 
comparable to 1.7 nm for 1faf which has five rings, Figure 2.5a.  Whiteside’s structure is 
like a straight rod whereas 1 twists to accommodate the chiral piperidinones making it 
shorter between the N- and C-termini. 
CD spectra of minimalist mimics are rarely informative because it is unusual to 
have a series that represents systematic changes to the scaffold structure.74  However, in 
this particular study, several oligo(piperidinone-piperidine)s of different lengths were 
available, and this facilitated meaningful correlations of elipticities with structure.  
Figure 2.6a shows UV spectra of compounds represented by the generic structure B (n = 
1 is 11ff; n = 2, 12fff; n = 3, 13ffff; and, n = 4, 14fffff; D-configuration throughout).  
Absorbance maxima at approximately 290 – 310 nm (MeOH) are attributed to additive 
3 nm
e
two X-ray structures
overlaid at C- and N-termini
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effects of the enamide chromophores (red box on B); more absorbance correlates with 
higher values of n.  If the compounds were non-randomly distributed amongst 
stereoisomeric secondary structures (eg right- and left-handed helices) then increased 
molar elipticities would be expected as n increases.  Figure 2.6b shows that molar 
elipticities in the 290 – 310 nm wavelength region do, in fact, increase with n, implying 
some degree of ordering in solution. 
 
 
Figure 2.6.  UV and CD spectra of oligo-piperidinone-piperidines. a UV; and, b CD 
spectra of B (n = 1 is 11ff; n = 2, 12fff; n = 3, 13ffff; and, n = 4, 14fffff) in MeOH.  UV 
spectra were recorded at 20 µM, and CD at 200 µM. 
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Figure 2.6.  Continued. 
 
We hypothesized scaffold 1 could present three amino acid side-chains in 
orientations resembling extended secondary structures with wide side-chain separations. 
To test our hypothesis, a large number of accessible (<3 kcal•mol-1) conformations for 
each stereomer of 1 were simulated with quenched molecular dynamics,75,76 then 
systematically matched with the most common ideal secondary structure elements with 
EKOS.57  
Figure 2.7 features data for all stereomers of 1; it shows the RMSDs for the best 
fitting conformers corresponding to each element of secondary structure.  These data are 
calibrated relative to the average RMSDs for all the best fitting conformers for a given 
stereomer.  Thus for LLL-1aaa 0.65 Å was the average for the seven best fitting 
conformers on the seven secondary structures indicated.  This graphic indicates the LLL-
isomer is predicted to mimic a sheet-turn-sheet closely, ideal helical structures less well, 
n = 1
2
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b
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and extended parallel β-sheet- and -strand structures very poorly (Figure 2.7a).  
Comparing this with the plot for the DLD-isomer (selected because the X-ray data in 
Figure 2.5a was accumulated for that isomer) shows a similar tendency towards helical 
conformations.  The fact that the overlays on sheet-turn-sheet and antiparallel β-sheet 
structures have identical RMSD values is indicative of the fact that the antiparallel β-
sheet region is part of the sheet-turn-sheet motif, and this is where the mimic overlaid.  
Figure 2.7i shows the corresponding data for LLL-Aaaa.  Scaffold A has a strong 
tendency to mimic β-sheet structures, but not helical ones, and that trend is in fact 
consistent for all the stereomers of A.  
 
 
Figure 2.7.  Predicted mimicry of secondary structures for: a-h all diastereomers of 
1aaa and i LLL-Aaaa. 
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Figure 2.7.  Continued. 
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Figure 2.7.  Continued. 
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Figure 2.7.  Continued. 
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Figure 2.7.  Continued. 
 
2.4 Data-mining of All Crystallized PPIs in Protein Data Bank 
Minimalist mimics are usually designed to perturb real protein-protein 
interactions (PPIs) by displacing a secondary structure at the interface.  However, 
interfaces rarely have ideal secondary structures, and many do not feature secondary 
structures at all.  Exploring Key Orientations (EKO) is data mining to compare 
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simulated conformational ensembles of minimalist mimics with crystallographically 
characterized PPI regions, irrespective of the secondary structures involved.58  Here 
EKO analyses for LLL-1aaa and LLL-Aaaa were performed to determine if the biases 
for ideal secondary structures predicted above (using EKOS) are consistent with the 
statistical match of accessible conformations on real interface secondary structures.  To 
do this we developed a script to assess the secondary structure content of the interface 
regions that best match simulated conformers.  After analyses of tens of thousands of 
PPI structures, EKO found 68 interface regions that matched a simulated conformer of 1 
with RMSDs of <0.3 Å, and 32 that similarly matched conformers of A.  Figure 5 shows 
only LLL-1aaa matched on helical regions at PPI interfaces though it found relatively 
more sheet interface regions.  LLL-1aaa and LLL-Aaaa had a similar proclivity to match 
with contiguous or non-contiguous motifs of no particular secondary structure (called 
“single segment” and “multiple segments” in Figure 2.8).  Overall, these observations 
are consistent with those from comparisons of the simulated conformational ensembles 
with ideal secondary structures in Figure 2.7. Four representative overlays for LLL-1aaa 
at interfaces are illustrated in Figure 2.9. 
 
  33 
 
 
Figure 2.8.  The most favorable PPI matching regions from EKO analyses of LLL-1aaa 
and LLL-Aaaa compared in terms of the secondary structure motifs that they overlay 
upon.  “Single segment” means the side-chains are three residues on a single chain 
segment, whereas “multiple segments” refers to situations for which the three important 
side-chains are on non-contiguous regions of the protein. 
  
undefined secondary 
structure motifs
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Figure 2.9.  EKO predicts LLL-1aaa can overlay well on different secondary structure 
motifs at PPI interfaces.  a Helical motif of L-aspartate ammonia lyase, RMSD = 0.29 Å, 
PDBID: 1jsw.  b β-Sheet of ectodysplasin A, RMSD = 0.27 Å, PDBID: 1rj7.  c On a 
contiguous chain-segment without a defined secondary structure for prolyl-tRNA 
synthetase, RMSD = 0.21 Å, PDBID: 1h4s.  d On discontiguous segments of a PPI 
interface for RNA polymerase II, RMSD = 0.30 Å, PDBID: 2cw0. 
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Figure 2.9.  Continued 
2.5 Conclusions 
In summary, a route to mimics 1 that is not vulnerable to epimerization, and 
involves facile couplings, was devised.  Solution phase syntheses of mono-, di-, tri-, 
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d
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tetra-, and penta-oligo(piperidinone-piperidine)s were convenient.  Solid state structures 
of three compounds of intermediate lengths in this series showed they tend to adopt 
extended conformations, and provided evidence to suggest a 36 Å longitudinal 
dimension for the pentamer 14fffff.  CD studies of milestone intermediates in this 
synthesis indicates the conformational ensemble tends towards progressively more 
ordered structures in solution. 
Only six methylene groups differentiate the structures of 1aaa and Aaaa but that 
drastically changes side-chain orientations in their solution conformers.  Overall, we 
assert that even though none of the conclusions about the secondary structure 
preferences for 1 in solution can be confirmed spectroscopically, and limited inferences 
can be drawn from X-ray data, it is much better to have insight from EKOS and EKO 
than to have none at all.  EKOS indicated there are significant differences between the 
ways simulated preferred conformers of the featured scaffolds overlay on secondary 
structures; 1aaa is predicted to be more linear, and has a bias towards helical motifs 
whereas Aaaa best mimics β-strands.  Overall, simulated preferred conformers of 
molecules 1 and A optimally superimpose on different interface regions and proteins 
when they are systematically overlaid on a huge database of PPI structures using EKO; 
in other words, these two scaffold designs complement each other.  Applications of 
mimics 1 in perturbation of a particular PPI based on EKO analyses will be discussed in 
Chapter IV. 
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CHAPTER III  
THE DESIGN AND SYNTHESIS OF OLIGO-PIPERIDINE-
PYRROLIDINONES* 
3.1 Introduction 
Previous studies from our laboratories have reported on the minimalist mimics A 
(Figure 3.1).62,63 We were intrigued by the fact that small changes to the backbone 
structure A must affect the accessible conformations of these molecules, and therefore 
the types of protein-ligand interface regions they can resemble.65  However, if the 
compounds are not synthetically accessible, then it will be impossible to test their effects 
in a cellular environment.  Our group has shown mimics A can be prepared with a 
variety of amino acid side-chains, but not without limitations.62,63 An alternative mimic 1 
was developed in Chapter II and this scaffold is synthetically more accessible and 
conformationally distinctive compared with mimic A. Research described in this chapter 
covers a brief investigation of the pyrrolinones-piperidine mimics 15 that features a 
hybrid structure of 1 and A, and the discovery of a general and chemoselective 
methodology to synthesize mimics 15 and other β-enamino derivatives. 
*Reprinted in part with permission from “Extended Piperidine-piperidinone Protein
Interface Mimics”, Dongyue Xin, Arjun Raghuraman and Kevin Burgess, J. Org. Chem.
2015, 80, 4450-4458. Copyright 2015 American Chemical Society and from “A
Chemoselective Route to β‑Enamino Esters and Thioesters”, Dongyue Xin and Kevin
Burgess, Org. Lett. 2014, 16, 2108-2110. Copyright 2014 American Chemical Society.
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Figure 3.1.  Structures of mimics 1 and 15, conceptually derived from A. 
 
Scaffolds A, 1 and 1566 have different conformational ensembles that orientate 
the three side-chains on each scaffold in different ways.  Each scaffold will therefore 
overlay on different types of PPI interfaces, as determined using massive screening of 
the PDB with the data mining routine we developed as part of the EKO strategy. 
 
3.2 Exploratory Studies on the Syntheses of Pyrrolidinone-piperidine Oligomers 15 
Synthesis of the chiral center pyrrolidines A necessitated SN2 displacement of a 
triflate from an enantiomerically enriched, N-protected, 3-hydroxypyrrolidine; this was 
not a reaction that proceeded cleanly from starting material to product.62,63  Superficially, 
syntheses of mimics 15 appeared to be more facile because reductive amination to give 
the diamines 16 does not introduce a chiral center. In the event, diamines 16 were easy 
to prepare, and they were easily converted to piperidine-functionalized tetramic acid 
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esters 18;77-79 the first chromatographic separation was required only at this stage, hence 
these monomers were conveniently prepared in gram amounts (Scheme 3.1).   
 
Scheme 3.1.  Preparation of pyrrolidine-piperidines 19. 
 
 
 
 
 
Surprisingly, it proved to be difficult to couple the piperidines 18 with tetramic 
acids 17 compared to the pyrrolidines used in syntheses of scaffolds A.  Considerable 
optimization of these reaction conditions was required, as documented in Table 3.1. In 
the event, the highlighted conditions (entry 11: EDCI, KHCO3, HOAt80) afforded the 
scaffold with two side-chains 19aa more efficiently than any other set of conditions 
studied.   
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Table 3.1.  Optimization of coupling the piperidines 18a with the tetramic acids 17a. 
 
 
      
1 TBTU TEAa - n. d.c 10 % 
2 HBTU TEAa - n. d. 23 % 
3 PyBOP TEAa - n. d. complex mixture 
4 TFFH TEAa - n. d. < 10 % 
5 EDCI TEAa - n. d. 30 % 
6 EDCI TEAa HOBt n. d. 45 % 
7 EDCI TEAa HOAt n. d. 59 % 
8 EDCI KFb HOAt n. d. 40 % 
9 EDCI Li2CO3b HOAt n. d. 39 % 
10 EDCI Cs2CO3b HOAt 10 % 86 % 
11 EDCI KHCO3b HOAt none 74 % 
12 EDCI KHCO3b Oxyma81  n. d. 
complex 
mixture 
13 EDCI KHCO3b 
N-
hydroxysuccinimide n. d. 10 % 
a 2.0 equiv. of TEA;  b 5.0 equiv. of the base; c not determined. 
 
 
A major difficulty arose when the optimized conditions that gave 19aa without 
epimerization were applied to make 19as’ and 19fs’; approximately 15 and 30 % 
NHN
O
OtBu
17a
coupling 
reagent
base
CH2Cl2, 25 oC
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NN
O
OtBuHN
O
18a 19aa
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epimerization was observed by 13C NMR and analytical HPLC, respectively (Scheme 
3.2).   
 
Scheme 3.2.  Epimerization observed in the synthesis of 19. 
 
 
 
A series of experiments were undertaken to determine which of the two chiral 
centers was most vulnerable to epimerization. Firstly it was established that compound 
18s’ is basic enough to mediate its own racemization when stored as a concentrated oil at 
room temperature overnight.  Evidence for this assertion was from an experiment in 
which “aged” 18s’ was coupled with racemic tetramic acid 17a resulting in four 
stereoisomeric products that could be separated via analytical HPLC with a chiral 
support (Chiralpak AD).  When freshly prepared 18s’ was coupled with optically pure 
tetramic acid 17a, three products were observed: one of these was formed in even 
greater amounts when the experiment was repeated with aged (partially racemized) 18s’.  
The fact that a significant amount of the fourth possible stereoisomer was not observed 
in the experiments involving optically pure 17a indicates epimerization of the 18s’ 
fragment dominates.  A possible reason for this is inductive stabilization of the enolate 
from 18s’ that would not effect 17a or the N-terminal part of product 19as’. 
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At this stage it became clear that the targeted pyrrolidinone-piperidine oligomers 
15 were too stereochemically delicate, especially if they contained side-chains that 
somehow promoted epimerization. Nevertheless, we were able to synthesize the three 
side-chain system 15aaa without epimerization (Scheme 3.3).   
 
Scheme 3.3.  Synthesis of 15aaa. 
 
 
 
Application of the EKOS routine indicated accessible conformations of 15aaa 
contain some that overlaid on a sheet-turn-sheet motif more accurately than any of the 
conformers matched the other common secondary structures (310-, α-, π-helices; parallel 
and antiparallel β-sheets, and β-strands).  Figure 3.2 shows the same overlay with 
conventional atoms colors on the left, and the ideal sheet-turn-sheet motif highlighted in 
purple on the right. 
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Figure 3.2.  Overlay of 15aaa on an ideal sheet-turn-sheet motif. 
 
3.3 A General and Chemoselective Route to β-Enamino Derivatives 
Our interest in β-enamino derivatives arose when pursuing the interface mimics 
A, 1 and 15. Scaffolds A, 1 and 15 have several β-enamino amide functionalities, and 
overall yields in their syntheses are directly related to efficient formation of the bonds 
indicated.  Consequently, the method for efficient formation of β-enamino derivatives 
under mild conditions was extensively studied in this section.82  
β-Enamino esters are versatile synthons for many heterocycles and benzenoid 
compounds.  There are too many applications of these building blocks to cite them all, 
but illustrative ones include syntheses of amino-furanones, indoles,83-86 oxazoles,87 
pyrazoles,88 pyridines89 and dihydropyridines,90 pyrimidineones,91 pyrroles,92-95 
quinolines96 (Figure 3.3). Existing methods to prepare β-enamino carbonyl derivatives 
were summarized in two papers.97,98 These methods tend to involve acids, elevated 
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temperatures, and oxidizing agents, ie characteristics that limit the range of products that 
can be formed.  
 
 
 
Figure 3.3.  Illustrative uses of β-enamino esters. 
 
Apparently the literature on formation of β-enamino esters from β-keto esters 
contains few, if any, references to conditions most commonly associated with amide 
bond couplings.  We envisaged these types of conditions might be effective, and data 
from exploratory experiments to test this hypothesis are shown in Table 3.1 and Table 
3.2.  These pilot reactions in Table 3.2 were performed on phenolic esters to allow the 
opportunity for the amines to displace phenoxide, ie a more stringent chemoselectivity 
test than if less reactive esters were used.  In the event, such acylation reactions did not 
account for significant product formation under the best conditions identified. 
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Table 3.2.  Pilot Reactions for Formation of β-Enamino Derivatives. 
 
 
 
entry activating reagent base solvent additive yield (%) 
      
1 EDCHCl TEA CH2Cl2 HOBt 11 
2 EDCHCl KHCO3 CH2Cl2 - 12 
3 EDCHCl KHCO3 CH2Cl2 DMAP 17 
4 EDCHCl KHCO3 CH2Cl2 HOBt 74 
5 EDCHCl KHCO3 CH2Cl2 HOAt 85 
6 EDCHCl imidazole CH2Cl2 HOAt 71 
7 EDCHCl - CH2Cl2 HOAt 33 
8 EDCHCl KHCO3 CHCl3 HOAt 93 
9 EDCHCl KHCO3 DMF HOAt 13 
10 HBTU99 KHCO3 CHCl3 - 60 
11 PyBOP KHCO3 CHCl3 - 80 
12 PyBOP imidazole CHCl3 - 87 
 
Together, entries 1 - 5 of Table 3.2 indicate HOAt (1-hydroxy-7-
azabenzotriazole)80 is preferred as an additive over HOBt or DMAP.  Entry 7, compared 
with all the others strongly indicates that a weak base is required.  Chloroform seems to 
be a better solvent for this reaction type than dichloromethane or DMF (cf entries 8 and 
12 vs 5 and 9).  The best yield was obtained using EDCHCl (N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride) in entry 8, but the PyBOP 
((benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate)100 conditions in 
entry 12 were only marginally inferior and sometimes, depending on the substrate, have 
+ H2N Bn 25 oC, 10 h
O
OPh
O NH
OPh
OBn
activating agent
base, additive
solvent
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advantages with respect to work-up simplicity.  Figure 3.4 shows products and yields for 
other β-enamino esters formed via the method illustrated in entry 12. 
 
 
 
 
Figure 3.4.  β-Enamino esters formed using the conditions shown for entry 12 in Table 
3.2. Except: a 36 h; and, b 2 equiv. of amine and 24 h.  
 
The next step in this study was to investigate β-ketothioesters as substrates.  
Figure 3.5 illustrates how, in the absence of additive, an amine is preferentially acylated 
by a β-ketothioester, rather than condensing with it.  It is potentially valuable to be able 
to invert this chemoselectivity because that would enable preparation of β-enamino 
thioesters.  Previous syntheses of β-enamino thioesters are limited to the N-unsubstituted 
forms (via multi-step procedures,101 or by adding ammonia under buffered conditions102) 
or via condensations of tert-butyl β-ketothioesters in the presence of ceric ammonium 
nitrate (CAN) where the large S-alkyl group attenuates the reactivity of the thioester.98   
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Figure 3.5.  Innate reactivity of β-ketothioesters. 
 
Inverted chemoselectivity relative to the reaction above was achieved by 
modifying the Table 3.2, entry 12 conditions to include the acid HOAt and hydrogen 
carbonate buffer.  This enabled syntheses of the β-enamino thioesters shown in Figure 
3.6. 
 
 
 
 
Figure 3.6.  Illustrative syntheses of β-enamino thioesters. 
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Figure 3.6 demonstrates that both aliphatic and aromatic amines can be used as 
the nucleophile in these reactions.  Formation of the β-enamino thioesters 21j and 21p 
indicates that acetal and S-trityl groups are tolerated, whereas they presumably would 
not be in the presence of acids.  Products 21k, 21l, and 21m demonstrate primary 
alcohols and phenols are compatible with the featured condensation reaction.  Phenylthio 
ester products 21r – t were formed, even though PhS- is a better leaving group than in 
the other reactions. 
Three Nenitzescu indole syntheses103-105 were performed to illustrate how β-
enamino thioesters can be used (Figure 3.7).106 All three reactions did not perturb the 
thioester functionality, even when this involved a more reactive phenylthiolate leaving 
group, ie for indole 22b.  Formation of the regioisomers shown was confirmed via 
NOESY experiments. 
 
 
 
 
Figure 3.7. Illustrative Nenitzescu indole syntheses. 
 
NH
SR2
OR
1
+
O
O
MeNO2
25 oC, 24 h N
R1
SR2
O
HO
21 22
22a, 75%
N
SnBu
O
HO
Ph
N
SPh
O
HO
Ph
22b, 68%
N
Ph
SnBu
O
HO
22c, 53%
(72 h)
  49 
An isolable intermediate azabenzotriazole ether was formed when 1,3-
cyclohexandione was reacted under the conditions used under typical coupling 
conditions (Figure 3.8).  It seems probable that this intermediate is more stable than the 
corresponding one in the thioester reactions.  If similar intermediates are formed 
throughout, this reaction indicates a two-step conjugate addition-elimination process is 
operative.  This would also explain why HOAt is superior to HOBt in these 
transformations: because the aza-derivative can “lever” proton transfer in the amine 
addition step as indicated in transition state in Figure 3.8.  
 
 
 
Figure 3.8.  Intermediate formation in HOAt-mediated reactions. 
 
Finally, Figure 3.9 illustrates how the conditions developed for formation of β-
enamino amides were applied in reactions typical of those used to make the interface 
mimics.107  Good yields were obtained, and the near-neutral conditions indicate there is 
likely to be a broad substrate scope. 
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Figure 3.9.  Application of the featured conditions for syntheses of interface mimic 
fragments. 
 
In summary, β-enamino derivatives can be formed via carefully buffered 
conditions featuring activation agents like EDCHCl and PyBOP.  These conditions are 
sufficiently mild to facilitate synthesis of a wide range of examples, including relatively 
delicate synthons like β-enamino thioesters. 
 
3.4 Conclusions 
In this chapter, a minimalist mimic based on pyrrolidinone-piperidine scaffold 
was designed and synthetic route to the mimic was explored.  The mimic can be 
synthesized but the chiral centers are too vulnerable to epimerization.  Conformational 
studies indicated that the scaffold could mimic a sheet-turn-sheet motif better than the 
other common secondary structures.  The synthetic methodology developed to prepare 
oligo-pyrrolidinone-piperidine was thoroughly explored and extended to the synthesis of 
other β-enamino derivatives.  This method enabled the chemoselective synthesis of a 
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series of β-enamino thioesters, which cannot be prepared efficiently with other currently 
existing methods. 
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CHAPTER IV  
OLIGO-PIPERIDINE-PIPERIDINONE PROBES THAT PERTURB A 
PROTEIN-PROTEIN INTERFACE IN ANTITHROMBIN* 
 
4.1 Introduction 
Serpins are proteins that, in their monomeric forms, function as naturally 
occurring serine protease inhibitors.  Monomeric serpins are metastable,108 and they 
revert to thermodynamically more favorable (ca 32 kcal/mol)109 dimeric, then 
oligomeric, forms. Oligomeric serpins assemble into fibrils that are associated with a 
series of diseases known as “serpinopathies”110 encompassing conditions as diverse as 
some neurological conditions and liver sclerosis.  
α-Antithrombin is a serpin that inhibits thrombin.  It played an important role in 
the development of understanding how serpins may form fibrils because Huntington et 
al were able to crystallize a physiologically relevant dimer that now serves as a model 
for the formation of oligomers (the oligomers have not yet been structurally 
characterized on a molecular level, presumably because they are non-homogenous 
involving a range of molecular masses).  Figure 1 illustrates how the red and purple 
sheet regions of the α-antithrombin monomer (PDB: 2ANT) reorganize to form a purple 
cleft to accept an interface hairpin from the partner, and donate a red hairpin to it in the 
dimer (2ZNH).109,111 Consequently, one of the several models for serpin oligomer 
                                                
*Reproduced in part from “Small Molecule Probes That Perturb a Protein-protein 
Interface in Antithrombin”, Dongyue Xin, Andreas Holzenburg and Kevin Burgess, 
Chem. Sci. 2014, 5, 4914-4921. Copyright 2014 The Royal Society of Chemistry. 
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formation109,111-118 is via domain swapping to form a dimer, then repetition of this 
process to form oligomers.117,118 Thus serpin-dimer formation is potentially critical in 
serpinopathies, and has been described as “infectious”.112,119,120   
 
 
 
Figure 4.1.  Structures of the α-antithrombin monomer and the self-terminated dimer. 
 
Scaffolds 1, as featured in Chapter II, are a good example of the kind of 
chemotype that can be processed using the EKO approach.  Molecules in this series 
contain three β-amino acid fragments (blue) that can be made from the corresponding α-
amino acid chirons, and have only two significant degrees of freedom (red arrows). 
(Figure 4.2) 
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Figure 4.2.  Oligo-piperidine-piperidinone probes studied. 
 
Synthetic protocols were described for compounds 1 in Chapter II.65 EKOS was 
used to compare the simulated conformations of all isomers of 1aaa with ideal 
secondary structures; this indicated that stereomers of chemotypes 1 can adopt 
conformations that resemble all common secondary structures, with a bias towards 
extended sheet-turn-sheet and β-sheet conformations more than helical ones.65   
For the work described in this chapter, EKO identified several PPI interface 
regions that correspond to side-chain orientations found in synthetically accessible 
conformations of 1.  Consequently, we set out to ascertain if the compounds 1 implicated 
in this EKO analysis would in fact perturb PPIs that influence α-antithrombin 
oligomerization.  These experiments were not performed as part of a drug discovery 
effort, but rather to test if EKO could be used to identify compounds that perturb PPIs in 
this particular test case.  Specifically, the goal was to explore if the structures implicated 
by EKO would perturb PPIs in antithrombin and impact (positively or negatively) the 
oligomerization process.121   
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4.2 Perturbation of α-Antithrombin Oligomerization by Interface Mimics 
Results from EKO imply scaffold 1 might present side-chains in several ways 
that resemble the α-antithrombin dimer PPI interface; the four that were experimentally 
tested in this work are listed in Table 4.1, and three representative overlays are shown in 
Figure 4.3.  One (RMSD 0.26 Å) involves three residues on a single strand of the β-
hairpin in an i, i + 2, i + 5 relationship (i.e. 384Ala, 386Thr, and 389Val; Figure 4.3a and 
entry 1 in Table 4.1).  Conversely, the scaffold spanned the two strands of the β-hairpin 
in other overlays, matching 373Leu and 371Ala on one strand and 386Thr on the other in 
Figure 4.3b, and in Figure 4.3c 383Ala/385Ser on one strand and 368Phe on the other.  
Another issue surrounding data mining within the EKO strategy relates to the polarity of 
the overlays.  Scaffolds like 1, being formed from amino acids, have recognizable N- and 
C-termini, and these can be overlaid parallel or antiparallel to the protein.  In Figure 4.3a 
and b the overlay is antiparallel so the mimics that should be prepared are LDD-1vta and 
LLD-1lat.  Figure 4.3c however, shows mimic conformers overlaid on the strands in a 
parallel fashion hence the target is DDD-1asf and not DDD-1fsa.  Like entry 2, the 
fourth overlay referred to in Table 4.1 (entry 4, but not shown in Figure 4.3) also 
corresponds to the 1lat sequence, but the stereochemistry and polarity is different.   
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Table 4.1.  Conformational matches identified by EKO on interface regions in the α-
antithrombin dimer structure. 
 
entry isomer RMSD(Å) residues polarity 
     
1 LDD 0.26 V389-T386-A384 antiparallel 
2 LLD 0.33 L373-A371-T386 antiparallel 
3 DDD 0.35 A383-S385-F368 parallel 
4 DLL 0.37 L373-A384-T386 parallel 
 
 
 
 
Figure 4.3.  Conformers of scaffolds 1 can overlay side-chains on the β-hairpin structure 
in the α-antithrombin dimer.  a on one strand; or, b and c spanning across two strands.  
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Figure 4.3.  Continued.  
  
386Thr
373Leu
371Ala
b  overlay across two strands
RMSD = 0.33 Å
385Ser 368Phe383Ala
RMSD = 0.35 Å
c  overlay across two strands
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The compounds specified in Table 4.1 were prepared to test the hypothesis that 
EKO can implicate small molecules to disrupt PPIs in the α-antithrombin dimer,109 but 
with one exception.  Entry 1 of Table 4.1 calls for synthesis of DDL-1vta.  However, it is 
considerably easier to make DDL-1vva, with Val replacing the Thr, because of issues 
with side-chain hydroxyl protection. Consequently, we elected to prepare DDL-1vva in 
place of DDL-1vta on the basis that the shape of the Val side-chain (CHMe2) is similar 
to that of Thr (CH(OH)Me). 
The next step in the process was to devise assays to test perturbations of PPIs in 
α-antithrombin dimer.  α-Antithrombin oligomerizes more readily at temperatures above 
ambient, and at low pH values.  After some experimentation, it was shown that such 
oligomerizations occur at convenient rates for our purposes above 50 °C at pH 7.4.  
When α-antithrombin was incubated at 50 °C for 8 h at pH 7.4, it showed little sign of 
oligomerization as monitored via native PAGE (i.e. non-denaturing gel; Figure 4.4a).  
Experiments were conducted to determine the effects of control or target compounds 
being present during incubation (Figure 4.4b, where target compounds are shown in red 
and controls or “partial controls” are shown in blue).  Thus, lane 2 of Figure 4.4b shows 
that the scaffold with three methyl side-chains (LLL-1aaa) gave a small amount of 
oligomerization; this was unsurprising because all the EKO-implicated targets in Table 
4.1 have a methyl side-chain and share the same scaffold, so LLL-1aaa is too similar to 
be a true negative control.  However, tests with indigo, a compound that is known to 
bind many proteins non-specifically,122 showed no evidence that it catalyzed 
oligomerization (see Figure 4.4d).  
  59 
 
 
Figure 4.4.  Native gel electrophoresis study of α-antithrombin oligomerization. 
Throughout, controls are delineated in blue, and assays of target compounds are shown 
in red. After 1 h at 50 °C in pH 7.4 at 0.25 mg/mL concentration, α-antithrombin shows 
the following. a α-Antithrombin was incubated at 50 °C for 0 h (lane1), 1 h (lane2), and 
8 h (lane3). b (Lane): 1 little or no oligomerization on its own; and, 2 only slightly more 
in the presence of the scaffold LLL-1aaa (only methyl side-chains).  However, lane 3 
shows a target compound implicated in EKO, DDD-1asf catalyzes formation of 
significantly more oligomers, particularly the ones having lower molecular mass.  Lane 
4 shows oligomer formation is slightly suppressed for LDD-1asf relative to DDD-1asf 
(corresponding to one inverted stereocenter).  Lanes 5 – 7 show the indicated target 
compounds implicated by EKO also induce oligomerization, though less than DDD-1asf 
under the same conditions.  c A similar comparison for some benzyl-protected target 
compounds (red) and protected or otherwise hydrophobic controls (blue). 200 fold of 
indicated compounds were used in all cases. d α-Antithrombin (0.25 mg / mL) was 
incubated with 200 fold compound LLL-1aaa (negative control in this series, lane 1), 
200 fold DDD-1as’f (lane 2), 200 fold indigo (control for non-specific hydrophobic 
interactions, lane 3), 0.025 % Triton-X 100 (control for surfactant, lane 4), 200 fold 
sodium dodecyl sulfate (SDS, control for amphiphilic compounds, lane 5) at 50 °C for 1 
h. 
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Figure 4.4.  Continued. 
 
Lanes 3, 5 – 7 in Figure 4.4b showed that the four compounds targeted (DDD-
1asf, LLD-1lat, DLL-1lat and LDD-1vva, in red) imparted significantly more 
oligomerization than LLL-1aaa.  Lane 4 shows data for another interesting “partial 
control”, LDD-1asf.  EKO did not indicate that conformers of this compound would 
match the featured PPI interface, but it might be expected to do so to some degree since 
it is an epimer of ones that EKO did implicate (DDD-1asf, lane 3).  In the event, both 
LDD-1asf and DDD-1asf do mediate oligomerization, but the target compound DDD-
1asf did it more effectively than the partial control LDD-1asf.  Finally, the gel in Figure 
4.4b shows that all the conditions give oligomers bias towards the lower molecular mass 
range.   
Figure 4.4c shows a gel that compares benzyl-protected forms of the targeted 
compounds with some similarly hydrophobic derivatives of the same scaffold 1, but 
which have side-chains and/or stereochemistries that were not implicated by EKO.  Lane 
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2 shows DDD-1as’f, the benzyl-protected derivative of the most active compound in 
Figure 3a, also catalyzed the oligomerization process.  The “partial control” DDL-1t’al 
in lane 3 has two amino acids interchanged relative to the protected, targeted compound 
LLD-1lat’, and a different stereochemistry; the protected targeted compound accelerated 
the oligomerization most.  Moreover, another protected, targeted compound having the 
same sequence of amino acids, DLL-1lat’ in lane 5, also gave more acceleration than the 
control with two side-chains switched, DDL-1t’al.  Finally, LDD-1vt’a is the only 
protected, target compound that did not markedly accelerate the oligomerization process.  
The hydrophobic compounds DLD-1faf and DDD-1fff, having the same scaffold but no 
side-chain correspondence, also did not promote oligomer formation significantly. 
All the PAGE data presented above are based on qualitative silver-stains.  
Kinetic data from the band intensities were determined to quantitate and compare effects 
of the compounds.123,124  Figure 4.5a shows an illustrative data correlation of rate 
constants for oligomerization of α-antithrombin with the concentration of mimic DDD-
1as’f.  In Figure 4.5b, rate constants for the same oligomerization but in the presence of 
five featured mimics are compared; DDD-1as’f was the best catalyst.  Kinetics was not 
performed on all the unprotected mimics shown in Table 4.1 because it was apparent 
that the protected forms tend to be better catalysts. 
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Figure 4.5.  Kinetics of α-antithrombin oligomerization.  Induced by a DDD-1as’f; and, 
b benzyl-protected forms of the four featured mimics, and the best unprotected 
compound, DDD-1asf (all at 200x the protein concentration). 
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Another way to assay these compounds was to test antithrombin samples after 
oligomerization for their residual activity as thrombin inhibitors.  Thus, inhibition of 
thrombin by α-antithrombin (optionally, after putative oligomerization mediated by the 
small molecule probes 1) was used to assay the featured compounds.  Thus, the probes 
were incubated with α-antithrombin (time variable), and aliquots of this solution were 
used to inhibit thrombin-mediated hydrolysis of a peptide containing 4-nitroaniline 
(Spectrozyme® TH, from American Diagnostica); this type of assay is a standard test 
for thrombin activity (performed in the presence of heparin).125,126  In the event, 
thrombin was most active when inhibited by samples of α-antithrombin that had been 
incubated with DDD-1as’f (Figure 4.6a).  This observation is consistent with the 
assertion made above, that DDD-1as’f promotes α-antithrombin deactivation by 
oligomerization well.  When α-antithrombin deactivation in this assay was compared for 
DDD-1as’f and DDD-1asf, the benzyl-protected compound induced significantly more 
deactivation. 
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Figure 4.6.  Activity of antithrombin as thrombin inhibitors revealed by enzyme kinetics 
studies.  a Absorption of 4-nitroaniline formed by thrombin, and inhibited by α-
antithrombin that was previously incubated with DDD-1as’f for the times shown.  
Correlation of residual thrombin activities with α-antithrombin monomer concentrations 
are shown in: b for DDD-1as’f; and, c for DDD-1asf. 
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Figure 4.6.  Continued. 
 
A subtle difference in the data depicted in Figure 4.6 is that 50 % residual α-
antithrombin monomer in 4.6b (for DDD-1as’f) corresponds to high thrombin activity, 
but in 4.6c (for DDD-1asf) 50 % residual α-antithrombin monomer corresponds to low 
thrombin activity; that observation appears to be counterintuitive.  However, recall from 
Figure 4.4 the protected probe DDD-1as’f favors formation of longer α-antithrombin 
oligomers than the deprotected form, DDD-1asf.  In general, formation of oligomers 
involves burying the free “reactive center loop” that complexes to thrombin to give 
inhibition in a protein cavity.  α-Antithrombin oligomers have a free reactive center loop 
at one end, which may still inactivate thrombin even though the protein is oligomerized.  
In short oligomers, the proportion of free reactive center loops available to inactivate 
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thrombin is higher than in long oligomers.  Thus data in Figures 4.6b and c can be 
reconciled by accounting for the proportion of uncomplexed reactive center loops in the 
oligomeric products. 
Alterations of protein tertiary and quaternary structures are often followed using 
circular dichroism (CD) and isothermal calorimetry (ITC).  In this study, addition of the 
compounds to α-antithrombin under conditions that were expected to cause 
oligomerization resulted in changed CD spectra, as anticipated.120  However, the data 
was hard to interpret beyond this crude observation because transformation of an α-
antithrombin tertiary structure to another similar one in the dimeric and oligomeric 
forms involves only small changes in elipticity.  When α-antithrombin (at 20 µM) was 
mixed with the optimal probe, DDD-1as’f, under conditions up to a 1:1 ratio in an ITC 
bomb, the enthalpy change could not be detected.  This also is unsurprising because the 
binding of the probe to the protein may not liberate sufficient enthalpy to detect in ITC 
under these conditions.  Overall, these experiments are hard because they are not simple 
binding events, but instead the molecule acts as a catalyst to induce different 
oligomerization states.   
Whereas CD and ITC are apparently inappropriate to follow induced α-
antithrombin oligomerization, electron microscopy enabled direct visualization of the 
process.  Negatively stained untreated antithrombin molecules revealed a range of 
projections and a representative area is depicted in Figure 4.7 (inset). In the most 
frequent projection, the molecules assume a roughly elliptical shape.  Molecular mass 
can be determined from the dimensions of these particles, if a 3D shape can be inferred. 
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Assuming a prolate ellipsoid as the overall 3D shape and a partial specific volume (υ) of 
0.74 ml/g127,128 the molecular mass (m) can be calculated according to the formula m 
(Da) = volume of the protein (ml) x Avogadro’s number x 1/υ.128,129 Using this formula 
together with the long and short half axes determined as 3.1 ± 0.3 nm and 2.3 ± 0.3 nm, 
respectively, one arrives at a molecular mass of 56 kDa. This finding suggests that the 
imaged untreated particle constitute a monomeric antithrombin population as the 
published molecular mass for antithrombin is 58 kDa.109 The dramatic change in 
appearance upon treating antithrombin with the mimic DDD-1as’f is readily apparent in 
Figure 4.7 which is characterized by a large population of higher order oligomer.  α-
Antithrombin oligomerized by treatment with the optimal probe (DDD-1as’f at 50 °C) 
appears as small fibrils as shown in Figure 4.7.  
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Figure 4.7.  Electron micrographs of negatively stained α-antithrombin.  Prior to any 
polymerization conditions (inset); and incipient α-antithrombin fibrils induced by the 
action of DDD-1as’f at 50 °C for 1 h.  Expansions A – D highlight regions of interest 
where the oligomers can be directly observed. 
 
Finally, the featured compounds were designed for perturbation of the dimer 
intermediate in Figure 4.1, but the evidence outlined above would also be consistent with 
the compounds acting via perturbation of the monomer.  This motivated us to consider 
how the monomer might fare in the EKO analysis, but there was one critical problem.  
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The algorithm that EKO uses is specifically designed for PPIs involving more than one 
chain, so it will not “pick up” hits on the antithrombin monomer interface.  
Consequently, to answer this question, we tricked the algorithm by breaking the 
monomer PDB so that it appears to be a PPI involving two chains.  When the EKO 
process was applied to that pseudo-dimer, hits were found on the pivotal β-sheet region 
corresponding to in the chain swapped dimer. 
 
4.3 Conclusions 
Application of the EKO strategy to chemotypes 1 led us to hypothesize that 
selected probes in this series would perturb PPIs in α-antithrombin.  In the event, four 
target compounds, and four benzyl-protected precursors, were tested, and all catalyzed 
oligomerization of α-antithrombin.  This conclusion is supported by observation of 
oligomers on gels, by monitoring residual α-antithrombin inhibition activity in thrombin 
assays, and via direct observation using EM.  These findings are consistent with the 
original hypothesis that the targeted probes perturb PPIs in α-antithrombin.   
An interesting outcome of this study is that benzyl-protected forms of the target 
compounds proved to be better oligomerization catalysts than the non-protected 
compounds.  This does not appear to be a non-specific hydrophobic effect because true 
negative controls (eg indigo), and closely related compounds with conformational states 
that were not marked by EKO as being appropriate, did not catalyze the oligomerization 
to the same extent.  Figure 4.8 overlays based on EKO for two benzyl-protected target 
compounds (one protein removed and only protein-binding partner remains).  To explain 
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why DDD-1as’f is more active than the deprotected form we propose that the side-chain 
benzyl (shown as a red sphere in 4.8a) precludes the dimer protein conformation via a 
clash with the strand-helix motif shown on the right of that graphic.  In support of this, 
literature observations indicate disruption of that region may promote unfolding in the 
oligomerization process (based on α-antithrombin mutagenesis experiments).130  Figure 
4.8b suggests the binding of LLD-1lat’ may be favored by placing the side-chain benzyl 
in a hydrophobic pocket. 
 
 
Figure 4.8.  Proposed binding modes based on EKO analyses.  a DDD-1as’f; and, b 
LLD-1lat’.   
 
extra benzyl group 
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a  DDD-1as'f
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Figure 4.8.  Continued.   
 
Sheet and strand mimics have been reported in the literature,60,131-135 but, to the 
best of our knowledge, no small molecules have been reported to perturb the 
oligomerization of α-antithrombin.  One report described small molecules that perturb 
oligomerization of another serpin, a mutant of α1-antitrypsin or “Z α1-antitrypsin”,117 
but this was discovered via virtual screening of molecules to fit in a cavity; molecules 
docking with that site appear to cause an allosteric interaction.136 However, 
hydrophobic 
pocket
hydrophobic 
pocket
b  LLD-1lat'
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corresponding cavity is not present at the α-antithrombin PPI interface,136 so exactly the 
same type of allosteric interaction is impossible for this protein.  Unfortunately, 
elucidation of the protein regions where the small molecules impact would be hard due 
to the transient nature of the binding, and the heterogeneous mixture of proteins formed 
in α-antithrombin oligomerization; consequently, catalysis of oligomerization via 
docking of the probes with an allosteric site not at the PPI interface cannot be ruled out 
at this stage.  However, perturbation of serpin oligomerization via compounds that act at 
the PPI interface is possible since peptides based on this region have that effect,137 
including ones that impact Z α1-antitrypsin138,139 or α-antithrombin.140,141   
The EKO strategy applied in this study led to compounds that promoted the 
oligomerization of α-antithrombin.  EKO has no provision to determine what the 
biochemical effects of disrupting a particular PPI may be; in the event the perturbation 
here promoted α-antithrombin oligomerization. 
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CHAPTER V  
CYCLIC PEPTIDES AS TURN MIMICS 
 
5.1 Introduction 
Cyclization of linear peptides increases their proteolytic stabilities and rigidities.   
In ideal cases these structures will adopt only one preferred conformation; if that occurs, 
less entropy will be surrendered on interaction with biomolecular receptors, increasing 
the free energies for the interactions.  Observation of a strongly preferred conformation 
in solution also makes it probable that the molecule will bind to the receptor in a similar 
conformation, compared to other situations in which the compound exists in several 
solution conformations.  Moreover, exclusion of competing conformational states 
reduces possibilities for off-target binding.  In the context of our studies on EKO, hits 
from conformationally rigid hits are potentially more interesting than hits from more 
flexible compounds because the entropy of binding is more favorable.  Moreover, cyclic 
peptides are routinely made via solid phase methods, and, after laboring to prepare 
oligopiperidine-pyrrolidionone chemotypes, we realized how critical convenience 
synthetic accessibility is. 
Inconveniently, cyclic peptides composed of the 20 genetically encoded amino 
acids miss a “sweet spot” ring size where conformational homogeneity is attained 
without compromising ease of syntheses.  By this we mean, cyclic tri-142-145 A and tetra-
peptides B146-152 are notoriously difficult to prepare because they are constrained in 9- 
and 12-membered ring conformations.  Analogs of cyclic tetrapeptides, like the 12-
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membered ring system C, may be more easily prepared but another problem arises: 
cis/trans amide bond equilibria introduces conformational heterogeneity.153  Cyclic 
pentapeptides,154-156 are easier to make than cyclic tri- or tetrapeptides157 because their 
15-membered rings are less strained, but they tend to equilibrate between conformers 
D1–5 containing β- and γ-turns.  Certain states in the D1–5 equilibrium can be favored if 
one of the amino acids has a D-configuration, especially D-Pro,158 but most cyclic 
pentapeptides and higher homologs overall do not tend to be rigid unless further 
constrained.159,160  
 
Figure 5.1.  Representative previously reported cyclic peptide systems.  a 12-Membered 
ring peptidic systems (eg cyclic tetrapeptides) are highly constrained and their 
conformations may be complicated by cis-trans isomerism.  b Cyclic pentapeptides tend 
to equilibrate between similar states containing both γ and β-turns, ie they tend to be 
conformationally heterogeneous.  c 13-Membered rings may give only one preferred 
conformer (eg E - G) but this issue has not previously been studied for systems 
containing the Anth residue (eg for H and I). 
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Figure 5.1.  Continued. 
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Figure 5.1.  Continued. 
 
Based on the observations above, there should be favored ring sizes in 
peptidomimetic design where non-genetically encoded residues replace one amino acid 
to give conformationally rigid 13- or 14-membered rings.  Ghadiri and co-workers, for 
instance,161,162 have used copper-mediated azide-alkyne cycloadditions to give the 13-
membered rings E which were conformationally rigid.163  In other illustrative work, 
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Fairlie et al substituted β-amino acids into cyclic tetrapeptides and found some 13-
membered ring systems, including F164 and G165, that could be prepared efficiently, and 
were conformationally rigid.  However, that same work showed similar, but 
conformationally heterogeneous, 13-membered ring systems.165 
Anthranilic acid is readily available and more rigid than most other β-amino 
acids.  Several peptidic macrocycles containing anthranilic acid occur in Nature, most 
where this unit is one of five in a pentapeptide ring.166-179  There are also numerous 
examples of similar hexapeptides and higher homologs incorporating anthranilic 
acid,166,180-186 a few 10-membered tripeptide derivatives187-189 and several cyclic systems 
containing the “Anth” residue and another non-encoded amino acid.190-192  However, 13-
membered ring systems containing this ubiquitous residue have been under-explored.  
Only one natural tetrapeptide H that features Anth in a 13-membered ring has been 
discovered,193 and the only 13-membered cyclic peptide containing Anth that has been 
synthesized is compound I, prepared as part of a medicinal chemistry project.194  To the 
best of our knowledge, neither H nor I have been studied in solution to determine their 
conformational biases.  
We hypothesized compounds 1 (Figure 5.2) could be prepared from readily 
available starting materials, and would be conformationally rigid. This chapter describes 
how those compounds were made, and the conformational biases of one complete set of 
enantiomers in this series.  In the event the conformations of these molecules were 
shown to correlate with their chiral amino acid stereochemistries in a logical, easily 
understood, way that is useful for predicting the preferred shapes of these rigid scaffolds. 
  78 
 
 
Figure 5.2.  The structure of designed constrained cyclic peptide. 
 
5.2 Syntheses of Cyclic Peptides via Iterative Precipitations 
Couplings to anthranilic acid are not facile because the aromatic amine is 
deactivated via resonance.  However, Scheme 5.1 describes how solution-phase 
syntheses of several compounds were achieved using a large excess of Anth and a high 
concentration of all agents; if high concentrations were not used then epimerization was 
competitive with product formation.  Use of a relatively weak base (N-methyl 
morpholine) and of the superior, though more expensive, carrier agent HOAt,80 was also 
beneficial in this step. 
Early in this study we realized the physiochemical properties of peptides 
containing anthranilic acid facilitated their isolation.  Thus, coupling three amino acids 
to the Anth unit gave products that precipitated from dichloromethane/hexanes with 
sufficient purities to use in the next steps.  In fact, the only chromatography needed in 
the “Boc-approach” to the cyclic systems shown in Scheme 5.1 was to isolate the 
cyclized product.  Serine and tyrosine residues in the compounds prepared were 
protected with benzyl groups.  Glutamic acid side-chain protection was achieved using a 
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tert-butyl ester, which withstands selective deprotection of the N-Boc functionality with 
4M HCl.195 
 
Scheme 5.1.  Boc approach to products 1. 
 
 
 
 
 
Scheme 5.2 shows a similar solution-phase approach to the same types of 
products but using Cbz protected amino acids and Nα-deprotection via hydrogenolysis.  
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deprotection under acidic conditions, as in Scheme 1, might have eroded the yield of this 
COOMe
NH2
COOMe
NH
O
R3
NHBoc
73 - 91 %
no racemization
Boc-AA-OH
EDC, HOAt, NMM, CH2Cl2
(i) TFA/CH2Cl2
(ii) Boc-AA-OH, EDC
HOBt, DIPEA, CH2Cl2
(iii) TFA/CH2Cl2
COOMe
NH
O
R3
N
H
O
R2
NH2
Boc-AA-OH
EDC, HOBt, DIPEA
 CH2Cl2
COOMe
NH
O
R3
N
H
O
R2
H
N
O
R1
NHBoc (i) LiOH, THF/H2O
(ii) 4 M HCl, dioxane
70 - 90 % over four steps
COOH
NH
O
R3
N
H
O
R2
H
N
O
R1
NH2
EDC, HOAt, NMM
2 mM in CH2Cl2/DMF
NH
O
R3
N
H
O
R2
HN
O
H
N
R1O
cyclo-LAla-LAla-LPhe-Anth, 41 %
cyclo-DAla-LAla-LPhe-Anth, 55 %
cyclo-LAla-DAla-LPhe-Anth, 48 %
cyclo-DAla-DAla-LPhe-Anth, 44 %
cyclo-DGlu'-DAla-LPhe-Anth, 35 % 
cyclo-LVal-LSer'-LTyr'-Anth, 45 %
cyclo-DTyr'-DSer'-DVal-Anth, 31 %
NH
O
R3
N
H
O
R2
HN
O
H
N
R1O
Pd/C/H2 
MeOH
cyclo-LVal-LSer-LTyr-Anth, 87 %
  80 
product, but N-deprotection via hydrogenolysis circumvented this potential problem.   A 
complementary solid phase Fmoc-approach was also established (Scheme 5.3), based on 
2-chloro-trityl polystyrene resin and involves cleavage from the support then cyclization 
in the final step.  
 
Scheme 5.2.  Cbz approach to products 1. 
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Scheme 5.3.  Fmoc approach to products 1. 
 
 
 
 
5.3 Conformational Analyses 
One goal in this study was to elucidate the intrinsic conformational biases of the 
stereoisomeric scaffolds 1 with minimal perturbation from side-chain interactions.  The 
ideal system to study might have been the simple peptide 1aaa (or cyclo-
AlaAlaAlaAnth).  However, there was insufficient dispersion of the 1H NMR peaks in 
that particular compound to facilitate convenient conformational analyses.  
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conformations on the NMR time-scale, and that in solution each exists predominantly in 
one form.  Temperature coefficient data196,197 and rates of H/D exchange198,199 were also 
measured.  Neither set of data were particularly informative, except that they indicate 
there are no “endo-cyclic” H-bonds, consistent with the conformations deduced from 
NMR and calculations that are described immediately below.  NOE data were collected 
for all the compounds, and no cis-amide bonds were present (CαH – CαH cross-peaks 
absent). 
 
Table 5.1.  Comparison of experimentally observed 3JNH-α coupling constants with those 
calculated using the NMR constrained structures simulated in Figure 5.3b. 
 
 Ala(R1)  Ala(R2)  Phe (R3) 
 exp’l a  calc.b  exp’l a calc.b  exp’l a calc.b 
LLL 5.0 6.2-6.7  - 7.8-8.3  7.0 6.5-7.8 
DLL 7.7 7.6-8.2  8.9 6.6-7.9  7.9 8.0-9.0 
LDL 7.2 6.8-8.0  8.8 7.9-8.9  7.7 6.9-8.1 
DDL 5.2 5.6-6.3  - 6.6-7.1  5.6 6.6-7.1 
 
a Directly from NMR spectra.  b Based on the structures simulated from the NOE data, 
and calculated using the Poulson form of the Karplus equation.200 
 
Two methods were used to deduce the predominant conformations of compounds 
1 in polar solvents.  First, the molecules 1aaa were simulated in a medium of dielectric 
46.7 representing DMSO (and 80 representing water, see supporting) using the quenched 
molecular dynamics (QMD) technique.75,76 QMD simulations are valuable because they 
are not bias by NOE data which over-represents some conformations because the NOE 
effect depends on 1/r6 distance relationships.201 Moreover, QMD thoroughly explores 
possible local minima in a Boltzmann equilibrium. Second, and independently, NOE 
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restraints were applied in a Macromodel202 simulation of molecules 1aaf in dielectric 
46.7.  
One conformational cluster (maximum RMSD of the Cα – Cβ coordinates 0.5 Å) 
arose from the QMD simulations of each of the 1aaa stereoisomers, Figure 5.3a (QMD 
simulated scaffold conformations are shown in black throughout this chapter).  The fact 
that >1000 conformers (all below 3 kcal•mol-1 of the lowest energy one identified) all 
converged to one cluster emphatically indicates conformational rigidity. Comparison of 
the QMD-generated structures with the NOE data showed they are consistent.  Similarly, 
the MacroModel simulations with NMR constraints also gave one predominant 
conformation for each 1aaf stereoisomer, Figure 5.3b (MacroModel simulated scaffold 
conformations involving NOE constraints are grey throughout).  None of the 3JNH-α 
coupling constants were above 9 Hz (see Table 5.1); only couplings >9 Hz are indicative 
of unambiguous calculated dihedral angles, hence none were used as constraints in the 
MacroModel calculations. 
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Figure 5.3.  Conformations simulated by QMD and NMR conformations.  a QMD 
calculations for 1aaa stereomers without NOE constraints; and, b MacroModel for 1aaf 
stereomers with NOE constraints.  The blue arrows approximate the orientation of the 
NH bond vectors to either pointing up or below the ring system. 
  
LLL DLL
a
LDL DDL
LLL DLL
b
LDL DDL
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Overlays of the conformations generated using the approaches described above, 
ie without and with NOE constraints, showed close agreement (RMSD 0.18 – 0.34 Å for 
the Cα – Cβ coordinates; Figure 5.4).  Moreover, even though the fit of these overlays 
was based on Cα – Cβ vectors, it is clear that the ring structures also are very similar.  
 
 
 
 
 
Figure 5.4.  Overlays of 1 simulated structures without (black, 1aaa) and with (grey, 
1aaf) NOE constraints are within 0.18 – 0.34 Å based on 6 coordinates. 
  
RMSD 0.20 Å RMSD 0.24 Å
LLL DLL
LDL DDL
RMSD  0.18 Å RMSD  0.34 Å
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Comparisons of favored conformations for stereomers of 1 revealed a simple 
correlation.  When drawn with the ring on the equator, and the Anth residue on the West, 
then L-amino acids point their N-H vectors South, while N-H vectors for D-amino acids 
are North-oriented, irrespective of the other amino acid stereochemistries.  Thus the 
cyclic 13-membered ring scaffold is constrained to one highly predictable conformation 
per stereoisomer.  This observation held for all the compounds prepared in this study 
based on similarities in NOE cross-peaks, ie for cyclo-DGlu'-DAla-LPhe-Anth, cyclo-
LVal-LSer'-LTyr'-Anth, cyclo-DTyr'-DSer'-DVal-Anth, cyclo-LVal-LSer-LTyr-Anth, 
cyclo-LPhe-DAla-LPhe-Anth, cyclo-DPhe-LAla-LGlu'-Anth, cyclo-DPhe-LAla-LGlu-
Anth (see Appendix E); those observations imply the conformations are governed by the 
scaffold and the side-chain variables are less significant. 
 
 
 
 
Figure 5.5.  “North south orientations” of the amide N-H vectors in stereomers of 1 
correlate with the amino acid configurations.  L-Amino acid N-H vectors point South, 
and while the D-isomers give North-aligned local N-H vector orientations, when drawn 
in the orientations shown.  
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Table 5.1 compares NH-CαH coupling constants directly from NMR spectra 
with those calculated from the MacroModel simulations involving NOE constraints.  In 
some cases the coupling was obscured, and in several cases the true J-values were 
marginally (by 1.2 Hz at most) outside the calculated range, but the rest were consistent 
with the values inferred from simulations.  
Circular dichroism (CD) data for the 1aaf stereomers are shown in Figure 5.6 
(solid lines).  Unsurprisingly, significantly greater molar elipticities were observed for 
these compounds compared with related linear peptides (dotted lines), indicative of more 
conformational ordering in the cyclic systems.  Moreover, there are logical trends in the 
data.  For instance, the LLL-1aaf stereomer (red line) has minima at ca 195 and 215, and 
a maximum at ca 230 nm.  Substitution of two L-amino acids in LLL-1aaf giving DDL-
1aaf is accompanied by near complete inversion of the CD maxima and minima.  The 
two possible “intermediate” diastereomers, ie DLL-1aaf and LDL-1aaf, in which only 
one L-amino acid of LLL-1aaf is replaced, show shallower peak intensities.  The CD 
spectrum of DLL-1aaf (green) is more closely related to that for LLL-1aaf (red) than it is 
to DDL-1aaf (purple), whereas for LDL-1aaf (blue) the inverse is true; this implies the 
amino acid opposite the Anth residue in the cyclic scaffold has a more profound effect on 
the molar elipticity. 
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Figure 5.6.  CD spectra of compounds 1aaf (solid lines) and closely related linear 
peptides (dashed lines). 
 
5.4 Comparisons of the Anth-Cyclic Peptidomimetics with Peptide and Protein 
Structures  
Exploring key orientations on secondary structures (EKOS)57 facilitates 
comparison of all the favored QMD simulated conformers with all the common ideal 
secondary structures based on Cα – Cβ coordinates.  For 1aaf there was only one 
preferred conformer cluster for each stereomer.  Not surprisingly, then, most stereomers 
matched on only one secondary structure, or none at all, ie they are not universal 
peptidomimetics.46,47  One apparent exception was LLL-1aaf which gave an acceptable 
fit on γ- and type II β-turn conformations (Figure 5.7); however, γ- and type II β-turn 
conformations have similar side-chain orientations that overlay well on each other.  An 
LLL-1aaf
DLL-1aaf
LDL-1aaf
DDL-1aaf
LLL-aaf
DLL-aaf
LDL-aaf
DDL-aaf
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inverse γ-turn matched reasonably well with LDL-1aaf, and DLL-1aaf overlaid closely 
with a type I β-turn. 
 
 
Figure 5.7.  Preferred conformations of select stereoisomers of 1aaf overlaid on γ-, 
inverse γ-, type I β-, and type II β-turns.  RMSD values indicated are for overlay of the 
side-chain Cα – Cβ vectors. 
 
Whereas, Figure 5.7 depicts preferred overlays of select 1aaf stereoisomers on 
ideal secondary structures, the EKO routine58 facilitates matching QMD generated 
overlay on γ-turn
RMSD 0.56 Å
LLL LDL
overlay on inverse γ-turn
RMSD 0.62 Å
overlay on type I  β-turn
RMSD 0.37 Å
overlay on type II  β-turn
RMSD 0.41 Å
DLL LLL
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structures of 1aaa with crystallized protein-protein interaction interfaces based on Cα – 
Cβ coordinates.  Thus, preferred conformations of each stereomer were compared with 
around 160,000 protein-protein interfaces, and each match of RMSD <0.3 Å was 
analyzed in terms of what secondary structure type at the interface was implicated in the 
overlay.  There were between 106 - 258 matches of <0.3 Å RMSD for each stereomer.  
The term “no secondary structure” is used here to describe situations in which the region 
overlaid did not contain any discernable secondary structure.  “Turns” refers to a turn of 
any type (α, β, γ, δ) that has appropriate intrachain hydrogen bonds, while loops and 
turns without any intra-ring H-bonding interactions are classified as “bends”.  Figure 5.8 
shows the distribution of overlays within those categories and some other secondary 
structures.  Thus the preferred 1aaa conformations are strongly bias towards turns and 
bends, consistent with the EKOS study presented in Figure 5.7.  
 
 
Figure 5.8.  Distribution of best overlays on PPI interface segments with respect to 
secondary structure for the stereomers featured in Figure 5.7. 
310 helix
LLL
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Figure 5.8.  Continued. 
 
Finer detail of the secondary structure types that were overlaid in the EKO 
analysis of PPIs in the PDB is indicated by φ,ψ-angles, indicative of the type of 
secondary structure implicated.  Figure 5.9 shows select data for the stereomers featured 
in Figure 5.7.  Thus, the number of occurrences where LLL-1aaa, LDL-1aaa, and DLL-
310 helix
LDL
310 helix
DLL
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1aaa overlaid closely with γ-turns, type I β-turns, inverse γ- and type II β-turn 
conformations are consistent with the favored conformations predicted in Figure 5.7.  
 
 
 
Figure 5.9.  Each dot on these plots is associated with a φ,ψ-bond vector of a protein 
interface region that overlaid closely with a preferred conformer of the 1aaa stereomer 
indicated. 
 
γ-turn
β-turn (II, i+2)
LLL
inverse γ-turn
LDL
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Figure 5.9.  Continued. 
 
5.5 Physiochemical Properties 
HPLC was used to monitor the stability of LLL-1aaf under aqueous conditions of 
pH 2,7, and 12, and, in separate experiments, the mixture of proteases called Pronase203 
that is used to extensively hydrolyze proteins in proteomics studies (any amide between 
two hydrophobic residues could be cleaved by this enzyme mixture). 
  
β-turn (I, i+2)
DLL
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Table 5.2.  Stabilities of LLL-1aaf under different pH conditions. 
 
 conditions t1/2 / h 
pH stability of LLL-1aaf 
pH 2.0a >500 
pH 12.0b 240 
pH 7.4c >500 
LLL-1aaf 
linear LLL-aaf 
Pronasec no cleavage after 12 h 
Pronasec 1.5 
 
a 10 mM HCl, b 10 mM NaOH, c PBS buffer. 20 % MeOH was added in all cases to 
increase solubilities. 
 
 
Figure 5.10 shows data calculated (QikProp)204,205 for the polar surface area 
(PSA) and cell permeability of LLL-1aaf.  The implications of this data are that LLL-
1aaf has less PSA and a higher tendency to permeate into cells than closely related linear 
peptide controls.  Polar surface areas <140 Å2 are generally preferable for cell 
permeability.206 Similarly, compounds with predicted PCaco-2 permeability rates >20 
nm/s are usually cell permeable; data calculated for LLL-1aaf exceeds both expectations, 
and predict cell permeability.   
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Figure 5.10.  Comparison of PSA (blue) and predicted Caco-2 cell permeabilities (red) 
for linear peptides based on aaf and a featured cyclic molecule 1aaf. 
 
5.6 Conclusions 
The Anth containing peptides featured in this study have a greater tendency 
towards conformational homogeneity than systems based on other β-amino acids related 
to F and G.165  In view of this, and other observations outlined in the introduction, we 
suggest 13-membered systems based on the Anth residue are at a favorable point on the 
crossroads between ease of synthesis and conformational rigidity.   
Predictability of conformational preferences for a set of cyclic peptidomimetics 
is an attractive feature of the systems studied here.  It is possible that different side-
chains to the ones in 1aaf could perturb the predicted conformations, and this study does 
not encompass the special case of systems that contain Pro- or Gly-.  Nevertheless, the 
data above clearly indicates strong intrinsic conformational biases of the scaffolds based 
on other amino acids.   Moreover, stereochemistries of the scaffolds can be manipulated 
so that they orient their side-chains in ways that resemble the same orientation for 
regular and inverse γ-turns, and for the two most common β-turns (types I and II).  
H-aaf-OH Ac-aaf-OH H-aaf-OMe Ac-aaf-OMe LLL-1aaf
polar surface area (PSA)
predicted Caco-2 cell permeability
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Consistent with this, conformations of 1aaa stereomers have a pronounced tendency to 
orient side-chains in ways that some turns and bends do at PPI interfaces.  Overall, while 
tens of naturally occurring cyclic peptides containing Anth have been discovered, the 
potential of this simple residue in designs of conformationally rigid protein interface 
mimics has hitherto been under-appreciated. 
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CHAPTER VI 
EVALUATING MINIMALIST MIMICS WITH EXPLORING KEY 
ORIENTATIONS ON SECONDARY STRUCTURES* 
 
6.1 Introduction 
Semi-rigid scaffolds that express amino acid side-chains are interesting 
chemotypes because these “minimalist mimics”47 of secondary structure motifs have the 
potential to disrupt protein-protein interactions (PPIs).  They have this potential because 
PPI interfaces are dominated by side-chain to side-chain contacts48 hence semi-rigid 
small molecules that project side-chains in similar orientations to one protein component 
might competitively interact with the protein-binding partner.  Minimalist mimics do not 
have peptidic polyamide backbones so they are not degraded by proteases and tend to 
have improved cell- and oral-bioavailabilities relative to peptides.207   
Chronologically, scaffolds 1,208-210 2,211 3,212-214 4,215,216 5,217 6,218 7,45 and 8219 
(Figure 6.1) were reported as mimics of helical secondary structures, and are typical of 
ones in the literature.44,220 Our interest in the concept of “universal mimics”, wherein 
several secondary structures are represented in one conformational ensemble,46 led us to 
wonder if scaffolds that had been described only as α-helical mimics might also be able 
to access conformers that match other secondary structures.  None of the α-helical 
                                                
*Reproduced in part from “Evaluating Minimalist Mimics by Exploring Key 
Orientations on Secondary Structures (EKOS)”, Dongyue Xin, Eunhwa Ko, Lisa M. 
Perez, Thomas R. Ioerger and Kevin Burgess, Org. Biomol. Chem. 2013, 11, 7789-7801. 
Copyright 2013 The Royal Society of Chemistry. 
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mimics 1 – 8 have been claimed to orient side-chains in ways that resemble the less 
common 310- and π-helical motifs, but it seemed possible that they could at least do this.  
Moreover, there is another important issue that it is convenient to refer to here as side-
chain correspondence; by this we mean the particular side-chains in a secondary 
structure that best overlay on an accessible conformation of a minimalist mimic.  For 
instance, a scaffold that rigidly presents side-chains in an i, i+4, i+7 orientation has that 
side-chain correspondence, whereas it might be unsuitable as a mimic of i, i+3, i+4 
helical motifs because this is a different side-chain correspondence.  When evaluating 
molecules to perturb different protein-protein interfaces it is at least highly desirable, and 
probably essential, to have a selection of mimics that cover a range of possible side-
chain correspondences, and it is important to understand what these are for a given 
mimic.  Of course, the community working in this area is well aware of the need to use 
the correct side-chain correspondences, but there is no rigorous, systematic approach to 
assessing what they are for a particular minimalist mimic.  
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Figure 6.1.  Helical mimics featured in this chapter. 
 
After a side-chain correspondence has been determined, there needs to be a 
standard parameter to gauge how each minimalist helical mimics fits on that particular 
side-chain combination.  For instance, if two mimics orient i, i+3, i+7 side-chains in an 
ideal α-helical conformation, which one does it most closely?  What are the best 
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minimalist mimics to present side-chains in i, i+3, i+4 and i, i+4, i+7 orientations 
corresponding to an ideal 310 helix?  Questions like these are difficult to answer using 
the approaches that have been employed in the literature so far; currently there is no 
widely accepted method to evaluate the bias of a given scaffold toward a particular 
conformation.  One objective of this chapter is to propose a strategy that is applicable to 
this issue. 
Several experimental methods have been applied in the context of elaborating 
equilibrating conformations of minimalist mimics in solution, but none of them, or any 
combination of them, are suitable for determining the side-chain correspondences and 
goodness of fit of helical mimics.  Broadly speaking these are methods to observe the 
mimics in solution (eg NMR and CD), and crystallography. 
Arora’s study of helical mimic 745 illustrates what direct spectroscopic evidence 
can be collected to characterize equilibrating conformational states of a minimalist 
mimic in solution.  Circular dichroism (CD) of the molecules 7 in methanol and in 
acetonitrile had a similar shape to ones for peptide helices, but the minima were red-
shifted by 10 nm.  NOE experiments were conducted on one compound (actually, in 
CDCl3), and cross peaks that correspond to the trans-isomer, but not the cis-one, were 
observed.  However, in solution, minimalist mimics exist as rapidly equilibrating 
conformational states for which CD and NOE data are averaged.  In NMR, NOE cross 
peaks over-represent close contacts relative to distal ones because of the inverse six-
power distance relationship; consequently, poorly populated states can appear to be more 
abundant than prevalent ones.  Moreover, some NOE cross peaks for molecules of 
  101 
approximately this molecular mass can be vanishingly small, so absence of cross peaks 
does not prove that the corresponding conformation is unpopulated; ROESY spectra can 
help with this, but they have to be carefully calibrated to the properties of the 
molecule.221,222 In any case, minimalist mimics definitely have multiple conformations, 
so it is very difficult to unravel which sets of NOE crosspeaks, or CD elipticities, are 
associated with individual ones. Consequently, none of the techniques often used53,214,223 
give detailed information on the ensemble of preferred conformations in solution. 
Researchers often turn to crystallography to elucidate conformations of 
minimalist mimics.  Crystallography reveals only a few conformations at best, and these 
may not be representative of favored ones in solution because of crystal packing forces.  
Nevertheless, crystallography may provide circumstantial evidence that desired solution 
states can be accessed, and this type of conclusion is most convincing when molecules 
crystallize in a conformation that is anticipated to be strongly preferred in solution.    
This is true of the benzamide mimics 3 and 6 where H-bonding between the amide-NH 
and the 2-methoxy substituent is expected to disfavor rotation about the aryl-NH bond, 
and X-ray structures show this.224,225   Similarly, an X-ray crystal structure of one of 
Hamilton’s terphenyls was obtained to reveal a relevant solid state conformation.210  
However, minimalist mimics sometimes crystallize in conformations that are not 
relevant for secondary structure mimicry.  Single crystal X-ray studies reported in a 
recent contribution from Hamilton, for example, describe how a scaffold that is 
putatively a sheet mimic in solution crystallizes in some other conformation.55  In 
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summary, crystallography does not characterize rapidly equilibrating conformational 
ensembles of minimalist mimics in solution. 
Given that there seems to be no experimental strategy to characterize 
equilibrating conformations of minimalist mimics in solution, researchers often turn to 
calculations.  Hamiliton’s terphenyls 1 were originally conceived to match i, i+3, i+7 
side-chains on an ideal α-helix (though he has used it as an i, i+4, i+7 mimic on some 
actual helices in PPIs).208,210  To validate that design his group used Still’s 
Macromodel202 to simulate some of the preferred trimethyl-substituted terphenyl 
conformers, and focused on an accessible state that had similar angular projections to the 
i, i+3, i+7 side-chains of an ideal (all-Ala) α-helix.  Incidentally, it is relevant to what 
follows in this work that they observed their simulated structure had 4 – 25 % shorter 
distances than was optimal, and that the root mean square deviation (RMSD) of the 
overlay based on Cα - Cβ coordinates was 0.85 Å.210  Similarly, Arora’s hypothesis for 
α-helical mimicry by 7 is based on modeling of that scaffold using Macromodel (MMFF 
force field in chloroform).  In both the Arora and Hamilton work, the existence of one 
preferred helical conformer supports the assertion that the scaffold is an α-helical 
mimic,226 but this does not comment on the other equilibrating conformations in 
solution.  In other work, researchers have used molecular dynamics simulations on 
mimics 3 to determine if and how these molecules might bind a groove in the p53 
protein that recognizes a helical motif on MDM2,227 and for the free mimic in water.228 
These studies were not performed with the objective of simulating the ensemble of 
preferred conformers but instead were used to search for one desired conformer.  All 
  103 
these approaches are intended to find particular conformations of putative helical 
mimics.  Such computational strategies sample multiple conformations, but only select 
certain favored states for analyses.   
Near the beginning of this introduction, three important parameters were outlined 
for evaluating how minimalist mimics can match ideal secondary structures.  Essentially 
these involve considering every accessible member of a representative conformational 
ensemble for: (i) overlay of conformers on various secondary structures; (ii) side-chain 
correspondences; and, (iii) goodness of fit.   Conveniently, scaffolds 1 – 8 are relatively 
rigid, so the calculated bond lengths and angles for each particular conformation are 
likely to be reliable relative to more complex and flexible structures (eg peptides); in 
other words, simulated conformers of these molecules tend to be quite realistic.  
However, it is important to recognize the importance of generating and considering a 
large set of conformers for these molecules; this is because conformers that are quite 
similar can project side-chains in significantly different ways.  For example, sampling a 
360° aryl-aryl rotation in terphenyls 1 in 1° increments gives a continuum of 360 states, 
most of which are accessible at room temperature in solution.  Within that group of 
conformers, a difference of only a few degrees in the torsion angle will give significantly 
different side-chain orientations. Consequently, for the purposes of this work, where 
most of the accessible side-chain orientations should be considered, it is important to 
avoid computational approaches that minimize and cluster accessible conformations into 
families representing local minima.  Methods based on Monte Carlo or molecular 
dynamics with simulated annealing would be inappropriate here.  In summary, 
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minimizing routines that cause conformations to converge on local minima are 
unsuitable for simulating conformational ensembles of minimalist mimics. 
A representative conformational ensemble for a minimalist mimic might involve 
hundreds of conformations, all of which are significantly populated, ie within, for 
instance, 3 kcal/mol of the minimum energy conformer located.  It is necessary to match 
each of those conformations on every three amino acid side-chain combination in every 
common secondary structure to characterize how a minimalist mimics fits, ie to evaluate 
the three parameters that reveal how minimalist mimics can match ideal secondary 
structures; this is a data mining problem rather than a modeling issue.  It requires 
specialized algorithms similar to those we already developed for Exploring Key 
Orientations (EKO) in protein-protein interactions.58 
On the basis of the considerations outlined above, we devised a strategy to 
evaluate how accessible conformations of minimalist mimics match a collection of 
idealized secondary structures.  This strategy consist of the following steps: 
i. use quenched molecular dynamics (QMD) to generate an ensemble consisting of 
hundreds of accessible, low energy conformers of the mimics; 
ii. represent each of these as a set of Cα and Cβ coordinates corresponding to three 
amino acid side-chains displayed by the scaffolds; 
iii. represent each combination of three side-chains in each ideal secondary structure 
as a set of Cα and Cβ coordinates corresponding to three amino acid side-chains 
displayed by the scaffolds; and,  
iv. overlay Cα and Cβ coordinates of all the conformers on all the sets of side-chain 
“triads” in the ideal secondary structures and express their goodness of fit in 
terms of root mean squared deviation (RMSD, Å) for each overlay.  
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The strategy outlined above is different to the EKO process58 which explores key 
orientations at protein-protein interfaces and is not concerned with secondary structure 
classifications.  However, the strategy outlined here is similarly motivated and facilitated 
by the process of data mining a conformational ensemble on target structures, so we 
refer to it as Exploring Key Orientations on Secondary structures (EKOS).  To the best 
of our knowledge, it is fundamentally different to any computational approach that has 
been applied to evaluate minimalist mimics to date. EKOS has the considerable 
advantage that every accessible conformer in large conformational ensemble is evaluated 
on every side-chain triad in every secondary structure, and the results are systematically 
ranked in terms of goodness of fit. 
In this chapter, we focus on the α-helical mimics 1 – 8 using EKOS to enable 
quantitative evaluations of solution state structures that are not conveniently possible via 
spectroscopy or other methods.229  Smith’s β-sheet scaffold 9,230 and an interface mimic 
10 developed on our laboratory62 were used as “controls” in this study. (Figure 6.2)  
Scaffold 10 has already been shown to analog several secondary structures with a bias 
towards β-sheets and, relatively speaking, no notable inclination to mimic helical 
structures.  
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Figure 6.2.  Smith’s β-sheet 9 and oligo-pyrrolidine-pyrrolidinone 10. 
 
Throughout these discussions it is important to remember that helical mimicry is 
only a means to an end: to use these compounds to displace a protein or peptide that has 
a helical conformation at a PPI interface.  In specific applications of this kind, mimicry 
of ideal helices is less important than matching the actual helical structure at the 
interface, which can be distorted and non-ideal.  Consequently, even though this study is 
primarily about evaluating ideal helical mimics in general, we have also used EKO to 
compare the accessible conformations of the helical mimics with helical structures in 
some of the PPIs that have been perturbed using these mimics.  The objective of that part 
of the study was to ascertain how well scaffolds 1 – 8 may fit on some well-studied 
helices in PPIs and compare this with the data for ideal helical mimics.  
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6.2 Bases for Comparison: Ideal Secondary Structures and How to Compare Them 
Secondary structures at protein-protein interfaces are rarely ideal.  α-Helices, for 
instance, can be stretched, compressed, bent, kinked, and partially unwound.  In the 
minimalist mimic area, the most direct approach to designing a scaffold to specifically 
perturb a particular PPI is to match the secondary structures at that interface, including 
their distortions and other peculiarities.  However, it is often logical to begin the process 
of mimicking a real helical motif with the most closely related ideal helical mimic.  
Recognizing this, a significant proportion of the research community who work on 
minimalist helical mimics base their designs on ideal secondary structures without 
stating a target PPI; this strategy affords generally interesting data because they mimic 
ideal secondary structures representative of the most common states found in proteins.  
For the reasons stated above, we decided ideal secondary structures should be the focus 
of our analysis here.  However, the end of this chapter relates the findings to some 
helical mimics that have been shown to perturb specific PPIs.   
Amino acid Cα and Cβ coordinates are the best simple method for defining side-
chain orientations.  This is because setting a Cα - Cβ vector excludes many orientations 
of the “downstream” side-chain bonds; it would be inappropriate to use other side-chain 
vectors because Cβ - Cγ linkages and beyond are much less constrained.  Overlaying Cα 
and Cβ side-chain coordinates may be used to access goodness of fit of a conformational 
state on a secondary structure in terms of RMSDs.  This procedure has been used when 
applying Bartlett’s CAVEAT algorithm,231,232 Hamilton used it on his mimics of 
secondary structures,55,210 and we have used it extensively too.46,58,62   
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6.3 Method for Comparisons of Scaffold Conformations with Ideal Secondary 
Structures 
Preferred conformations of scaffolds that express only Cα and Cβ atoms, ie 
methyl substituted ones, show how the molecular core is biased to project amino acid 
side-chains.  Any conformational state of all-methyl-substituted compounds may be 
approximated to three Cα – Cβ vectors or six (3 × Cα + 3 × Cβ) coordinates to represent 
how that state projects side-chains.  Thus each conformation can be described in terms of 
irregular prismatic shapes formed by joining these coordinates (Figure 6.3).  Similarly, 
any set of three side-chains in an ideal secondary structure may be described in the same 
way.  
 
 
Figure 6.3.  Side-chain matching on secondary structures based on 3 x (Cα – Cβ) 
coordinates.  
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equilibration between conformers; this is not the case for scaffolds 1 – 8.  To evaluate 
the thermodynamically favorable conformational states, we used Pettit’s QMD 
procedure.75,76 Specifically, the scaffolds were minimized (molecular mechanics) then 
subjected to molecular dynamics at high temperature (1000 K) for 600 ps; 600 
conformational states were thereby recorded during this run (ie one every 1 ps).  These 
conformers were then minimized via molecular mechanics and all the simulated 
conformers within 3 kcal/mol of the most stable identified were considered.  Table 6.1 
shows that in this strategy the number of accessible conformers generated for each 
mimic was 282 or more, implying that motions about each significant degree of freedom 
were explored in small increments by this conformer set.  Thus all the accessible 
conformers generated in this way for each scaffold were systematically overlaid on 
every combination of side-chains in idealized secondary structures using procedures also 
used for the Exploring Key Orientations (EKO) approach as described.58   
 
Table 6.1.  Number of conformers below 3.0 kcalmol-1 for each mimic from QMD. 
 
mimic 1 2 3 4 5 6 7 8 9 10 
           
number of 
conformers 600 599 567 469 282 507 299 421 600 490 
 
The prime objective of this work was to ascertain the bias of semi-rigid scaffolds 
1 – 10 on secondary structures.  Consequently, the medium used for the simulations was 
a constant (featureless) one of dielectric 80, corresponding to an aqueous environment.  
Explicit water molecules were not used because they would be displaced as the small 
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molecule begins to interact with the protein-binding partner.  Similarly, interactions 
between specific extended side-chains (eg Glu-Lys salt bridges) also tend to be nullified 
if these are interface side-chains that dock with a protein-binding partner. Assessing all 
the various side-chain to side-chain interactions that could occur therefore is unimportant 
for this method, besides being impractical.  What is important is the conformational bias 
of semi-rigid scaffolds 1 – 10 with methyl side-chains, ie ones that reveal the intrinsic 
biases of the scaffolds.  
Mimics 2, 6 and 7 have four, not three, side-chains on the scaffold.  For 2 the 
three side-chains highlighted in red (Figure 6.1) were considered because these have 
different orientations to those in the terphenyl 1.  In 6 and 7 the side-chains chosen were 
two terminals and one internal because we estimated that combinations of this kind are 
most likely to resemble those on one face of a helix.  Selection of those side-chains for 7 
corresponds to the ones Arora originally used to generate overlays. 
Six common ideal secondary structures were chosen for the overlay process (310-, 
α-, and π-helices; β-strands; parallel- and antiparallel β-sheets).  Templates for ideal 
structures were obtained from Discovery Studio 2.5 (310-, α- and π-helices, and β-
strands) and modified β-sheet builder (www-lbit.iro.umontreal.ca/bBuilder/index.html; 
parallel- and antiparallel-β-sheet and sheet/turn/sheets).  Strand-turn-strand structures 
were also included, even though these are closely related to antiparallel β-sheets, 
because mimics 1 – 10 have extended structures that can simultaneously overlap with 
both the β-turn and β-sheet regions.  Figure 6.4 illustrates this, and is also intended to 
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show that mimics can achieve optimal goodness-of-fit by overlaying on one strand or by 
“lying across” two or more regions in a sheet. 
 
 
Figure 6.4.  Overlays considered in this chapter place mimics on secondary structures in 
any orientation. 
 
6.4 Comparisons of Scaffold Conformations with Ideal Secondary Structures 
Table 6.2 summarizes the lowest RMSDs obtained for fitting all the selected 
conformers for each mimic on ideal secondary structures.  These data are color coded to 
enable rapid evaluation of trends, but no absolute significance to the color distinctions is 
implied.  The one case that corresponded to an excellent fit is shaded in red, very good 
ones are shown in yellow, good ones are shown in green, and any “best-fit” with an 
RMSD of more than 0.70 Å is not shaded.  To the best of our knowledge, there are no 
prior literature reports of minimalist mimics overlaid on α-helical motifs with RMSDs 
less than 0.70 Å, so these arbitrary delineations of “excellent”, “very good”, and “good” 
fits are relatively stringent. 
Data in Table 6.2 are remarkable in several ways.  As a whole they indicate some 
putative α-helical mimics actually have conformers that resemble β-strands, parallel and 
sheet-
turn-
sheet
anti-
parallel
β-sheet
parallel
β-sheet
β-strand310-           α-             π-
helices
minimalist mimics may overlay in
different orientations
  112 
antiparallel β-sheets, and/or sheet-turn-sheets.  Mimic 8 had no conformers that match 
any of the three helical types at RMSD 0.70 Å or less, but did have ones that fitted well 
on extended, sheet-related, conformations. Similarly, mimic 7 was shown to be a 
significantly better strand-turn-strand analog than it was for any of the helices, and the 
only helical structure that matched well was the rarer π-form.  Hamiliton’s terphenyl 
mimic 1 gives better matches on 310- and π-helices than on the α-form, and overlaid 
unexpectedly well on a sheet-turn-sheet.  In fact, the only very good α-helical mimic in 
the series was oligobenzamide 3.  Based on this analysis, scaffolds 3 and 4 appear to 
have the most potential as “universal mimics”46 since they gave conformers that fit all 
six secondary structures well.  However, this comparison is not even because it treats 
scaffolds 3, 6, and 8 in a different way to the others, for the reasons described below. 
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Table 6.2.  Matching preferred conformations of scaffolds on ideal secondary 
structuresa. 
 
 310-helix α-helix π-helix β-strand 
β-sheet 
(parallel) 
β-sheet 
(anti-
parallel) 
sheet-
turn-
sheet 
        
1 0.65 0.71 0.59 - - - 0.58 
2 0.39 0.59 0.78 - 0.89 0.81 0.84 
3 0.30 0.31 0.47 0.70 0.58 0.43 0.43 
4 0.36 0.51 0.55 0.57 0.60 0.59 0.59 
5 0.60 0.51 0.55 - - - 0.54 
6 0.60 0.61 0.57 0.96 0.93 0.90 0.51 
7 0.81 0.72 0.51 1.05 0.89 0.95 0.36 
8 0.74 0.80 0.85 - 0.61 - 0.61 
9 0.82 0.79 0.91 0.65 0.41 0.69 0.44 
10 0.58 0.78 0.63 0.73 0.42 0.55 0.46 
 
a RMSD ≤ 0.30 Å, red background; 0.31 - 0.50 Å, yellow; 0.51 - 0.70 Å, green.  RMSDs 
of over 1.1 Å are not shown. 
 
The bonds highlighted in red Figure 6.1 are the ones that the original researchers 
used to overlay with Cα - Cβ vectors.  However, the highlighted bonds for mimics 1, 2, 
4, 5, 7, 9 and 10 are directly attached to the scaffold, but those for templates 3, 6, and 8 
are not; at least one vector in the latter group of structures is one bond removed from the 
core.  Thus the highlighted bonds in 3, 6, and 8 are closer to Cβ and Cγ atoms in a side-
chain than to Cα and Cβ's hence they are less constrained than those in the other mimics 
(illustrated for the oligobenzamide scaffold in Figure 6.5).  A consequence of assigning 
Cα and Cβ bonds in the original way for 3, 6, and 8 is that this covers more 
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conformational space than, for instance, structure 3’ that focuses on bonds adjacent the 
scaffold.  This issue is accentuated for 3 and 6 because all three side-chains are of this 
type, whereas only one side-chain is impacted for 8 (ie the one involving the exocyclic 
amine). 
 
 
 
Figure 6.5.  Original and revised Cα and Cβ assignments illustrated for mimic 3. 
 
As a result of the considerations above, conformational and matching analyses 
were repeated using structures 3’, 6’, and 8’ with Cα and Cβ assignments revised so that 
they correspond to vectors attached to the scaffold (Table 6.3).  Under these conditions, 
all the mimics fit somewhat less well on most secondary structures, but conformers of 
the oligobenzamide system 3’ gave an excellent fit on the ideal α-helix.  In fact, that was 
the best fit identified in this work for any mimic on any secondary structure.  
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Table 6.3.  Matching preferred scaffold conformations using revised Cα and Cβ 
assignmentsa. 
 
 310-helix α-helix π-helix β-strand β-sheet (parallel) 
β-sheet 
(anti-
parallel) 
sheet-
turn-
sheet 
        
3’ 0.33 0.25 0.36 0.66 0.41 0.39 0.40 
6’ 0.59 0.66 0.70 - - - 0.53 
8’ 0.99 0.79 0.71 0.88 0.40 0.95 0.40 
a RMSD ≤ 0.30 Å, red background; 0.31 - 0.50 Å, yellow; 0.51 - 0.70 Å, green. 
 
Figure 5a - d compares overlay data for the ten mimics for each of the three 
helical secondary structures, with an arbitrary 0.5 Å RMSD cutoff shown by a red line.  
Thus, for instance, Figure 6.6a shows conformers of 3, 4, and 2 overlaid well on an ideal 
310-helix relative to the other mimics; scaffold 3 gave the best overlay and this is shown 
on the right.  Only the oligobenzamide system 3 overlaid with an RMSD of < 0.5 Å on 
the ideal α-helix (6.6b), and the matching was improved when bonds adjacent the 
scaffold were considered (3’, 6.6c).  Similarly, mimic 3’ (and 3, overlay not shown but 
data in Table 6.2) gave the best overlays for the π-helix. 
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Figure 6.6.  Overlays of mimics 1 – 10 on ideal helical structures. The best match for 
each helical structure is shown on the right. 
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Figure 6.7 shows overlay data for the mimics on extended, sheet-like structures.  
There were no good (<0.5 Å RMSD) correspondences for the ideal β-strand (6.7a).  As 
expected, Smith’s sheet mimic 9 and the pyrrolinones-pyrrolidine oligomer 10 both gave 
preferred conformers that matched parallel β-sheets almost equally well (6.7b).  
However, contrary to expectations: (i) the putative helical mimics 3’ and 8’ also match 
parallel β-sheets; (ii) scaffolds 9 and 10 do not overlay exceptionally well on anti-
parallel β-sheets; and, (iii) the oligobenzamide mimic (analyzed using the 3’ or the 3 
designation) populates conformers that do correspond to anti-parallel β-sheets.  
Finally, mimic 7 was shown to have preferred conformers that overlay better on 
the sheet-turn-sheet than any other mimic; to do this it spans the two sheets and part of 
the turn region (6.7d).  Scaffolds 3, 3’, 8’, 9, and 10 also had conformers that overlaid 
well on the sheet-turn-sheet motif. 
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Figure 6.7.  Overlays of mimics 1 – 10 on ideal extended sheet-like structures.  The best 
match for each motif is shown on the right. 
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The strategy used for comparing preferred conformations of the mimics with 
secondary structures described above does not consider the number of conformers that 
matched well (below RMSD 0.5 Å), or how much more energetic these matching 
conformers are relative to the lowest energy conformer detected (ΔE).  To delve into 
these issues it is necessary to plot RMSDs vs ΔEs for each conformer and Figure 6.8 
shows illustrative data. 
Figure 6.8 shows the distribution of conformers of the 3’ oligobenzamide 
description that overlay with 310-, α-, and π-helices at less than 1.0 Å RMSD and within 
3 kcal•mol-1 of the lowest energy form observed.  All of the 310-helical conformers that 
did so with an RMSD of <0.5 Å had an i, i+3, i+6 side-chain correspondence (red dots 
boxed in red).    Smith’s analog 9 overlaid on a parallel β-sheet is shown for comparison.  
This scaffold is the most rigid in the series 1 – 10, hence it is unsurprising that its 
conformers cluster tightly; in fact, they aggregate in approximately two groups, each 
with similar RMSDs.  One of these conformational groups overlays parallel β-sheets 
well with a high population of low energy conformers.   
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Figure 6.8.  Scatter plots of RMSD values of conformers vs energies relative to the 
lowest energy conformer detected (ΔE) indicate how well each mimic populates the 
featured overlay states.  The following numbers of conformers match the indicated 
secondary structures: a compound 3’ on 310-helix, 19 of 567 conformers, 3.4 %; b 
compound 3’ on α-helix, 26/567, 4.6 %; c compound 3’ on π-helix, 17/567, 3 %; 
compound 9 on β-sheet, 386/600, 64.3 %. 
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 For brevity, this data is summarized in Table 6.4, which gives a semi-
quantitative summary of all the dot-plot data for each scaffold type.   For instance, no 
conformers were found for mimic 1 that were below 0.5 Å for overlay on any secondary 
structure (open circles for whole row), while mimic 10 had some conformers between 
1.0 and 3.0 kcal•mol-1 that overlaid with β-sheets or strand-turn-strand motifs (purple 
ticks).  Conformers less than 1 kcal•mol-1 above the minimum energy one that also 
matched ideal secondary structures with RMSDs of <0.5 Å were found for mimics 2, 3 
(and 3’), 4, 8, and 9.  
 
Table 6.4.  Summary of data from RMSD/ΔE scatter plots. 
 
 310-helix α-helix π-helix β-strand β-sheet (parallel) 
β-sheet 
(anti-
parallel) 
strand-
turn-
strand 
        
1 O O O O O O O 
2 ✓✓ O O O O O O 
3 ✓✓ ✓✓ ✓✓ O O ✓✓ ✓✓ 
3’ ✓✓ ✓✓ ✓✓ O ✓✓ ✓✓ ✓✓ 
4 ✓✓ O O O O O O 
5 O O O O O O O 
6 O O O O O O O 
6’ O O O O O O O 
7 O O O O O O ✓ 
8 O O O O O O O 
8’ O O O O ✓✓ O ✓✓ 
9 O O O O ✓✓ O ✓✓ 
10 O O O O ✓ O ✓ 
 
✓✓, RMSD < 0.50 Å and ΔE < 1.0 kcal/mol; ✓, RMSD < 0.50 Å and 1.0 kcal/mol < ΔE 
< 3.0 kcal/mol; O, RMSD > 0.50 Å 
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6.5 Combinations of Side-chains that Best Fit α-Helical Structures 
Scaffolds 1 – 8 were originally designed to resemble α-helices.  Overlays of each 
were shown by their discoverers to illustrate combinations of amino acid side-chains in 
the secondary structures that were presumed to match with preferred conformations of 
the mimics.  These original assignments of side-chain combinations are shown in blue 
below each structure in Figure 6.1.  Shown in red are the side-chain combinations that 
correspond to the best overlay on an ideal α-helix as determined using our analysis.  
Those assignments of side-chain combinations are different to the ones originally made 
for all the scaffolds shown, except for Smith’s β-sheet mimic.  For our mimic 10 the 
procedure reported (by us) was the same as that used here,62 so there is no difference. 
Higher energy conformers were probed to determine if the side-chain 
combinations originally proposed for α-helix mimicry were present in our analyses at 
higher energies than the one with lowest RMSD.  Data for this analysis are shown in 
Table 6.5. 
Red combinations in Table 6.5 are those for the conformer with lowest RMSD 
overlay on an α-helix.  Those shown in purple indicate favored conformations from our 
analyses that corresponded to side-chain combinations that are different to the most 
favorable conformation and necessarily have higher RMSDs.  For instance, our analysis 
of mimic 1 found the overlay with the lowest RMSD corresponded to matching the i, 
i+2, i+5 α-helix side-chains.  However, some other conformations of 1 matched three 
other side-chain sets with higher RMSD (i, i+3, i+5; i, i+4, i+5; i, i-3, i-5, the latter being 
an anti-parallel overlay on the secondary structure, ie one that opposes the N-to-C 
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polarity).  Absence of any side-chain combinations shown in blue for 1 indicates that 
none of the preferred conformers in our analysis corresponded to the amino acid side-
chain combinations originally proposed (in this particular case that was i, i+4, i+7).   
Overview of Table 6.5 shows only one case where a conformer was found that 
corresponded to the original assignment; specifically, one with an RMSD of 0.91 Å 
corresponding to the i, i+3, i+7 set originally proposed for mimic 4. For comparison, 
Smith’s sheet scaffold 9 was included and compared with a parallel β-sheet; the 
proposed side-chain combinations were identical to the exclusive one found via our 
analysis (thus could be shown in red or blue and were arbitrarily shown in blue). 
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Table 6.5.  Side-chain combinations for preferred conformer with lowest RMSD relative 
to the α-helix.  
 
 sequence correspondence for α-helicesa 
  
1 i, i+2, i+5; i, i+3, i+5; i, i+4, i+5; i, i-3, i-5 
2 i, i+2, i+3 
3 i, i+4, i+8; i, i+4, i+9; i, i+5, i+8; i, i-4, i-8 
3’ i, i+4, i+8 
4 i, i+3, i+5; i, i+2, i+5; i, i+4, i+6; i, i+2, i+6; i, i-1, i-5; i, i+3, i+6; i, i+3, i+7 
(0.91); 
5 i, i+2, i+5; i, i+1, i+5; i, i-4, i-5; i, i+3, i+5; i, i+4, i+5; i, i-3, i-5 
6 i, i+2, i+6; i, i-2, i-6 
6’ i, i-1, i-5; i, i+1, i+5 
7 i, i+1, i+3; i, i+1, i+5; i, i-1, i-3; i, i-1, i+3; i, i+3, i+5; i, i-3, i-6; i, i+1, i-3; i, 
i-1, i+2; i, i-1, i-5; i, i+2, i+4; i, i+1, i+4 
8 i, i+4, i+5; i, i-4, i-5; i, i+2, i+5; i, i-3, i-5; i, i+3, i+5 
8’ i, i+1, i+2; i, i-1, i-2 
9 i, i+1, i+2 for parallel β-sheet  
10 i, i+4, i+8; i, i+1, i+5; i, i+2, i+6; i, i+3, i+7; i, i+4, i+7 
 
a red indicates amino acid side-chain combinations for the best matching conformer 
found in this work; purple indicates other conformers found in this work; blue indicates 
amino acid side-chain combinations indicated for the original publications.  Designations 
with negatives, eg i, i-3, i-5, indicate conformations that overlay antiparallel to the N-to-
C orientation in the secondary structure.  
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6.6 Helical Mimics Do Not Need to Be Ideal to Perturb Protein-protein Interactions 
In several cases, helical mimics featured in this study have been made and tested 
for their ability to perturb PPIs that involve a helix at an interface.  Specifically, the PPIs 
shown in Table 6 have been assayed using mimics 1,41 3,226,233 and 8 (p53/MDM2),219 1 
(smMLCK/calmodulin),208 1209,210 and 3226 (BakBH3/Bcl-xL), and 1234 (gp41, C-/N-
helical region).  Just as this work was submitted examples featuring mimic 3 to inhibit 
the androgen receptor-coregulator interaction were reported too.235  Red-shaded regions 
in Table 6 indicate overlays with low RMSD values while yellow- and green- colored 
ones, respectively, fitted less well.   
Table 6.6 also indicates side-chain correspondences colored to show how they 
correspond to those predicted here for ideal secondary structures, and with the 
predictions in the original papers.  Thus in several cases the side-chain correspondences 
observed when all conformers of the mimics were overlaid on the PPI helical motifs did 
not match either the predictions based on ideal secondary structures (Table 6.2) or the 
ones made in the original work; these are shown in black in Table 6.6.  However, in the 
majority of cases (shown in red) the side-chain correlations did match those predicted 
here for ideal secondary structures.  Only in one case, shown in blue for mimic 3 
overlaid on p53/MDM2, the original prediction coincided with the side-chain 
correlations found by our overlay procedure applied to the interface helical motifs.   
Most of the data shown in Table 6.6 corresponds to mimic/PPI combinations that 
have not been assayed so far.  In two cases a mimic/PPI interface combination seems 
mutually well suited.  In the first, mimic 3 is matched well with BakBH3/Bcl-xL,236 
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gp41, and smMLCK/calmodulin, but tests have only been reported for the first.  Second, 
and surprisingly, Smith’s system 9 shows an excellent match for the BakBH3/Bcl-xL; no 
assays have been reported for this since it has, until now, been regarded as exclusively a 
β-sheet mimic.  Closer examination reveals this overlay is on a helical-terminus where 
the conformation begins to unwind.   
Data in Table 6.6 do not mean that the authors of the original papers should have 
chosen different side-chain correspondences, for various reasons.  For instance, some of 
the side-chains that overlay well when our conformational search routine is used point 
away from the interface.  Thus Table 6.6 should only be used to select mimics to disrupt 
those PPIs after the orientation of the mimic side-chains have been checked to see if they 
are appropriate to interact with the protein-binding partner. 
Differences between the data in Tables 6.2 (RMSDs for overlays on ideal 
secondary structures) and 6.6 (on actual PPI interfaces) reflect the fact that secondary 
structures in proteins are not ideal.  For instance, Table 6.2 indicates mimics 7 – 10 are 
relatively poor helical mimics, but they overlay on the p53/MDM2 interface with 
RMSDs that are superior to nearly every entry in Table 6.2 for matching all the mimics 
on any ideal secondary structure.  
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Table 6.6.  RMSD values for preferred mimic conformations overlaid on PPI 
componentsa. 
 
PPI 1 2 3 3’ 4 5 6 6’ 7 8 8’ 9 10 
              
p53/MDM2
b 
0.57 0.66 0.46 0.55 0.51 0.54 0.50 0.59 0.34 0.43 0.33 0.34 0.47 
i,i+2
,i+3 
i,i+2
,i+3 
i,i+4
,i+7 
i,i+4
,i+7 
i,i+3
,i+6 
i,i+1
,i+3 
i,i+2
,i+4 
i,i+4
,i+5 
i,i+1
,i+3 
i,i+2
,i+3 
i,i+1
,i+2 
i,i+1
,i+2 
i,i+4
,i+8 
smMLCK/c
almodulinc 
0.68 0.60 0.25 0.21 0.35 0.52 0.52 0.57 0.57 0.65 0.77 0.68 0.68 
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BakBH3/Bc
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0.61 0.67 0.28 0.42 0.45 0.61 0.47 0.59 0.43 0.90 0.59 0.23 0.49 
i,i+3
,i+5 
i,i+2
,i+3 
i,i+3
,i+7 
i,i+4
,i+8 
i,i+3
,i+6 
i,i+1
,i+4 
i,i+2
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i,i+4
,i+5 
i,i+1
,i+3 
i,i+4
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i,i+1
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i,i+1
,i+2 
i,i+4
,i+8 
gp41C-/N-
helical 
regione 
0.73 0.55 0.28 0.26 0.40 0.46 0.54 0.62 0.58 0.71 0.73 0.60 0.72 
i 
i+3,i
+5 
i,i+2
,i+3 
i,i+4
,i+8 
i,i+4
,i+8 
i,i+3
,i+5 
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,i+5 
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,i+7 
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,i+7 - 
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,i+7 - 
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a Red background RMSD ≤ 0.30 Å; 0.30 Å < RMSD ≤ 0.50 Å, yellow; 0.50 Å < RMSD 
≤ 0.70 Å, green.  Side-chain correspondences shown in black did not correspond to the 
original predictions or those from matching ideal secondary structures as described here, 
blue denotes correspondence to the original prediction, and red indicates correspondence 
to the matches deduced here. b Helical component shown first throughout; PDB 
identifier, 1YCR.  c1CDL.  d1BXL  e1AIK 
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Finally, even if a mimic displaces a helical protein fragment at a PPI this does 
not prove that the small molecule binds in a helical conformation, and it is hard to 
confirm that it does by most methods.  Binding of a helical mimic to a receptor pocket 
for a protein helix gives only circumstantial evidence.  Hamilton et al proved various 
terphenyls 1 could influence the interaction of calmodulin with the α-helical domain of 
smooth muscle myosin light-chain kinase,208 and used the same scaffold to perturb the 
α-helical binding domain of Bak BH3 interacting with Bcl-xL (selectively over 
p53/HDM2).210  In the former case the compound was used as a i, i+3 and i+7 mimic, 
but as a i, i+4 and i+7 mimic in the latter case.  HSQC experiments with 15N-labeled Bcl-
xL proved the mimic bound in that binding cleft.210  Such HSQC experiments are a gold 
standard in the field; they confirm a mimic binds in the targeted region, and that is still 
rare in the field of minimalist mimics of secondary structures.237   In Hamilton’s studies 
those experiments proved the terphenyl associates with the hydrophobic cavity where the 
helical BH3 peptide binds, but the perturbation of protein 15N-chemical shifts on binding 
does not reveal the conformation of the bound mimic.  Moreover, Hamilton’s docking 
studies indicated the terphenyl mimic could occupy the same hydrophobic cleft as Bak in 
Bcl-xL but in a slightly different orientation.  In Hamilton’s work it was not critical to 
elucidate the exact binding mode since they achieved their objective: to find a small 
molecule to perturb Bak/Bcl-xL. However, for helical mimicry in general, the 
conformation of the small molecule bound to the protein is interesting.  This would 
require crystallography of the complex, and no group has reported such X-ray data for 
any of the mimics 1 – 8.  That type of crystallographic data can be hard to obtain for 
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compounds that bind one protein component with low affinity, and for PPIs where the 
isolated proteins have different structures compared with the PPI complex. 
 
6.7 Conclusions 
Computational simulations of rapidly equilibrating conformational states of 
minimalist mimics in solution reveal information that cannot be obtained via direct 
spectroscopic measurements.  Preferred simulated conformations of methyl-substituted 
scaffolds in a continuous dielectric of 80 represent the intrinsic bias of that scaffold with 
methyl groups in the absence of explicit water molecules.  In other words, they represent 
how the scaffold-core is bias to project Cα - Cβ vectors as it surrenders water of 
solvation and begins to interact with a protein-binding partner.   
Orientations of Cα and Cβ atoms in preferred conformations of minimalist 
mimics can be related to the same vectors in secondary structures by automated overlay 
routines.  Computational methods like this can be repeated for hundreds of conformers, 
making it possible to evaluate a whole conformational ensemble in terms of quantitative 
RMSD outputs; this is faster and more reliable than could ever be achieved by matching 
two 3D molecules “by eye” based on a 2D representation on a screen, or by docking a 
few conformations from large ensembles via MD simulation routines.  The key 
innovation in the research described here is to introduce this type of procedure as a 
means to evaluate the general applicability of the featured compound types in secondary 
structure and interface mimicry. 
  130 
There have been so many papers on minimalist helical mimics that readers who 
do not follow the field might assume the major challenges must have been surmounted, 
but this study convinced us that the opposite is true.  It is difficult to relate the mimics to 
their preferred side-chain correspondences, and there are many side-chain 
correspondences which, based on these simulations, cannot be matched by any of the 
mimics 1 – 10 with an RMSD of less than 0.5 Å.  It would be optimal to have at least 
one minimalist mimic that can attain a good match (arbitrarily this might be 0.5 Å 
RMSD) for each side-chain correspondence in every secondary structure, but this has not 
been achieved.  Within the constraints of the methods presented here (limitations of the 
force fields, assumptions regarding the media for simulations) our simulations indicate 
that the best mimic of an α-helix is 3, and that happens to correspond to i, i+4, i+8 side-
chain orientations (RMSD of 0.31).  In fact, none of the other helical mimics cover other 
side-chain combinations with an RMSD of <0.50.  Another challenge in the field of 
helical mimicry is to improve the suitability of helical mimics for applications as cell 
permeable chemical probes and pharmaceutical leads.  Compounds containing scaffold 
3, for instance, are unlikely to be cell permeable due to the amide H-bond donors.  There 
are ample opportunities for refined design of minimalist secondary structure mimics. 
Simulated conformational equilibria of the featured scaffolds reveals that many 
err towards being universal mimics46 (several secondary structures represented in one 
conformational ensemble).  Thus, the compounds have the potential to be used as α-
helical mimics and to resemble other secondary structures; the featured scaffolds might 
be used in ways that may not have been obvious before.   
  131 
Some of the mimics 1 – 8 were probably conceived to match non-ideal helices at 
specific PPI interfaces.  Simulations here indicate that many of the featured helical 
mimics cannot access conformations that overlay well (eg <0.5 Å RMSD) with ideal 
secondary structures, but can match distorted helices at particular PPI interfaces.  In 
general, research focused on perturbing PPIs requires close consideration of side-chain 
orientations at the particular targeted interface.  We feel that this is the direction the 
field is already moving in: design and synthesis of interface mimics, rather than 
secondary structure mimics.  However, it does not matter if the target conformation is an 
ideal secondary structure or a completely “non-classical” one observed in a PPI, 
simulations of the type outlined here will be valuable because evaluation of minimalist 
mimic conformations with PPI target conformations can reveal information that is not 
conveniently obtained via spectroscopy.  This is, of course, especially true for predictive 
work to evaluate potential interface mimics before they have been prepared (cf Table 
6.6).  Thus simulations such as these are a possible opening steps in a process that 
should be followed by checking for the absence of unfavorable backbone interactions of 
the scaffold with the protein receptor, syntheses, binding assays, and determination of 
the site of binding. 
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CHAPTER VII 
CONCLUSIONS 
 
Overall, this thesis describes design, synthesis, conformational studies and 
selected applications of several novel minimalist mimic scaffolds.  These scaffolds tend 
to exist in conformations that can mimic the amino acid side-chain orientations of certain 
protein secondary structures and PPI interface regions.  Some of the mimics are shown 
to be active in disturbing PPI targets.  Specifically, the oligomeric mimics are able to 
mimic extended interface regions while the constrained cyclic peptide scaffolds can be 
used to target compact areas at PPIs. 
As an extension for the oligo-pyrrolidine-pyrrolidinone oligomeric mimic 
previously studied in Burgess group, I examined a new oligo-piperidine-piperidinone 
scaffold.  In Chapter II, divergent-convergent synthetic route was developed and it is 
efficient enough to enable the preparation of three-side-chain mimics with a broad range 
of side-chain combinations and extended oligomers with up to five amino acid side-
chains.  The use of β-amino acids and piperidine linker solved the problem of 
epimerization identified in the synthesis of the oligo-pyrrolidine-pyrrolidinone scaffold.  
Conformational studies of the new scaffold with X-ray crystallography revealed that the 
new mimic exist in a helical conformation in solid state.  The solid-state conformer is 
shown to mimic the side-chain arrangements of the i, i + 5 and i + 10 side-chain 
sequence of an ideal α-helix.  Molecular modelings and data mining (QMD and EKOS) 
in solution revealed that the scaffold can be a multi-faceted secondary structure mimic 
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with a preference towards α-helix and β-sheet.  Results from data mining with EKO 
further validated the conclusions from EKOS studies on ideal secondary structures.  
These results lead us to believe that small molecules derived from this scaffold are 
promising in disturbing real protein-protein interactions.  
Another relevant oligo-piperidine-pyrrolidinone scaffold was studied in Chapter 
III.  This mimic was designed by hybridizing the features in oligo-pyrrolidine-
pyrrolidinone and oligo-piperidine-piperidinone scaffolds and synthetic accessibility of 
this scaffold was evaluated.  Similar to the oligo-pyrrolidine-pyrrolidinone scaffold, this 
mimic suffered from significant epimerization at the chiral centers during the synthesis. 
Although the application of this mimic is limited in disturbing real PPIs due to the 
epimerization, an interesting synthetic methodology was discovered during the 
optimization of the synthetic route and it is further applied to the chemoselective 
synthesis of a broad range of β-enamino esters, thioesters and amides.   
In biological studies, derivatives of the oligomeric mimics were shown to disturb 
the oligomerization of antithrombin in Chapter IV.  These derivatives were chosen based 
on EKO prediction and synthesized with methods described in Chapter II.  The effects of 
the mimics on the oligomerization state of antithrombin were investigated with native 
gel electrophoresis.  This technique allows the separation of antithrombin oligomers with 
monomers and provides a fast and convenient way to evaluate the biological activity of 
the compounds.  Besides the initial screening, a modified quantitative native gel 
electrophoresis procedure was applied in the study of antithrombin oligomerization 
kinetics and confirmed the importance of mimic concentration and amino acid side-
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chains on the scaffold.  Moreover, enzyme kinetics assay has successfully differentiated 
the modes of action between mimics.  One mimic tended to induce the formation of 
short antithrombin oligomers while others favored long oligomers.  Finally, transmission 
electron microscope enables the direct visualization of the linear antithrombin oligomers 
induced by incubation with the small molecules.  These biological studies support the 
prediction of EKO analysis and represent a significant step forward in validating EKO 
and EKOS approaches.   
Intrigued by the fact that turns are involved in many PPIs, a new constrained 
cyclic peptide scaffold is also explored in Chapter V of this thesis.  The design features a 
13-membered macrocyclic ring and an anthranilic acid motif that facilitates the 
cyclization and increases the conformational rigidity of the macrocycle.  We were 
pleased to find that the scaffold is conformational homogeneous with experiments and 
with molecular modeling.  Furthermore, the macrocyclic ring conformation is not 
significantly affected by the substituents on amino acid side-chains but has a simple and 
strong correlation with the stereochemistry of the amino acids based on the 2D NMR 
studies.  In EKOS analysis, different stereomers of the scaffold are found to closely 
mimic several common turn types.  This indicates that the application of this scaffold 
would not be limited to a certain type of turn structure at PPI interfaces.  Besides, after 
cyclization, the mimics become more drug-like with a lower calculated polar surface 
area, higher predicted cell permeability and better proteolytic stability.  These 
constrained cyclic peptides described in Chapter V are favorable scaffolds for compact 
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interface regions.  The biological activities of the cyclic peptide derivatives are still 
under evaluation for selected PPI targets. 
In Chapter VI, we have compared the existing key helical mimic scaffolds 
published by other research groups with our EKOS technique.  The major discovery in 
this research is that although these scaffolds are designed to reproduce the side-chain 
arrangement of an α-helix, they can potentially mimic other secondary structures besides 
α-helix, such as 310-helix, π-helix or β-sheet.  Moreover, even for α-helix, those scaffolds 
are inclined to mimic side-chain sequences other than those claimed in the original 
publications.  These results suggest that researchers have underestimated the potential of 
these scaffolds and EKOS is useful in revealing new opportunities for existing 
minimalist mimics.  Further experimental research would be needed to find out new 
applications for these molecules in disturbing PPI targets.  
Overall, the designed scaffolds in this thesis show promises in mimicking protein 
secondary structures and crystallized PPI interface regions.  These molecules represent 
suitable scaffolds in the EKO and EKOS analysis.  EKO and EKOS has been proven to 
be successful in several cases but it still remains to be studied how general these 
computational methods are in finding small molecules for other protein-protein 
interaction targets.  Further research would be necessary to achieve a better 
understanding of the scope of EKO and EKOS.   
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APPENDIX A  
GENERAL PROCEDURES 
 
A. General Experimental Procedures 
All reactions were carried out under nitrogen atmosphere with dry solvents under 
anhydrous conditions.  Glassware was dried in an oven at 140 oC for minimum 6 h prior 
to use.  Dry solvents were obtained by passing the previously degassed solvents through 
activated alumina columns.  Reagents were purchased at a high commercial quality 
(typically 97 % or higher) and used without further purification, unless otherwise stated.  
Flash chromatography was performed using silica gel (230–600 mesh).  Analytical thin 
layer chromatography (TLC) was carried out on Merck silica gel plates with QF-254 
indicator and visualized by UV or potassium permanganate stains.  1H and 13C spectra 
were recorded on a 300 MHz or a 400 MHz spectrometer and were calibrated using 
residual non-deuterated solvent as an internal reference.  Chemical shifts (δ) are reported 
in ppm, and coupling constants (J) are given in Hz.  The following abbreviations were 
used to explain the multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, dd = 
double doublet, dq = double quartet m = multiplet, br = broad.  HRMS were obtained 
using ESI or MALDI ionization.  Melting points were recorded on an automated melting 
point apparatus and are uncorrected. 
All the HPLC analyses were carried out with UV detection monitored at 254 nm.  
Analytical reversed phase HPLC analyses were performed with a 150 x 4.6 mm C-18 
column using gradient conditions (10 – 90 % acetonitrile in water, flow rate = 0.75 
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mL/min).  Chiralpak AD (250 x 4.6 mm ID) column was utilized for the chiral HPLC 
analysis (hexanes : isopropyl alcohol 85 : 15, flow rate = 1 mL / min). 
All the UV spectrums were recorded on a UV spectrometer using a 10 mm quartz 
cuvette at 20 µM in MeOH.  Circular Dichroism spectrums were recorded on a CD 
spectrometer using a 2 mm quartz cuvette at 200 µM in MeOH. 
 
B. General Procedure for Quenched Molecular Dynamics 
NAMD1 was used for the molecular simulations performed in this work.  Explicit 
atom representations were used throughout the study.  The protein structure files (PSF) 
for all the peptidomimetics were built using Discovery Studio 2.5 (Accelrys Inc) using 
the CHARMm force field.  
Quenched molecular dynamics simulations were performed using the CHARMm 
force field as implemented in Discovery Studio 2.5.  All four molecules were modeled as 
neutral compounds in a dielectric continuum of 80 (simulating H2O).  Thus, the starting 
conformers were minimized using 3000 steps of conjugate gradient.  The minimized 
structures were then subjected to heating, equilibration, and dynamics simulation.  
Throughout, the equations of motions were integrated using the Verlet algorithm with a 
time step 1 fs.  Each peptidomimetic was heated to 1000 K over 10 ps and equilibrated 
for another 10 ps at 1000 K, then molecular dynamics runs were performed for a total 
time of 600 ps with trajectories saved every 1 ps.  The resulting 600 structures were 
thoroughly minimized using 1000 steps of SD followed by 3000 steps of conjugate 
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gradient. Structures with energies less than 3.0 kcal mol-1 relative to the global minimum 
were selected for further analysis. 
The VMD2 package was used to display, overlay, and classify the selected 
structures into conformational groups.  The best clustering was obtained using a 
grouping method based on calculation of RMS deviation of a subset of atoms, in this 
study these were the Cα - and Cβ- atoms.   Thus, threshold cutoff values 0.5 Å were 
selected to obtain families with reasonable homogeneity.  The lowest energy 
conformation from each family was considered to be a typical representative of the 
family as a whole. 
 
C. Procedures for Matching on Ideal Secondary Structures and Crystal Structure 
Standard template for overlays with 310-helix, α-helix, π-helix, and β-strand were 
obtained from Discovery Studio 2.5. Parallel β-sheet, anti-parallel β-sheet and 
sheet/turn/sheet templates were obtained by modified β-sheet builder (http://www-
lbit.iro.umontreal.ca/bBuilder/index.html). 
After minimization in the QMD process, the conformers were grouped into 
families base on their Cα - Cβ coordinates.  The process of systematically matching 
preferred conformers with secondary structures was performed in the following way.   
All the conformers within 3.0 kcal/mol were considered to be “preferred”.  
Each of these conformers was overlaid on ideal secondary structures, the crystal 
structure or the NMR structure using an in house generated algorithm that compared 
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Cα - Cβ coordinates of the side chains which generates a list of structures ranked in 
terms of the RMSD for the overlay process. 
 
D. Procedures for Data Mining of 3D Complex Database 
The data mining of 3D complex database was performed for LLL-1aaa 
according to the procedure described previously.3 The overlays were analyzed by DSSP 
to get the secondary structure information for individual residues.  
 
  
  154 
APPENDIX B  
EXPERIMENTAL PROCEDURES FOR CHAPTER II 
 
A.  General Procedures 
General Procedure for Boc Deprotection: 
The substrate was dissolved in 1:1 TFA/dichloromethane to give 0.1 M 
concentration at 0 ºC and the reaction was stirred for 30 min at room temperature. 
Toluene (30 mL) was added and the solution was concentrated. Residual TFA was 
azeotroped 3 times with toluene (3 × 30 mL) and the residue was placed under high 
vacuum for 3 h to give the crude mixture. The crude mixture was purified with 
procedures indicated for specific compounds. 
 
General Procedure for Cbz Deprotection: 
To a solution of substrate in methanol (0.1 M) under nitrogen was added 10 wt % 
Pd/C (0.1 equiv. Pd). The reaction was placed under an atmosphere of hydrogen (1 atm, 
balloon) for 12 h. After the reaction finished, the flask was purged with N2. The reaction 
mixture was filtered over a celite pad and concentrated to afford the crude product. The 
crude mixture was purified with procedures indicated for specific compounds. 
 
General Procedure for Coupling Reaction: 
To a 0.5 M solution of 1.0 equiv. of the amine in CH2Cl2 was added 100.0 equiv. 
of anhydrous KHCO3 powder. 1.0 equiv. of the vinyl chloride was then added as a 0.5 M 
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solution in CH2Cl2 to the reaction mixture. While stirring at room temperature, the 
solvent was removed with nitrogen. The resulting solid was heated up to the indicated 
temperature under N2 for the indicated time. During the reaction, at about half of the 
indicated time, 0.5 mL anhydrous THF was added, stirred for 10 mins and then removed 
with nitrogen. After the reaction finished, CH2Cl2 was added and the inorganic solids 
were removed by filtration. The solution was concentrated to give the crude product. 
 
B. Synthesis of Compounds 1 
 
 
General Procedure for the Syntheses of 5 
The N-Boc-protected amino alcohol was prepared from N-Boc-protected amino 
acid with literature procedures.4 The crude N-protected amino nitrile compounds were 
synthesized on large scale from corresponding N-Boc-protected amino alcohols with the 
procedure from the literature.5 5a, 5l, 5v, 5g’, 5f can be obtained by crystallization of the 
crude mixture from CH2Cl2/hexanes. 5s’, 5t’, 5w, 5k’ can be purified by washing the 
ether solution of crude product 3 times with saturated NaHCO3 solution and 1 time with 
BocHN
R1
CNCOOHBocHN
R1
BocHN
R1
OH
BocHN
R1
COOH
5
2
1.0 M KOH
1 : 1 EtOH/H2O
90 oC, 3 h
(i) iBuOCOCl
NMM, DME
(ii) NaBH4, H2O
(i) MsCl, TEA
(ii) NaCN, DMSO
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water before drying over MgSO4 and the removal of solvent. In some cases, D-amino 
acid derivatives were used as the starting material. 
 
 
General Procedure for the Syntheses of 2 
5 (20 mmol) was dissolved in 20 mL EtOH at room temperature and 20 mL 2 M 
KOH aqueous solution was added in one portion. The resulting mixture was stirred at 90 
oC until the reaction was complete (usually 3 h was enough). The mixture was cooled 
down to room temperature and EtOH was removed under vacuum. The crude product 
was cooled to 0 oC and 1 M KHSO4 aqueous solution was slowly added until the pH of 
the solution reached about 2-3. The product was extracted with Et2O three times (80 mL 
× 3). The combined Et2O solution was washed twice with water (100 mL × 2) and brine 
(100 mL). The ether phase was dried over MgSO4 and concentrated under vacuum. The 
residue was used directly in the synthesis of 3 without further purification. 
 
(ii) TFA/CH2Cl2
25 oC, 30 min
BocHN
R1
COOH
(i) Meldrum's 
acid
EDCI, DMAP, 
CH2Cl2, 3h
2
HN O
O
R1
3
a, 45 %; f, 41 % 
g, 67 %; l, 58 % 
t', 48 %; v, 31 %
4
a, 61 %; f, 72 % 
l, 68 %; t', 65 %
HN
O
Cl
R1
R = H, g; Me, a; iBu, l;  
iPr, v; Bn, f;
OBn
, t';
OH
, t
OBn , s'
NH , w;
NHCbz , k'
PPh3 
CCl4
CHCl3 
50oC
5h
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General Procedure for the Syntheses of 36-8 
To a stirred solution of meldrum’s acid (476 mg, 3.3 mmol, 1.1 equiv) and 
DMAP (550 mg, 4.5 mmol, 1.5 equiv) at 0 ºC in dichloromethane (15 mL) was added N-
Boc-β-amino acid 2 (3.0 mmol, 1.0 equiv) in one portion. EDCI (978 mg, 5.1 mmol, 1.7 
equiv) was added in one portion and the reaction mixture was stirred at 25 ºC for 5 h. 
The yellow reaction mixture was transferred to a separatory funnel and diluted with 
dichloromethane (80 mL) and washed with cold 5 % KHSO4 (3 × 75 mL) and brine (75 
mL). The organic layer was dried over MgSO4 and filtered. The filtrate was concentrated 
under vacuum and 60 mL ethyl acetate was added. After refluxing for 5 h under N2, the 
solution was concentrated and Boc protection group was removed with the method 
described in general procedure for Boc deprotection. The crude product was purified 
with flash chromatography (CH2Cl2 – 5 % MeOH in CH2Cl2) to give the product. 
 
General Procedure for the Syntheses of 4 
Triphenylphosphine (524.6 mg, 2 mmol, 2.0 equiv.) was stirred in 2 mL dry CCl4 
at 55 oC for 3 h.  Then 2 mL CHCl3 was added, followed by 3a (127.1 mg, 1.0 mmol, 1.0 
equiv.). The resulting mixture was stirred at 55 oC under nitrogen for another 5 h.  
Solvent was removed under vacuum and the resulting dark red mixture was purified by 
flash chromatography (30 % ethyl acetate in hexanes) to give the product 4a as a white 
crystal. 
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General Procedure for the Synthesis of 7 
20 mL acetyl chloride was added dropwise into 20 mL MeOH at 0 oC over 30 
min. After stirring for another 10 min, 5a (1.84 g, 10 mmol) was added slowly as a 5 mL 
methanol solution. After the reaction mixture was stirred at room temperature for 12 h, 1 
mL H2O was added and stirred for 30 min. The solvent was removed under vacuum 
(note: the removal of solvents and HCl must be performed in a fume hood). Residual 
H2O was azeotroped 3 times with toluene (3 × 30 mL) and the residue was placed under 
high vacuum for 3 h.  (Note: When 5k’ or 5w was the substrate, the reaction was 
performed at 0 °C for 12 h.) 
Reductive amination reaction was performed with a modified literature 
procedure.9 100 mL 1,2-dichloroethane was added to the residue, followed by 
triethylamine (2.77 mL, 20 mmol, 2.0 equiv.) and then glacial acetic acid (0.58 mL, 10 
N N
O
OMe
R3
PhP=C=C=O
toluene
110 oC, 48 h
PG = Cbz
H2, Pd/C
MeOH, 25 oC, 12 h
or PG = Boc
TFA/CH2Cl2
25 oC, 30 min7
PG
HN N
O
OMe
R3
8
 a, 79 %; f, 85 %
g, 90 %; k',76 %
l, 72 %; t', 62 %
 w, 57 %
HN
R1
O
N N
R3
O
OMe
9
gg, 95 %; la, 85 % 
lk', 91 %; ll, 80 %
4
KHCO3
75 oC
24 h
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mmol, 1.0 equiv.). B (benzyl 4-oxopiperidine-1-carboxylate) (2.33 g, 10 mmol, 1.0 
equiv.) was added in one portion and the resulting mixture was stirred at room 
temperature for 20 min. The reaction was cooled to 0 oC and NaBH(OAc)3 (5.30 g, 25 
mmol, 2.5 equiv.) was added portionwise. Ice bath was removed and the reaction 
mixture was allowed to warm up to 30 oC and stirred for 3 h. CH2Cl2 (100 mL) was 
added and the mixture was washed with saturated NaHCO3 solution 3 times (3 × 100 
mL) (note: there will be a strong evolution of CO2 in the first wash) and then with brine 
(100 mL). The organic layer was separated, dried over anhydrous MgSO4, and 
concentrated in vacuum to give the product 6a as colorless oil and it is used directly in 
the next step.  
Bestmann ylide (recrystallized from toluene) (4.53 g, 15 mmol, 1.5 equiv.) was 
added to the solution of 6a in 100 mL dry toluene at room temperature under N2.  The 
resulting mixture was stirred at 110 oC under N2 for 48 h. After the reaction finished, 
toluene was removed under vacuum. 50 mL Et2O was added and the resulting crude 
mixture was stirred at 0 oC for 30 min. The mixture was then filtered through a thin layer 
of celite to remove the solids. The filtered solution was concentrated under vacuum to 
give the product as oil. The oil was the mixture of the cyclized product 7a and 
triphenylphosphine oxide and it was used without further purification in the next step for 
the syntheses of 8a or 10a. 
Note: B (benzyl 4-oxopiperidine-1-carboxylate) was used for the syntheses of 6a, 
6t’, 6s’, 6v, 6l, 6w, 6f and C (tert-butyl 4-oxopiperidine-1-carboxylate) was used for the 
syntheses of 6g, 6k’. 
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General Procedure for the Synthesis of 8 
Syntheses of 8a, 8t’, 8l, 8w 
General procedure for the deprotection of Cbz group was used to give the crude 
mixture. The crude product was purified by flash chromatography (3 % MeOH/ CH2Cl2 
containing 1 % Et3N - 8 % MeOH/CH2Cl2 containing 1 % Et3N ) to afford the product. 
 
Syntheses Of 8g, 8 k’  
General procedure for the deprotection of Boc group was used to give the crude 
mixture. The crude product was purified by flash chromatography (3 % MeOH/ CH2Cl2 
containing 1 % Et3N - 8 % MeOH/CH2Cl2 containing 1 % Et3N ) to afford the product. 
 
 
 
General Procedure for the Syntheses of 10 
7a (from 10 mmol 5a) was dissolved in 50 mL 9:1 TFA:H2O at 25 oC. After 
stirring for 18 h, toluene (50 mL) was added and the solution was concentrated. Residual 
TFA and water was azeotroped 3 times with toluene (50 mL × 5) and the residue was 
dissolved in 100 mL dichloromethane and the mixture was washed with 10 % KHSO4 
solution three times (3 × 50 mL) and then with brine (100 mL). The organic layer was 
CbzN N
O
OMe
R2
7
(i) TFA/H2O
(ii) PPh3,CCl4
CHCl3
CbzN N
O
Cl
R2
10
a, 41 %; s', 45 % 
t', 35 %; v, 31 %
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separated, dried over anhydrous MgSO4, and concentrated in vacuum to give the product 
as colorless oil and it is used in the next step without further purification. 
Triphenylphosphine (393 mg, 1.5 mmol, 1.5 equiv.) was stirred in 1.5 mL dry 
CCl4 at 55 oC for 3 h.  Then the piperidinedione product from the previous step was 
added as a 1.5 mL CHCl3 solution. The resulting mixture was stirred at 55 oC under 
nitrogen for another 5 h.  Solvent was removed under vacuum and the resulting dark red 
mixture was purified by flash chromatography (25 % ethyl acetate in hexanes) to give 
the product 10a as colorless oil.  
 
 
 
 
General Procedure for the Syntheses of 11 
The general procedure for the coupling reaction was used at 120 oC for 48 h. The 
product was purified by flash chromatography (3 % MeOH/CH2Cl2 - 6 % 
MeOH/CH2Cl2) to afford the product. 
CbzN N
R2
O
N N
R3
O
OMe
11
aa,  59 %; af, 52 %; at', 48 % 
s't', 51 %; t'a, 31 %; va, 45 %
8
KHCO3
120 oC, 48 h
(i) H2/Pd/C, 
MeOH
(ii) 4, KHCO3,
75 oC, 48 h
N N
R2
O
N N
R3
O
OMeHN
O
R1
1
aaa, 85 %; faf, 40 %; lat', 77 %; lat, 65 %; vt'a, 70 %
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General Procedure for the Syntheses of 1 
General procedure for the deprotection of Cbz group was used to give the crude 
mixture of the deprotected product. The crude product was used directly in the next step 
without further purification. 
 
The Removal of –OBn Group for the Synthesis of 1lat 
To a solution of deprotected two side-chain intermediate at’ in ethanol (0.1 M) 
under nitrogen was added 1.0 equiv. of HCl in dioxane (4 M), followed by 10 wt % Pd/C 
(0.5 equiv. Pd). The reaction was placed under an atmosphere of hydrogen (1 atm, 
balloon) for 24 h. After the reaction finished, the flask was purged with N2. The reaction 
mixture was filtered over a celite pad and concentrated to afford the crude product. The 
crude product was dissolved in dichloromethane and washed with saturated NaHCO3 
twice and then once with brine. The organic phase was dried over Na2SO4 and filtered. 
Dichloromethane was removed under vacuum to yield the desired product. The product 
was directly used in the next step.   
The general procedure for the coupling reaction was used at 75 oC for 24 h. The 
product was purified by flash chromatography (5 % MeOH/CH2Cl2 - 8 % 
MeOH/CH2Cl2) to afford the product. 
 
Compound 1aaa 
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(S)-4-Methoxy-6-methyl-1-(1-((S)-2-methyl-1-(1-((S)-2-methyl-6-oxo-1,2,3,6-
tetrahydropyridin-4-yl)piperidin-4-yl)-6-oxo-1,2,3,6-tetrahydropyridin-4-yl)piperidin-4-
yl)-5,6-dihydropyridin-2(1H)-one 
 
Light yellow oil, 85 %; [α]20 -30.7 (c 0.2, CHCl3) 
1H-NMR (300 MHz, CDCl3) δ 5.33 (s, 1H), 5.12 (d, J = 1.8 Hz, 1H), 4.97 (s, 1H), 4.90 
(s, 1H), 4.76-4.57 (m, 2H), 3.84-3.61 (m, 10H), 3.01-2.69 (m, 6H), 2.58-2.50 (m, 1H), 
2.49-2.39 (m, 1H), 2.12-1.98 (m, 2H), 1.90-1.57 (m, 8H), 1.34-1.27 (m, 9H); 
13C-NMR (75 MHz, CDCl3) δ 170.9, 166.5, 165.9, 165.4, 157.5, 153.8, 94.0, 92.8, 
90.5, 55.6, 50.5, 49.9, 46.3, 46.2, 46.1, 45.9, 45.4, 45.2, 45.1, 35.3, 34.0, 33.4, 30.2, 
29.9, 29.1, 28.9, 21.2, 20.4, 20.3; 
IR (film, cm-1) 3406, 2927, 2361, 1603, 1433, 1377, 1321, 1276, 1207, 1175, 1005, 808, 
731; 
HRMS (ESI) m/z calcd for C29H43N5O4 (M+H)+ 526.3393; found 526.3411 (3.4 ppm). 
 
N N
O
N N
O
OMeHN
O
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Compound 1lat’ 
(R)-6-((R)-1-(Benzyloxy)ethyl)-1-(1-((S)-1-(1-((R)-2-isobutyl-6-oxo-1,2,3,6-
tetrahydropyridin-4-yl)piperidin-4-yl)-2-methyl-6-oxo-1,2,3,6-tetrahydropyridin-4-
yl)piperidin-4-yl)-4-methoxy-5,6-dihydropyridin-2(1H)-one 
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Colorless oil, 77 %; [α]20 -21.5 (c 0.1, CHCl3) 
1H-NMR (300 MHz, CDCl3) δ 7.29-7.20 (m, 5H), 5.10 (s, 1H), 4.97 (s, 1H), 4.83 (s, 
2H), 4.65-4.47 (m, 2H), 4.32 (d, J = 11.7 Hz, 1H), 4.18-4.03 (m, 1H), 3.76-3.38 (m, 
11H), 2.94-2.75 (m, 2H), 2.70-2.24 (m, 6H), 2.18-2.01 (m, 2H), 1.92-1.41 (m, 10H), 
1.37-1.21 (m, 1H), 1.29 (d, J = 6.3 Hz, 3H), 1.07 (d, J = 6.3 Hz, 3H), 0.90-0.84 (m, 6H);  
13C-NMR (75 MHz, CDCl3) δ 170.7, 166.9, 166.5, 165.9, 157.4, 154.1, 138.1, 128.4, 
127.8, 127.7, 94.8, 92.6, 91.0, 75.2, 71.1, 55.7, 55.0, 53.8, 49.9, 48.3, 46.2, 46.0, 45.8, 
45.2, 44.4, 33.4, 32.7, 30.0, 29.8, 29.7, 29.4, 29.2, 28.4, 24.3, 23.0, 22.1, 20.3, 15.9; 
IR (film, cm-1) 2925, 1614, 1428, 1275, 1224, 1076, 807; 
HRMS (ESI) m/z calcd for C40H57N5O5 (M+H)+ 688.4438; found 688.4463 (3.6 ppm). 
 
N N
O
N N
O
OMeHN
O
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Compound 1vt’a 
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(S)-6-((S)-1-(Benzyloxy)ethyl)-1-(1-((R)-2-isopropyl-6-oxo-1,2,3,6-tetrahydropyridin-4-
yl)piperidin-4-yl)-4-(4-((R)-4-methoxy-6-methyl-2-oxo-5,6-dihydropyridin-1(2H)-
yl)piperidin-1-yl)-5,6-dihydropyridin-2(1H)-one 
 
Colorless oil, 70 %; [α]20 -32.4 (c 0.2, CHCl3) 
1H-NMR (300 MHz, CDCl3) δ 7.30-7.20 (m, 5H), 5.29 (br, 1H), 5.04 (s, 1H), 4.83 (s, 
1H), 4.79 (s, 1H), 4.59-4.44 (m, 2H), 4.34 (d, J = 12.0 Hz, 1H), 4.26-4.10 (m, 1H), 3.73-
3.22 (m, 11H), 2.89-2.51 (m, 5H), 2.42-1.84 (m, 5H), 1.82-1.38 (m, 9H), 1.17 (d, J = 6.6 
Hz, 3H), 1.07 (d, J = 6.3 Hz, 3H), 0.95-0.90 (m, 6H); 
13C-NMR (75 MHz, CDCl3) δ 171.0, 167.2, 166.5, 165.4, 157.7, 154.4, 138.2, 128.5, 
127.8, 127.7, 94.1, 93.7, 90.8, 75.6, 71.2, 56.1, 55.6, 54.5, 52.8, 50.5, 46.2, 46.1, 46.0, 
45.9, 45.4, 35.3, 31.8, 30.3, 30.0, 29.7, 29.4, 29.2, 29.1, 20.5, 18.4, 18.3, 15.8; 
IR (film, cm-1) 3406 (br), 2927, 2360, 1614, 1433, 1385, 1274, 1243, 1207, 1174, 1078, 
1008, 818, 733; 
HRMS (ESI) m/z calcd for C39H55N5O5 (M+H)+ 674.4281; found 674.4301 (3.0 ppm). 
 
N N
O
N N
O
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Compound 1lat 
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(R)-6-((R)-1-Hydroxyethyl)-1-(1-((S)-1-(1-((R)-2-isobutyl-6-oxo-1,2,3,6-
tetrahydropyridin-4-yl)piperidin-4-yl)-2-methyl-6-oxo-1,2,3,6-tetrahydropyridin-4-
yl)piperidin-4-yl)-4-methoxy-5,6-dihydropyridin-2(1H)-one 
 
White solid, 65 %; mp = 122.4 – 124.2 °C; [α]20 +15.7 (c 0.2, CHCl3) 
1H-NMR (300 MHz, CDCl3) δ 5.03 (d, J = 1.5 Hz, 1H), 4.90 (s, 1H), 4.87 (s, 1H), 
4.66-4.54 (m, 1H), 4.39-4.23 (m, 1H), 3.99-3.85 (m, 1H), 3.82-3.54 (m, 9H), 3.47-3.38 
(m, 1H), 2.97-2.43 (m, 6H), 2.42-2.38 (m, 2H), 2.20-2.14 (m, 2H), 1.90-1.44 (m, 11H), 
1.38-1.25 (m, 1H), 1.21 (d, J = 6.6 Hz, 3H), 1.13 (d, J = 6.3 Hz, 3H), 0.96-0.91 (m, 6H);  
13C-NMR (75 MHz, CDCl3) δ 170.9, 167.2, 166.7, 166.0, 157.5, 154.1, 94.6, 92.5, 
91.0, 67.9, 56.3, 55.7, 53.6, 50.0, 48.3, 46.1, 46.1, 45.9, 45.3, 44.4, 33.4, 32.7, 30.2, 
30.1, 29.7, 29.5, 28.9, 28.5, 24.3, 23.0, 22.2, 20.3, 19.4; 
IR (film, cm-1) 3286, 2927, 1601, 1432, 1383, 1277, 1225, 1078, 1007, 804; 
HRMS (ESI) m/z calcd for C33H51N5O5 (M+H)+ 598.3968; found 598.3941 (4.3 ppm). 
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Compound 1faf 
 
(R)-6-benzyl-1-(1-((S)-1-(1-((R)-2-benzyl-1-(4-bromobenzyl)-6-oxo-1,2,3,6-
tetrahydropyridin-4-yl)piperidin-4-yl)-2-methyl-6-oxo-1,2,3,6-tetrahydropyridin-4-
yl)piperidin-4-yl)-4-methoxy-5,6-dihydropyridin-2(1H)-one 
 
 
 
White solid, 40 %; mp = 135.1 – 136.4 °C; [α]20 -23.3 (c 0.2, CHCl3);  
1H NMR (400 MHz, CDCl3) δ 7.45 (d, J = 8.3 Hz, 2H), 7.39-7.20 (m, 6H), 7.18 (d, J = 
8.3 Hz, 1H), 7.16-7.04 (m, 4H), 5.34 (d, J = 15.3 Hz, 1H), 5.17 (d, J = 1.4 Hz, 1H), 5.07 
(s, 1H), 5.00 (s, 1H), 4.70 – 4.53 (m, 2H), 3.83 – 3.60 (m, 10H), 3.58-3.48 (m, 1H), 3.05 
– 2.76 (m, 8H), 2.61 (dd, J = 15.5, 5.9 Hz, 1H), 2.50 (dd, J = 16.9, 5.7 Hz, 1H), 2.36 (dd, 
J = 15.8, 6.1 Hz, 1H), 2.29 – 2.13 (m, 3H), 2.07 – 1.52 (m, 8H), 1.30 (d, J = 6.5 Hz, 3H); 
 
13C NMR (101 MHz, CDCl3) δ 166.64, 166.39, 165.77, 165.73, 153.97, 153.86, 138.17, 
138.16, 137.69, 131.62, 129.72, 129.31, 129.24, 128.77, 128.68, 126.89, 126.72, 120.98, 
94.60, 93.32, 91.70, 55.68, 55.34, 51.91, 51.35, 50.10, 46.92, 46.12, 46.01, 45.97, 45.39, 
39.50, 36.92, 33.57, 30.92, 30.57, 30.35, 29.66, 29.28, 28.95, 28.77, 20.41; 
N N
O
N N
O
OMeN
O
Ph Ph
Br
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HRMS (ESI) m/z calcd for C48H56BrN5O4 (M+H)+ 846.3594; found 846.3564 (3.5 ppm). 
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C. Synthesis of Oligomeric Mimic 14 
 
 
 
 
Anhydrous KHCO3 powder (4.00 g, 40.0 mmol, 40.0 equiv.) was added to a 0.5 
M solution of D-8f (300.5 mg, 1.0 mmol, 1.0 equiv.) in CH2Cl2.  The vinyl chloride D-
10f (439.0 mg, 1.0 mmol, 1.0 equiv.) was then added as a 0.5 M solution in CH2Cl2 to 
the reaction mixture.  While stirring at room temperature, the solvent was removed with 
nitrogen.  The resulting solid was heated up to the 120 ºC under N2.  After 24 h, 2 mL 
anhydrous 1,4-dioxane was added, stirred for 10 mins and then removed with nitrogen.  
The mixture was kept at 120 ºC under N2 for another 24 h.  After the reaction finished, 
the mixture was cooled down to room temperature.  20 mL CH2Cl2 was added and the 
inorganic solids were removed by filtration.  The solution was concentrated to give the 
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crude product.  The product was purified by flash chromatography (SiO2, 3 % 
MeOH/CH2Cl2 - 5 % MeOH/CH2Cl2) to afford the product DD-11ff. 
Benzyl 4-((R)-2-benzyl-4-(4-((R)-2-benzyl-4-methoxy-6-oxo-3,6-dihydropyridin-1(2H)-
yl)piperidin-1-yl)-6-oxo-3,6-dihydropyridin-1(2H)-yl)piperidine-1-carboxylate (DD-
11ff): white foamy solid, 454.3 mg from coupling of D-11f and D-8f with general 
procedure A, 65 % yield; 1H NMR (400 MHz, CDCl3) δ 7.40-7.20 (m, 12H), 7.18 – 7.04 
(m, 3H), 5.16 (s, 3H), 5.06 (s, 1H), 4.77 – 4.61 (m, 1H), 4.59-4.50 (m, 1H), 4.33 (br, 
2H), 3.75 – 3.60 (m, 7H), 3.14 – 2.71 (m, 8H), 2.54 (dd, J = 16.9, 5.6 Hz, 1H), 2.34 – 
2.09 (m, 3H), 1.99 – 1.55 (m, 8H); 13C NMR (101 MHz, CDCl3) δ 166.42, 166.17, 
165.75, 155.21, 153.67, 138.38, 137.75, 136.80, 129.26, 129.18, 128.79, 128.70, 128.51, 
128.03, 127.93, 126.91, 126.80, 94.60, 93.12, 67.19, 55.69, 52.16, 51.62, 51.53, 50.38, 
45.99, 45.71, 43.91, 43.82, 39.54, 39.16, 31.06, 30.83, 30.11, 29.79, 29.67, 28.57; 
HRMS (ESI+): m/z calcd for C43H50N4O5 [M+H]+ 703.3859; found 703.384. 
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Benzyl 4-((R)-2-benzyl-4-(4-((R)-2-benzyl-4-(4-((R)-2-benzyl-4-methoxy-6-oxo-
3,6-dihydropyridin-1(2H)-yl)piperidin-1-yl)-6-oxo-3,6-dihydropyridin-1(2H)-
yl)piperidin-1-yl)-6-oxo-3,6-dihydropyridin-1(2H)-yl)piperidine-1-carboxylate (DDD-
12fff). DD-11ff (351.3 mg, 0.5 mmol) was deprotected with general procedure B and the 
product was coupled with D-10f (220.5 mg, 0.5 mmol) using general procedure for 
coupling reaction to give DDD-12fff as a light yellow oil. 268.8 mg, 55 % yield; 1H 
NMR (400 MHz, CDCl3) δ 7.43 – 7.05 (m, 20H), 5.18 (s, 3H), 5.05 (s, 1H), 5.06 (s, 1H), 
4.76 – 4.48 (m, 3H), 4.35 (br, 2H), 3.74 – 3.63 (m, 10H), 3.12 – 2.76 (m, 12H), 2.55 (dd, 
J = 16.8, 5.6 Hz, 1H), 2.33-2.13 (m, 5H), 2.00 – 1.61 (m, 12H); 13C NMR (101 MHz, 
CDCl3) δ 166.42, 166.25, 165.76, 155.22, 153.72, 153.67, 138.41, 138.32, 137.74, 
136.80, 129.28, 129.19, 128.80, 128.75, 128.70, 128.51, 128.03, 127.93, 126.92, 126.87, 
126.79, 94.60, 93.11, 92.90, 67.20, 55.69, 52.20, 51.97, 51.66, 51.56, 50.91, 50.38, 
46.02, 45.77, 45.74, 43.92, 43.83, 39.54, 39.24, 39.16, 31.06, 30.84, 30.23, 30.09, 29.81, 
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29.67, 28.78, 28.56; HRMS (ESI+): m/z calcd for C60H70N6O6 [M+H]+ 971.5435; found 
971.5437. 
 
 
 
Benzyl 4-((R)-2-benzyl-4-(4-((R)-2-benzyl-4-(4-((R)-2-benzyl-4-(4-((R)-2-
benzyl-4-methoxy-6-oxo-3,6-dihydropyridin-1(2H)-yl)piperidin-1-yl)-6-oxo-3,6-
dihydropyridin-1(2H)-yl)piperidin-1-yl)-6-oxo-3,6-dihydropyridin-1(2H)-yl)piperidin-1-
yl)-6-oxo-3,6-dihydropyridin-1(2H)-yl)piperidine-1-carboxylate (DDDD-13ffff). DDD-
12fff (194.9 mg, 0.2 mmol) was deprotected with general procedure for Cbz 
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deprotection and the product was coupled with D-10f (175.6 mg, 0.4 mmol) using 
general procedure for coupling reaction to give DDDD-13ffff as a light yellow oil. 99.6 
mg, 41 % yield; 1H NMR (400 MHz, CDCl3) δ 7.44 – 7.08 (m, 25H), 5.19 (s, 3H), 5.10 
– 5.02 (m, 3H), 4.79 – 4.47 (m, 4H), 4.35 (br, 2H), 3.80 – 3.61 (m, 13H), 3.14 – 2.76 (m, 
16H), 2.55 (dd, J = 16.8, 5.8 Hz, 1H), 2.39 – 2.16 (m, 7H), 2.03 – 1.57 (m, 16H); 13C 
NMR (101 MHz, CDCl3) δ 166.41, 166.31, 166.24, 165.76, 155.23, 153.71, 153.66, 
138.42, 138.36, 138.32, 137.75, 136.80, 129.29, 129.20, 128.80, 128.75, 128.70, 128.51, 
128.03, 127.94, 126.92, 126.88, 126.79, 94.62, 93.15, 92.93, 92.92, 67.20, 55.69, 52.21, 
52.02, 51.66, 51.57, 50.95, 50.91, 50.36, 46.06, 46.03, 45.80, 45.75, 43.92, 43.83, 39.54, 
39.25, 39.17, 31.06, 30.84, 30.25, 30.10, 29.94, 29.82, 29.68, 28.79, 28.57; HRMS 
(MALDI+): m/z calcd for C77H90N8O7 [M+Na]+ 1261.6824; found 1261.6881. 
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Benzyl 4-((R)-2-benzyl-4-(4-((R)-2-benzyl-4-(4-((R)-2-benzyl-4-(4-((R)-2-
benzyl-4-(4-((R)-2-benzyl-4-methoxy-6-oxo-3,6-dihydropyridin-1(2H)-yl)piperidin-1-
yl)-6-oxo-3,6-dihydropyridin-1(2H)-yl)piperidin-1-yl)-6-oxo-3,6-dihydropyridin-1(2H)-
yl)piperidin-1-yl)-6-oxo-3,6-dihydropyridin-1(2H)-yl)piperidin-1-yl)-6-oxo-3,6-
dihydropyridin-1(2H)-yl)piperidine-1-carboxylate (DDDDD-14fffff): DDDD-13ffff (75.1 
mg, 0.06 mmol) was deprotected with general procedure B and the product was coupled 
with D-10f (88.5 mg, 0.2 mmol) using general procedure A to give DDDDD-14fffff as a 
light yellow oil. 27.6 mg, 31 % yield; 1H NMR (400 MHz, CDCl3) δ 7.49 – 7.07 (m, 
30H), 5.21-5.17 (m, 3H), 5.10 – 5.02 (m, 4H), 4.77 – 4.49 (m, 5H), 4.35 (br, 2H), 3.77 – 
3.62 (m, 16H), 3.15 – 2.79 (m, 20 H), 2.56 (dd, J = 16.9, 5.6 Hz, 1H), 2.37 – 2.15 (m, 
9H), 2.09 – 1.61 (m, 20H); 13C NMR (101 MHz, CDCl3) δ 166.42, 166.33, 166.26, 
165.77, 155.22, 153.73, 153.67, 138.40, 138.34, 138.31, 137.73, 136.79, 129.28, 129.19, 
128.80, 128.75, 128.69, 128.50, 128.03, 127.93, 126.91, 126.87, 126.79, 94.60, 93.10, 
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92.87, 67.19, 55.69, 52.22, 52.02, 51.69, 51.56, 50.98, 50.93, 50.38, 46.03, 45.81, 45.74, 
43.91, 43.83, 39.53, 39.24, 39.16, 31.06, 30.23, 30.09, 29.81, 29.67, 28.79, 28.56; 
HRMS (MALDI+): m/z calcd for C94H110N10O8 [M+Na]+ 1529.8398; found 1529.8406. 
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APPENDIX C  
EXPERIMENTAL PROCEDURES FOR CHAPTER III 
 
A. Synthesis of Oligo-piperidines-pyrrolidinones 
 
 
 
 
 
 
General Procedure for the Syntheses of 18 
NaBH(OAc)3 (6.36 g, 30.0 mmol) was added portionwise to a solution of L-
alanine tert-butyl ester hydrochloride (1.82 g, 10.0 mmol), benzyl 4-oxopiperidine-1-
carboxylate (2.33 g, 10.0 mmol), triethylamine (1.39 mL, 10.0 mmol) in 1,2-
dichloroethane (70.0 mL) at 0 ºC (ice bath) under nitrogen in a round bottom flask.  Ice 
bath was removed and after stirring at 27 ºC for 24 h, CH2Cl2 (100 mL) was added.  The 
N
O
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O
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O
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(ii) H2, Pd/C, MeOH, 25 oC, 10 h
(i)
R2 = Me, a, 94 %
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H
w, 90 %
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s', 96 %Bn, f, 96 %
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O
O
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O
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CH2Cl2, 25 oC, 10 h
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O
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O
aa, 74 %; af, 69 %; aw, 63 %
as', 60 %; fs', 23 %; ma, 25 %
19
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mixture was washed with saturated NaHCO3 solution 3 times (3 × 100 mL) and then 
with brine (100 mL).  The organic layer was separated, dried over anhydrous MgSO4, 
and concentrated in vacuo to give the product 16a 3.48 g (96 % yield) as a colorless oil.  
16a (2.90 g, 8.0 mmol) was dissolved in dry dioxane (70.0 mL) in a round 
bottom flask and heated to 100 ºC under nitrogen atmosphere.  Bestmann’s ylide (re-
crystallized from PhMe, 5.32 g, 17.6 mmol, 2.2 equiv) was added in one portion.  Then 
10 mL TFA solution (0.4 M in dry dioxane) was added dropwise over 10 mins.  The 
reaction was monitored by 1H NMR spectroscopy.  After completion of reaction (3 h), 
the solvent was removed under reduced pressure.  The resulting oil was dissolved in 
dichloromethane and filtered through a thin layer of silica gel (~ 1 cm).  The silica gel 
was further washed with 9:1 dichloromethane/ethyl acetate.  The solvent was removed 
under reduced pressure to give the cyclized product contaminated with Ph3PO. 
10 wt % Pd/C (0.85 g, 0.10 equiv Pd) was carefully added to a stirred solution of 
the crude cyclization product in methanol (60 mL) under nitrogen at 25 ºC.  The reaction 
was evacuated, refilled with N2, and placed under an atmosphere of H2 (1 atm, balloon) 
for 10 h.  The reaction mixture was purged with N2, and filtered over a pad of celite 
under a gentle vacuum (SAFETY NOTE: Do not let the pad run dry).  The celite pad 
was washed with methanol (2 × 15 mL), and the combined filtrates were concentrated.  
The residue was purified by flash chromatography (SiO2, 3 % MeOH/CH2Cl2 - 5 % 
MeOH/CH2Cl2 containing 1 % Et3N) to afford the product 18a (1.37 g, 68 %) as a white 
solid. 
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(S)-4-(tert-Butoxy)-5-methyl-1-(piperidin-4-yl)-1H-pyrrol-2(5H)-one (18a): 
white solid, 1.37 g, 68 % yield over two steps; mp = 130.5-131.0 ºC; 1H NMR (300 
MHz, CDCl3) d 4.96 (1H, s), 4.01-3.81 (2H, m), 3.18-3.04 (2H, m), 2.71-2.56 (3H, m), 
1.83-1.61 (4H, m), 1.39 (9H, s), 1.29 (3H, d, J = 6.9 Hz); 13C NMR (75 MHz, CDCl3) d 
172.2, 171.8, 95.2, 81.4, 56.6, 49.6, 46.3, 46.2, 32.9, 31.0, 27.4, 18.7. HRMS (ESI+): 
m/z calcd for C14H24N2O2 [M+H]
+
 253.1916; found 253.1908. 
(S)-5-Benzyl-4-(tert-butoxy)-1-(piperidin-4-yl)-1H-pyrrol-2(5H)-one (18f): 
white solid, 0.83 g from L-phenylalanine tert-butyl ester hydrochloride (1.03 g, 4.00 
mmol), 63 % yield over three steps; mp = 218.8-219.6 ºC; 1H NMR (300 MHz, CDCl3) d 
7.25-7.13 (5H, m), 5.30-5.22 (1H, br), 4.92 (1H, s), 4.16 (1H, t, J = 5.1 Hz), 3.64-3.52 
(1H, m), 3.28-3.18 (2H, m), 3.09 (1H, dd, J = 5.1, 14.4 Hz), 3.00 (1H, dd, J = 5.1, 14.4 
Hz), 2.78-2.59 (2H, m), 2.35-2.04 (2H, m), 1.89-1.69 (2H, m), 1.28 (9H, s); 13C NMR 
(75 MHz, CDCl3) d 174.0, 170.6, 136.0, 129.4, 128.1, 126.7, 96.8, 82.0, 61.6, 50.7, 45.6, 
45.5, 36.9, 30.1, 29.7, 27.3. HRMS (ESI+): m/z calcd for C20H28N2O2 [M+H]
+
 329.2229; 
found 329.2220. 
(S)-5-((1H-Indol-3-yl)methyl)-4-(tert-butoxy)-1-(piperidin-4-yl)-1H-pyrrol-
2(5H)-one (18w): white solid, 1.12 g from L-tryptophan tert-butyl ester hydrochloride 
(1.48 g, 5.00 mmol), 61 % yield over three steps; mp = 197.9-198.4 ºC; 1H NMR (300 
MHz, CDCl3) d 7.58 (1H, d, J = 6.6 Hz), 7.32 (1H, d, J = 6.6 Hz), 7.16-7.03 (3H, m), 
4.83 (1H, s), 4.29 (1H, t, J = 4.2 Hz), 3.38-3.19 (2H, m), 3.19-3.04 (2H, m), 2.66-2.53 
(2H, m), 2.53-2.32 (1H, br), 2.05-1.69 (4H, m), 1.07 (9H, s); 13C NMR (75 MHz, 
CDCl3) d 174.0, 170.7, 135.5, 128.1, 122.2, 121.6, 118.8, 118.6, 111.1, 108.7, 96.6, 81.6, 
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60.7, 50.9, 46.4, 46.3, 32.3, 31.4, 26.8, 25.4. HRMS (ESI+): m/z calcd for C22H29N3O2 
[M+H]
+
 368.2338; found 368.2324. 
(S)-4-(tert-Butoxy)-5-(tert-butoxymethyl)-1-(piperidin-4-yl)-1H-pyrrol-2(5H)-
one (3s’): colorless oil, 0.91 g from O-tert-butyl-L-serine tert-butyl ester hydrochloride 
(1.27 g, 5.00 mmol), 56 % yield over three steps; 1H NMR (300 MHz, CDCl3) d 4.96 
(1H, s), 3.97-3.82 (2H, m), 3.67 (1H, dd, J = 2.4, 9.3 Hz), 3.39 (1H, dd, J = 5.1, 9.3 Hz), 
3.18-3.03 (2H, m), 2.64-2.51 (3H, m), 2.08-1.82 (2H, m), 1.79-1.58 (2H, m), 1.38 (9H, 
s), 1.11 (9H, s); 13C NMR (75 MHz, CDCl3) d 172.9, 168.2, 96.9, 81.4, 72.9, 62.0, 61.2, 
50.5, 46.6, 46.4, 32.1, 31.2, 27.4, 27.3. HRMS (ESI+): m/z calcd for C18H32N2O3 
[M+H]
+
 325.2491; found 325.2479. 
 
General Procedure for the Syntheses of 19 
To a stirred solution of 18a (126.2mg, 0.5 mmol), 17a (113.1 mg, 1.0 mmol), and 
HOAt (149.7 mg, 1.1 mmol) in dry dichloromethane (5 mL) under nitrogen in a round 
bottom flask, KHCO3 (0.25 g, 2.5 mmol) and EDCI (210.9 mg, 1.1 mmol) was added 
and the resulting yellow mixture was stirred at room temperature for 10 h.  After the 
reaction is complete, dichloromethane (10 mL) was added to precipitate the urea by-
product.  The solvent was decanted and the dark red solid was washed twice with 
dichloromethane (2 × 10 mL).  The organic solution was combined and evaporated 
under reduced pressure.  The residue was purified by flash chromatography (SiO2, 3 % 
MeOH/CH2Cl2 - 5 % MeOH/CH2Cl2) to afford the product 19aa (128.4 mg, 74 % yield) 
as a colorless oil. 
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(S)-4-(tert-Butoxy)-5-methyl-1-(1-((S)-2-methyl-5-oxo-2,5-dihydro-1H-pyrrol-3-
yl)piperidin-4-yl)-1H-pyrrol-2(5H)-one (19aa): colorless oil, 128.4 mg, 74 % yield; 1H 
NMR (300 MHz, CDCl3) d 6.46 (1H, s), 4.95 (1H, s), 4.66 (1H, s), 4.16 (1H, q, J = 6.3 
Hz), 4.09-3.95 (1H, m), 3.83 (1H, q, J = 6.6 Hz), 3.59-3.40 (2H, m), 3.00-2.83 (2H, m), 
1.99-1.66 (4H, m), 1.38 (9H, s), 1.33 (3H, d, J = 6.3 Hz), 1.28 (3H, d, J = 6.6 Hz); 13C 
NMR (75 MHz, CDCl3) d 175.9, 172.3, 171.9, 169.4, 95.1, 90.8, 81.6, 56.7, 52.3, 49.2, 
48.0, 47.8, 31.2, 28.9, 27.4, 20.5, 18.7. HRMS (ESI+): m/z calcd for C19H29N3O3 
[M+H]+ 348.2287; found 348.2284. 
(S)-5-Benzyl-4-(tert-butoxy)-1-(1-((S)-2-methyl-5-oxo-2,5-dihydro-1H-pyrrol-3-
yl)piperidin-4-yl)-1H-pyrrol-2(5H)-one (19af): colorless oil, 145.9 mg from 18f (164.0 
mg, 0.5 mmol) and 17a (113.1 mg, 1.0 mmol), 69 % yield; 1H NMR (300 MHz, CDCl3) 
d 7.31-7.09 (5H, m), 6.17 (1H, s), 4.88 (1H, s), 4.65 (1H, s), 4.16-4.08 (2H, m), 3.62-
3.38 (3H, m), 3.11 (1H, dd, J = 4.8, 14.7 Hz), 2.92 (1H, dd, J = 5.4, 14.7 Hz), 2.85-2.70 
(2H, m), 2.20-2.14 (1H, m), 2.02-1.96 (1H, m), 1.83-1.79 (1H, m), 1.72-1.67 (1H, m),  
1.38-1.26 (12H, m); 13C NMR (75 MHz, CDCl3) d 175.8, 173.7, 170.3, 169.4, 136.2, 
129.2, 128.2, 126.9, 96.8, 90.8, 81.9, 61.7, 52.2, 51.1, 48.1, 47.8, 37.3, 29.8, 29.1, 27.3, 
20.5. HRMS (ESI+): m/z calcd for C25H33N3O3 [M+H]+ 424.2600; found 424.2605. 
(S)-5-((1H-Indol-3-yl)methyl)-4-(tert-butoxy)-1-(1-((S)-2-methyl-5-oxo-2,5-
dihydro-1H-pyrrol-3-yl)piperidin-4-yl)-1H-pyrrol-2(5H)-one (19aw): light yellow oil, 
145.5 mg from 18w (183.5 mg, 0.5 mmol) and 17a (113.1 mg, 1.0 mmol), 63 % yield; 
1H NMR (300 MHz, CDCl3) d 9.05 (1H, s), 7.53 (1H, d, J = 7.8 Hz), 7.34 (1H, d, J = 7.5 
Hz), 7.16-7.04 (2H, m), 7.01 (1H, d, J = 2.1 Hz), 6.19 (1H, s), 4.91 (1H, s), 4.60 (1H, s), 
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4.26 (1H, t, J = 5.1 Hz), 4.00 (1H, q, J = 6.3 Hz), 3.89-3.77 (1H, m), 3.44-3.06 (4H, m), 
2.83-2.64 (2H, m), 2.12-1.54 (4H, m), 1.28 (3H, d, J = 6.3 Hz), 1.23 (9H, s); 13C NMR 
(75 MHz, CDCl3) d 176.1, 173.8, 170.9, 169.5, 135.8, 127.7, 122.2, 121.8, 119.0, 118.4, 
111.4, 109.3, 96.4, 90.4, 81.9, 61.3, 52.2, 50.4, 48.1, 47.8, 30.3, 28.7, 27.1, 26.6, 20.4. 
HRMS (ESI+): m/z calcd for C27H34N4O3 [M+H]+ 463.2709; found 463.2692. 
(S)-4-(tert-Butoxy)-5-(tert-butoxymethyl)-1-(1-((S)-2-methyl-5-oxo-2,5-dihydro-
1H-pyrrol-3-yl)piperidin-4-yl)-1H-pyrrol-2(5H)-one (19as’): colorless oil, 100.4 mg 
from 18s’ (130.0 mg, 0.4 mmol) and 17a (90.5 mg, 0.8 mmol), 60 % yield; 1H NMR 
(300 MHz, CDCl3) d 6.14 (1H, s), 4.99 (1H, s), 4.66 (1H, s), 4.15 (1H, q, J = 6.6 Hz), 
4.10-3.95 (1H, m), 3.92 (1H, dd, J = 2.1, 6.6 Hz), 3.66 (1H, dd, J = 2.4, 9.6 Hz), 3.59-
3.39 (2H, m), 3.28 (1H, dd, J = 6.9, 9.6 Hz), 3.00-2.81 (2H, m), 2.34-2.00 (2H, m), 1.82-
1.59 (2H, m), 1.41 (9H, s), 1.34 (3H, d, J = 6.6 Hz), 1.14 (9H, s); 13C NMR (75 MHz, 
CDCl3) d 176.1, 172.8, 169.6, 168.1, 96.7, 90.2, 81.8, 73.4, 62.7, 62.3, 52.3, 49.9, 48.2, 
47.9, 30.2, 28.7, 27.5, 27.4, 20.5. HRMS (ESI+): m/z calcd for C23H37N3O4 [M+H]+ 
420.2862; found 420.2878. 
(S)-1-(1-((S)-2-Benzyl-5-oxo-2,5-dihydro-1H-pyrrol-3-yl)piperidin-4-yl)-4-(tert-
butoxy)-5-(tert-butoxymethyl)-1H-pyrrol-2(5H)-one (19fs’): colorless oil, 45.5 mg from 
18s’ (130.0 mg, 0.4 mmol) and 17f (151.4 mg, 0.8 mmol), 23 % yield; 1H NMR (300 
MHz, CDCl3) d 7.33-7.18 (5H, m), 5.22 (1H, s), 5.01 (1H, s), 4.73 (1H, d, J = 2.4 Hz), 
4.28 (1H, dd, J = 4.5, 9.9 Hz), 4.13-3.99 (1H, m), 3.95 (1H, dd, J = 2.4, 6.9 Hz), 3.73-
3.46 (3H, m), 3.34-3.27 (1H, m), 3.16 (1H, dd, J = 2.7, 7.8 Hz), 3.09-2.89 (2H, m), 2.55 
(1H, dd, J = 9.6, 13.8 Hz), 2.21-2.09 (2H, m), 1.88-1.67 (2H, m), 1.42 (9H, s), 1.14 (9H, 
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s); 13C NMR (75 MHz, CDCl3) d 175.2, 172.8, 168.1, 167.6, 137.1, 129.0, 128.8, 127.1, 
96.8, 91.9, 81.8, 73.4, 62.8, 62.4, 57.7, 50.0, 48.5, 48.1, 41.3, 30.2, 28.7, 27.5, 27.4. 
HRMS (ESI+): m/z calcd for C29H41N3O4 [M+H]+ 496.3176; found 496.3163. 
(S)-4-(tert-Butoxy)-5-methyl-1-(1-((S)-2-(2-(methylthio)ethyl)-5-oxo-2,5-
dihydro-1H-pyrrol-3-yl)piperidin-4-yl)-1H-pyrrol-2(5H)-one (19ma): light yellow oil, 
50.9 mg from 18a (126.2mg, 0.5 mmol) and 17m (173.2 mg, 1.0 mmol), 25 % yield; 1H 
NMR (300 MHz, CDCl3) d 6.45 (1H, s), 5.00 (1H, s), 4.78 (1H, d, J = 1.5 Hz), 4.33-4.29 
(2H, m), 4.11-3.98 (1H, m), 3.87 (1H, q, J = 6.6 Hz), 3.60-3.42 (2H, m), 3.04-2.91 (2H, 
m), 2.60 (2H, t, J = 7.8 Hz), 2.12 (3H, s), 2.10-1.71 (6H, m), 1.44 (9H, s), 1.32 (3H, d, J 
= 6.6 Hz); 13C NMR (75 MHz, CDCl3) d 176.0, 172.4, 171.9, 167.7, 95.2, 92.4, 81.7, 
56.7, 55.6, 49.2, 48.3, 48.1, 33.8, 31.2, 30.4, 28.9, 27.4, 18.7, 15.7. HRMS (ESI+): m/z 
calcd for C21H33N3O3S [M+H]+ 408.2321; found 408.2314. 
 
Procedure for the Syntheses of 15aaa  
19aa (277.7 mg, 0.5 mmol) was treated with TFA/CH2Cl2 (1:1, 5 mL) at 25 ºC.  
The reaction was stirred in a vented teflon-capped flask until complete disappearance of 
starting material (monitored by NMR spectroscopy, ~ 3 h).  Toluene (10 mL) was added 
and the reaction mixture was concentrated in vacuo.  Toluene (2 × 10 mL) was used to 
azeotrope residual TFA.  The crude oil was dissolved in dichloromethane (4 mL) and 
filtered through a thin layer of silica gel (~ 0.5 cm) to remove some polar impurities.  
The silica gel was washed with 5 % MeOH/CH2Cl2 5 times (5 × 5 mL).  The organic 
fractions were combined and the solvent was removed in vacuo to give the deprotected 
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19aa as a white solid.  The white solid was dried under high vacuum and used directly in 
the next step without further purification. 
To a stirred solution of 18a (75.6 mg, 0.3 mmol), deprotected 19aa from 
previous step, and HOAt (89.8 mg, 0.66 mmol) in dry dichloromethane (2 mL) under 
nitrogen, KHCO3 (150 mg, 1.5 mmol) and EDCI (126.5 mg, 0.66 mmol) was added and 
the resulting yellow mixture was stirred at room temperature for 16 h.  After the reaction 
was complete, dichloromethane (4 mL) was added to precipitate the urea by-product.  
The solvent was decanted and the light red solid was washed twice with 
dichloromethane (2 × 3 mL).  The organic solution was combined and evaporated under 
reduced pressure.  The residue was purified by flash chromatography (SiO2, 4 % 
MeOH/CH2Cl2 - 6 % MeOH/CH2Cl2) to afford the product 15aaa. 
(S)-4-(tert-Butoxy)-5-methyl-1-(1-((S)-2-methyl-1-(1-((S)-2-methyl-5-oxo-2,5-
dihydro-1H-pyrrol-3-yl)piperidin-4-yl)-5-oxo-2,5-dihydro-1H-pyrrol-3-yl)piperidin-4-
yl)-1H-pyrrol-2(5H)-one (15aaa): colorless oil, 64.6 mg, 41 % yield over two steps; 1H 
NMR (300 MHz, CDCl3)  d 5.74 (1H, s), 4.97 (1H, s), 4.77 (1H, s), 4.71 (1H, d, J = 1.8 
Hz), 4.18 (1H, q, J = 6.3 Hz), 4.12-3.91 (3H, m), 3.86 (1H, q, J = 6.3 Hz), 3.59-3.33 
(4H, m), 3.06-2.84 (4H, m), 2.19-1.68 (8H, m), 1.42 (9H, s), 1.35 (6H, d, J = 6.3 Hz), 
1.30 (3H, d, J = 6.6 Hz); 13C NMR (75 MHz, CDCl3) d 175.7, 172.8, 172.4, 171.9, 
169.3, 167.6, 95.2, 92.3, 90.8, 81.7, 56.8, 54.3, 52.1, 49.6, 49.3, 48.3, 48.1, 48.0, 47.9, 
31.3, 31.0, 29.0, 28.7, 27.4, 21.1, 20.6, 18.6. HRMS (MALDI+): m/z calcd for 
C29H43N5O4 [M+H]+ 526.3388; found 526.3384. 
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(S)-4-(tert-Butoxy)-5-methyl-1-(1-((S)-2-methyl-1-(1-((S)-2-methyl-5-oxo-2,5-
dihydro-1H-pyrrol-3-yl)piperidin-4-yl)-5-oxo-2,5-dihydro-1H-pyrrol-3-yl)piperidin-4-
yl)-1H-pyrrol-2(5H)-one (15aaa): 
 
 
 
 
B. Synthesis Of β-Ketoesters And β-Ketothioesters 
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Synthesis Of β-Ketoesters And β-Ketothioesters With 2,2,6-Trimethyl-4H-1,3-
dioxin-4-one 
 A solution of 20 mmol phenol or thiol and 20 mmol 2,2,6-trimethyl-4H-1,3-
dioxin-4-one in 10 mL xylenes was placed in a 50 mL Erlenmeyer flask. The the 
solution was vigorously stirred at 145 °C. After 30 minutes, the reaction mixture was 
cooled and the xylene was removed. The residue was purified by flash chromatography 
(hexanes/CH2Cl2 3:1 to 1:2) to give the desired product.10 
 
Procedure For The Alkylation Of β-Ketothioesters 
NaH (132 mg, 5.5 mmol) was added to a solution of S-butyl 3-oxobutanethioate 
(872 mg, 5 mmol) in 20 mL anhydrous 1,2-dimethoxylethane (DME) at 0 °C under N2. 
After stirring the resulting mixture at 0 °C for 30 min, anhydrous allyl bromide (480 uL, 
5.5 mmol) was added dropwise over 5 min. The mixture was stirred at room temperature 
for 18 h.  The reaction was quenched with saturated NaHCO3 (50 mL) and the aqueous 
phase was extracted with DCM three times (50 mL × 3). The combined organic phase 
was washed with brine and dried over MgSO4. The solvent was removed under vacuum 
and the crude product was purified by flash chromatography (hexanes/CH2Cl2 5:1 to 
1:1).11 
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C. Synthesis Of β-Enamino Esters And β-Enamino Thioesters 
General Procedures 
Method A with EDCI and HOAt: 
EDCI (144 mg, 0.75 mmol) and HOAt (82 mg, 0.6 mmol) were added to a 
mixture of the β-keto substrate (0.5 mmol) and KHCO3 powder (500 mg, 10 equiv.) in 
2.5 mL CHCl3 under N2 at 25 °C. The mixture was stirred for 10 min, followed by the 
addition of amine nucleophile. The resulting light yellow mixture was stirred at 25 °C 
for 12 h. 10 mL of DCM was added and the mixture was filtered through Celite. Solvent 
was removed under vacuum to give the crude product. The product was dissolved in 
DCM and filtered through a pad of silica gel and the silica gel was washed with DCM a 
couple times to give the pure β-enamino ester or β-enamino thioester. For the synthesis 
of β-enamino amides, the crude product was purified by flash chromatography (3 % - 6 
% MeOH in CH2Cl2). This method was applied to the syntheses of compounds 25. 
 
Method B with PyBOP and imidazole: 
PyBOP (312 mg, 0.6 mmol) and imidazole (170 mg, 2.5 mmol) were added to a 
mixture of the β-keto substrate (0.5 mmol) in 2.5 mL CHCl3 under N2 at 25 °C. The 
mixture was stirred for 10 min, followed by the addition of amine nucleophile. The 
resulting mixture was stirred at 25 °C for 12 h. 10 mL of DCM was added and the 
mixture was filtered through a short layer of silica gel and the silica gel was washed with 
DCM a couple times to give the pure β-enamino ester or β-enamino thioester unless 
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otherwise noted for specific compounds. This method was applied to the syntheses of 
compounds 20. 
 
Method C with PyBOP, HOAt and KHCO3: 
Same as method B except that HOAt (82 mg, 0.6 mmol) and KHCO3 powder (500 mg, 
10 equiv.) were used instead of imidazole. This method was applied to the syntheses of 
compounds 21. 
 
Compound 20a 
Phenyl (Z)-3-(benzylamino)but-2-enoate 
 
White solid, 87 %; mp = 116.8-118.0 °C;  
1H-NMR (400 MHz, CDCl3) δ 9.04 (s, 1H), 7.46-7.24 (m, 7H), 7.24-7.09 (m, 3H), 4.80 
(s, 1H), 4.47 (d, J = 6.2 Hz, 2H), 2.04 (s, 3H); 
13C-NMR (100 MHz, CDCl3) δ 168.9, 163.7, 151.3, 138.0, 129.1, 128.8, 127.5, 126.9, 
124.9, 122.1, 82.1, 47.0, 19.5; 
HRMS (ESI) m/z calcd for C17H17NO2 (M+H)+ 268.1338; found 268.1325. 
NH
OPh
OPh
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Compound 20b 
Ethyl (Z)-3-(benzylamino)but-2-enoate 
 
Colorless oil, 91 %;  
1H-NMR (400 MHz, CDCl3) δ 8.98 (s, 1H), 7.41-7.23 (m, 5H), 4.56 (s, 1H), 4.45 (d, J = 
6.4 Hz, 2H), 4.13 (q, J = 7.1 Hz, 2H), 1.94 (s, 3H), 1.28 (t, J = 7.1 Hz, 3H); 
NH
OEt
OPh
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13C-NMR (100 MHz, CDCl3) δ 170.5, 161.7, 138.7, 128.7, 127.3, 126.7, 83.2, 58.3, 
46.8, 19.3, 14.6; 
MS (ESI+) m/z calcd for C13H17NO2 (M+H)+ 220.13; found 220.12. 
 
 
 
Compound 20c 
(Z)-3-(1-(Benzylamino)ethylidene)dihydrofuran-2(3H)-one 
 
White solid, 92 %; mp = 104.6-106.2 °C;  
O
ONHPh
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1H-NMR (400 MHz, CDCl3) δ 8.66 (s, 1H), 7.38-7.18 (m, 5H), 4.41 (d, J = 6.5 Hz, 2H), 
4.27 (t, J = 7.9 Hz, 2H), 2.82 (t, J = 7.9 Hz, 2H), 1.89 (s, 3H); 
13C-NMR (100 MHz, CDCl3) δ 173.9, 156.7, 138.7, 128.6, 127.2, 126.4, 85.9, 65.0, 
46.6, 26.3, 16.2; 
HRMS (ESI) m/z calcd for C13H15NO2 (M+H)+ 218.1181; found 218.1175. 
 
 
 
Compound 20d 
Methyl (Z)-3-(benzylamino)-4-methylpent-2-enoate 
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Colorless oil, 88 %;  
1H-NMR (400 MHz, CDCl3) δ 9.10 (s, 1H), 7.49-7.22 (m, 5H), 4.63 (s, 1H), 4.48 (d, J = 
6.3 Hz, 2H), 3.67 (s, 3H), 2.75-2.65 (m, 1H), 1.13 (d, J = 6.9 Hz, 6H); 
13C-NMR (100 MHz, CDCl3) δ 171.8, 171.6, 138.9, 128.7, 127.3, 126.7, 78.3, 49.9, 
46.0, 28.6, 21.5; 
HRMS (ESI) m/z calcd for C14H19NO2 (M+H)+ 234.1494; found 234.1483. 
 
 
NH
OMe
OPh
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Compound 20e 
Ethyl 2-((1-phenylethyl)amino)cyclopent-1-ene-1-carboxylate 
 
Colorless oil, 89 %;  
1H-NMR (400 MHz, CDCl3) δ 7.83 (s, 1H), 7.38-7.19 (m, 5H), 4.61-4.51 (m, 1H), 4.20 
(q, J = 7.1, 2H), 2.58-2.45 (m, 3H), 2.32-2.19 (m, 1H), 1.80-1.66 (m, 2H), 1.52 (d, J = 
6.8 Hz, 3H), 1.31 (t, J = 7.1 Hz, 3H); 
13C-NMR (100 MHz, CDCl3) δ 168.5, 164.0, 145.2, 128.6, 127.0, 125.4, 93.5, 58.4, 
54.2, 32.3, 28.9, 24.9, 20.9, 14.7; 
HRMS (ESI) m/z calcd for C16H21NO2 (M+H)+ 260.1651; found 260.1639. 
 
NH
OEt
OPh
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Compound 20f 
Ethyl (Z)-3-(benzylamino)-3-phenylacrylate 
 
White solid, 75 % (this compound was purified by flash chromatography to remove 
unreacted β-keto ester starting material); mp = 62.5-64.4 °C;  
1H-NMR (400 MHz, CDCl3) δ 8.93 (s, 1H), 7.44-7.17 (m, 10H), 4.71 (s, 1H), 4.29 (d, J 
= 6.5 Hz, 2H), 4.18 (q, J = 7.1 Hz, 2H), 1.31 (t, J = 7.1 Hz, 3H); 
13C-NMR (100 MHz, CDCl3) δ 170.3, 164.7, 139.2, 135.9, 129.2, 128.6, 128.3, 127.8, 
127.1, 126.8, 86.3, 58.7, 48.3, 14.5; 
HRMS (ESI) m/z calcd for C18H19NO2 (M+H)+ 282.1494; found 282.1482. 
 
Ph
NH
OEt
OPh
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Compound 20g 
Methyl (E)-2-chloro-3-(propylamino)but-2-enoate 
 
Light yellow oil, 90 %;  
NH
OMe
O
Cl
  199 
1H-NMR (400 MHz, CDCl3) δ 9.15 (s, 1H), 3.77 (s, 3H), 3.23 (td, J = 7.0, 5.7 Hz, 2H), 
2.19 (s, 3H), 1.8-1.57 (m, 2H), 1.00 (t, J = 7.4 Hz, 3H); 
13C-NMR (100 MHz, CDCl3) δ 167.8, 160.2, 88.1, 51.3, 45.7, 23.5, 16.4, 11.2; 
HRMS (ESI+) m/z calcd for C8H14ClNO2 (M+H)+ 192.0791; found 192.0786. 
 
 
 
Compound 20h 
Ethyl (Z)-2-benzyl-3-((1-phenylethyl)amino)but-2-enoate 
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Colorless oil, 71 %;  
1H-NMR (400 MHz, CDCl3) δ 9.99 (d, J = 7.2 Hz, 1H), 7.43-7.12 (m, 10H), 4.75-4.62 
(m, 1H), 4.31-4.12 (m, 2H), 3.75 (d, J = 16.9 Hz, 1H), 3.64 (d, J = 16.9 Hz, 1H), 1.82 (s, 
3H), 1.59 (d, J = 6.8 Hz, 3H), 1.27 (t, J = 7.1 Hz, 3H); 
13C-NMR (100 MHz, CDCl3) δ 171.1, 160.7, 145.6, 143.0, 128.7, 128.0, 127.7, 126.9, 
125.5, 125.3, 92.0, 58.8, 53.3, 32.7, 25.2, 15.8, 14.6; 
HRMS (ESI+) m/z calcd for C21H25NO2 (M+H)+ 324.1964; found 324.1971. 
 
NH
OEt
OPh
Ph
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Compound 20i 
Ethyl (Z)-3-(phenylamino)but-2-enoate 
 
Colorless oil, 82 %;  
1H-NMR (400 MHz, CDCl3) δ 10.41 (s, 1H), 7.40-7.26 (m, 2H), 7.21-7.07 (m, 3H), 4.72 
(d, J = 0.5 Hz, 1H), 4.18 (q, J = 7.1 Hz, 2H), 2.03 (s, 3H), 1.31 (t, J = 7.1 Hz, 3H); 
13C-NMR (100 MHz, CDCl3) δ 170.3, 158.8, 139.4, 129.0, 124.9, 124.4, 86.1, 58.7, 
20.2, 14.5; 
HRMS (ESI+) m/z calcd for C12H15NO2 (M+H)+ 206.1181; found 206.1177. 
NH
OEt
OPh
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Compound 21a 
S-Butyl (Z)-3-(benzylamino)but-2-enethioate 
 
Colorless oil, 90 %;  
1H-NMR (400 MHz, CDCl3) δ 9.69 (s, 1H), 7.42-7.23 (m, 5H), 5.04 (s, 1H), 4.44 (d, J = 
6.4 Hz, 2H), 2.89 (t, J = 7.3 Hz, 2H), 1.92 (s, 3H), 1.65-1.57 (m, 2H), 1.50-1.38 (m, 2H), 
0.94 (t, J = 7.3 Hz, 3H); 
13C-NMR (100 MHz, CDCl3) δ 187.3, 159.4, 138.0, 128.8, 127.5, 126.8, 94.6, 46.9, 
32.5, 27.6, 22.0, 18.8, 13.6; 
HRMS (ESI) m/z calcd for C15H21NOS (M+H)+ 264.1422; found 264.1410. 
 
NH
SBu
OPh
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Compound 21b 
S-Butyl (Z)-3-((1-phenylethyl)amino)but-2-enethioate 
 
Light yellow oil, 94 %;  
1H-NMR (400 MHz, CDCl3) δ 9.70 (s, 1H), 7.41-7.21 (m, 5H), 4.98 (s, 1H), 4.71-4.62 
(m, 1H), 2.99-2.86 (m, 2H), 1.77 (s, 3H), 1.68-1.59 (m, 2H), 1.54 (d, J = 6.8 Hz, 3H), 
1.49-1.40 (s, 2H), 0.95 (t, J = 7.3 Hz, 3H); 
13C-NMR (100 MHz, CDCl3) δ 187.3, 159.0, 144.2, 128.8, 127.2, 125.4, 94.5, 53.1, 
32.4, 27.6, 24.7, 22.1, 19.1, 13.6; 
HRMS (ESI) m/z calcd for C16H23NOS (M+H)+ 278.1579; found 278.1573. 
NH
SBu
OPh
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Compound 21c 
S-Butyl (Z)-3-(phenylamino)but-2-enethioate 
 
 
Colorless oil, 92 %;  
NH
SBu
OPh
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1H-NMR (400 MHz, CDCl3) δ 11.05 (s, 1H), 7.41-7.26 (m, 2H), 7.20 (t, J = 7.4 Hz, 1H), 
7.11 (d, J = 7.5 Hz, 2H), 5.18 (s, 1H), 2.94 (t, J = 7.3 Hz, 2H), 1.98 (s, 3H), 1.70-1.57 
(m, 2H), 1.49-1.40 (m, 2H), 0.96 (t, J = 7.3 Hz, 3H); 
13C-NMR (100 MHz, CDCl3) δ 188.2, 156.5, 138.7, 129.1, 125.5, 124.6, 96.7, 32.4, 
27.8, 22.0, 19.7, 13.6; 
HRMS (ESI) m/z calcd for C14H19NOS (M+H)+ 250.1266; found 250.1277. 
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Compound 21d 
S-Butyl (Z)-3-((3-methoxyphenyl)amino)but-2-enethioate 
 
Colorless oil, 88 %;  
1H-NMR (400 MHz, CDCl3) δ 11.04 (s, 1H), 7.24 (t, J = 8.1 Hz, 1H), 6.74 (d, J = 8.0 
Hz, 1H), 6.70 (d, J = 8.0 Hz, 1H), 6.65 (s, 1H), 5.18 (s, 1H), 3.81 (s, 3H), 2.93 (t, J = 7.3 
Hz, 2H), 2.00 (s, 3H), 1.69-1.55 (m, 2H), 1.49-1.40 (m, 2H), 0.96 (t, J = 7.3 Hz, 3H); 
13C-NMR (100 MHz, CDCl3) δ 188.3, 160.2, 156.3, 139.9, 129.7, 116.8, 111.0, 110.3, 
96.8, 55.3, 32.4, 27.8, 22.0, 19.8, 13.6; 
HRMS (ESI) m/z calcd for C15H21NO2S (M+H)+ 280.1371; found 280.1385. 
NH
SBu
O
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Compound 21e 
S-butyl (Z)-3-((4-methoxyphenyl)amino)but-2-enethioate 
 
Colorless oil, 93 %;  
NH
SBu
O
MeO
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1H-NMR (400 MHz, CDCl3) δ 10.85 (s, 1H), 7.04 (d, J = 8.8 Hz, 2H), 6.87 (d, J = 8.9 
Hz, 2H), 5.14 (s, 1H), 3.81 (s, 3H), 2.92 (t, J = 7.3 Hz, 2H), 1.88 (s, 3H), 1.69-1.56 (m, 
2H), 1.49-1.40 (m,  2H), 1.28 (s, 1H), 0.95 (t, J = 7.3 Hz, 3H); 
13C-NMR (100 MHz, CDCl3) δ 187.8, 157.7, 157.6, 131.5, 126.7, 114.2, 95.7, 55.4, 
32.4, 27.7, 22.0, 19.5, 13.6; 
HRMS (ESI+) m/z calcd for C15H21NO2S (M+H)+ 280.1371; found 280.1379. 
 
 
 
 
Compound 21f 
S-Butyl (Z)-3-((4-bromophenyl)amino)but-2-enethioate 
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White solid, 91 %; mp = 55.0-56.1 °C;  
1H-NMR (400 MHz, CDCl3) δ 11.00 (s, 1H), 7.50-7.43 (m, 2H), 7.01-6.94 (m, 2H), 5.20 
(s, 1H), 2.93 (t, J = 7.3 Hz, 2H), 1.97 (s, 3H), 1.66-1.59 (m, 2H), 1.49-1.40 (m, 2H), 0.95 
(t, J = 7.3 Hz, 3H); 
13C-NMR (100 MHz, CDCl3) δ 188.7, 155.6, 137.9, 132.2, 126.0, 118.6, 97.4, 32.3, 
27.8, 22.0, 19.6, 13.6; 
HRMS (ESI) m/z calcd for C14H18BrNOS (M+H)+ 328.0371; found 328.0386. 
 
NH
SBu
O
Br
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Compound 21g 
S-Butyl (Z)-3-((3,5-dimethoxyphenyl)amino)but-2-enethioate 
 
Light yellow oil, 89 %;  
1H-NMR (400 MHz, CDCl3) δ 11.00 (s, 1H), 6.31 (t, J = 2.2 Hz, 1H), 6.26 (d, J = 2.1 
Hz, 2H), 5.16 (s, 1H), 3.78 (s, 6H), 2.93 (t, J = 7.4 Hz, 2H), 2.02 (s, 3H), 1.69-1.54 (m, 
2H), 1.52-1.34 (m, 2H), 0.95 (t, J = 7.3 Hz, 3H); 
13C-NMR (100 MHz, CDCl3) δ 188.3, 161.0, 156.2, 140.4, 102.8, 97.5, 96.9, 55.4, 32.3, 
27.8, 22.0, 19.8, 13.6; 
HRMS (ESI+) m/z calcd for C16H23NO3S (M+H)+ 310.1477; found 310.1486. 
NH
SBu
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Compound 21h 
S-Butyl (Z)-3-((2,4-dimethoxyphenyl)amino)but-2-enethioate 
 
Colorless oil, 92 %;  
NH
SBu
O
OMeMeO
  213 
1H-NMR (400 MHz, CDCl3) δ 10.58 (s, 1H), 7.01 (d, J = 8.6 Hz, 1H), 6.50 (d, J = 2.6 
Hz, 1H), 6.44 (dd, J = 8.6, 2.6 Hz, 1H), 5.15 (s, 1H), 3.82 (d, J = 2.7 Hz, 6H), 2.93 (t, J 
= 7.3 Hz, 2H), 1.85 (s, 3H), 1.67-1.58 (m, 2H), 1.49-1.41 (m, 2H), 0.94 (t, J = 7.3 Hz, 
3H); 
13C-NMR (100 MHz, CDCl3) δ 187.4, 159.0, 158.3, 154.8, 127.1, 120.9, 103.8, 99.2, 
95.6, 55.6, 55.4, 32.4, 27.7, 22.1, 19.3, 13.6; 
HRMS (ESI+) m/z calcd for C16H23NO3S (M+H)+ 310.1477; found 310.1467. 
 
 
 
Compound 21i 
S-Butyl (Z)-3-(naphthalen-1-ylamino)but-2-enethioate 
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Colorless oil, 85 %;  
1H-NMR (400 MHz, CDCl3) δ 11.24 (s, 1H), 8.04 (dd, J = 8.1, 1.4 Hz, 1H), 7.90 (dd, J 
= 6.6, 2.8 Hz, 1H), 7.79 (d, J = 8.2 Hz, 1H), 7.60-7.52 (m, 2H), 7.51-7.42 (m, 1H), 7.33-
7.26 (m, 1H), 5.30 (s, 1H), 3.00 (t, J = 7.3 Hz, 2H), 1.85 (s, 3H), 1.72-1.65 (m, 2H), 
1.54-1.46 (m, 2H), 0.98 (t, J = 7.3 Hz, 3H); 
13C-NMR (100 MHz, CDCl3) δ 188.4, 158.1, 134.7, 134.2, 130.2, 128.2, 127.0, 126.9, 
126.5, 125.2, 123.8, 122.7, 96.4, 32.4, 27.8, 22.1, 19.4, 13.6; 
HRMS (ESI) m/z calcd for C18H21NOS (M+H)+ 300.1422; found 300.1437. 
NH
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Compound 21j 
S-Butyl (Z)-3-((3,3-diethoxypropyl)amino)but-2-enethioate 
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Colorless oil, 95 %;  
1H-NMR (400 MHz, CDCl3) δ 9.37 (s, 1H), 4.97 (s, 1H), 4.50 (t, J = 5.5 Hz, 1H), 3.79-
3.68 (m, 2H), 3.60-3.49 (m, 2H), 3.34 (t, J = 6.0 Hz, 2H), 2.87 (t, J = 7.3 Hz, 2H), 1.93 
(s, 3H), 1.68-1.52 (m, 2H), 1.46-1.38 (m, 2H), 1.24 (t, J = 7.4 Hz, 6H), 0.93 (t, J = 7.3 
Hz, 3H); 
13C-NMR (100 MHz, CDCl3) δ 186.8, 159.3, 101.9, 94.5, 63.3, 46.2, 32.5, 27.5, 22.0, 
19.0, 15.2, 13.6; 
HRMS (ESI+) m/z calcd for C15H29NO3S (M+H)+ 304.1946; found 304.1955. 
 
NH
SBu
OEtO
OEt
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Compound 21k 
S-Butyl (S,Z)-3-((1-hydroxy-3-phenylpropan-2-yl)amino)but-2-enethioate 
 
 
Colorless oil, 94 %;  
1H-NMR (400 MHz, CDCl3) δ 9.43 (d, J = 9.8 Hz, 1H), 7.35-7.15 (m, 5H), 4.88 (s, 1H), 
3.90-3.52 (m, 3H), 2.96-2.85 (m, 3H), 2.73 (dd, J = 13.6, 8.1 Hz, 1H), 2.44 (s, 1H), 1.64-
1.54 (m, 5H), 1.51-1.36 (m, 2H), 0.95 (t, J = 7.4 Hz, 3H); 
13C-NMR (100 MHz, CDCl3) δ 187.4, 159.4, 137.6, 129.2, 128.6, 126.6, 94.6, 65.1, 
57.3, 39.3, 32.4, 27.7, 22.0, 18.9, 13.6; 
HRMS (ESI) m/z calcd for C17H25NO2S (M+H)+ 308.1684; found 308.1670. 
NH
SBu
OHO
Ph
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Compound 21l 
S-butyl (Z)-3-((3-(hydroxymethyl)phenyl)amino)but-2-enethioate 
 
NH
SBu
O
HO
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Colorless oil, 78 % (this compound was purified by flash chromatography CH2Cl2 to 5 
% EtOAc in CH2Cl2);  
1H-NMR (400 MHz, CDCl3) δ 11.04 (s, 1H), 7.32 (t, J = 7.8 Hz, 1H), 7.17 (d, J = 7.7 
Hz, 1H), 7.11 (s, 1H), 7.01 (d, J = 7.9 Hz, 1H), 5.18 (s, 1H), 4.69 (s, 2H), 2.92 (t, J = 7.3 
Hz, 2H), 2.08 (s, 1H), 1.98 (s, 3H), 1.64-1.58 (m, 2H), 1.47-1.42 (m, 2H), 0.95 (t, J = 7.3 
Hz, 3H); 
13C-NMR (100 MHz, CDCl3) δ 188.3, 156.3, 142.2, 139.0, 129.2, 123.7, 123.5, 122.7, 
96.9, 64.7, 32.3, 27.8, 22.0, 19.7, 13.6; 
HRMS (ESI) m/z calcd for C15H21NO2S (M+Li)+ 286.1453; found 286.1440. 
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Compound 21m 
S-Butyl (Z)-3-((3-hydroxyphenyl)amino)but-2-enethioate 
 
 
Light yellow oil, 51 % (this compound was purified by flash chromatography, CH2Cl2 to 
5 % EtOAc in CH2Cl2);  
1H-NMR (400 MHz, CDCl3) δ 10.96 (s, 1H), 7.18 (t, J = 8.0 Hz, 1H), 6.79-6.57 (m, 3H), 
5.20 (s, 1H), 2.93 (t, J = 7.3 Hz, 2H), 1.99 (s, 3H), 1.65-1.61 (m, 2H), 1.49-1.42 (m, 2H), 
0.94 (t, J = 7.3 Hz, 3H); 
13C-NMR (100 MHz, CDCl3) δ 189.0, 157.0, 156.6, 139.7, 130.0, 116.9, 112.9, 111.7, 
96.8, 32.2, 27.9, 22.0, 19.8, 13.6; 
HRMS (ESI) m/z calcd for C14H19NO2S (M+H)+ 266.1215; found 266.1226. 
NH
SBu
O
OH
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Compound 21n 
S-Butyl (Z)-3-(benzylamino)oct-2-enethioate 
 
Light yellow oil, 85 %;  
NH
SBu
OPh
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1H-NMR (400 MHz, CDCl3) δ 9.72 (s, 1H), 7.42-7.27 (m, 5H), 5.05 (s, 1H), 4.44 (d, J = 
6.4 Hz, 2H), 2.89 (t, J = 7.3 Hz, 2H), 2.23-2.14 (t, J = 7.8 Hz, 2H), 1.66-1.49 (m, 4H), 
1.46-1.40 (m, 2H), 1.38-1.14 (m, 4H), 0.98-0.83 (m, 6H); 
13C-NMR (100 MHz, CDCl3) δ 187.3, 163.5, 138.1, 128.8, 127.5, 126.8, 93.6, 46.6, 
32.5, 31.7, 31.5, 27.7, 27.6, 22.3, 22.1, 13.8, 13.6; 
HRMS (ESI) m/z calcd for C19H29NOS (M+H)+ 320.2048; found 320.2033. 
 
 
 
Compound 21o 
S-Butyl (Z)-2-(1-(benzylamino)ethylidene)pent-4-enethioate 
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Light yellow oil, 74 %;  
1H-NMR (400 MHz, CDCl3) δ 10.90 (s, 1H), 7.42-7.23 (m, 5H), 5.95-5.82 (m, 1H), 
5.25-4.97 (m, 2H), 4.48 (d, J = 6.2 Hz, 2H), 3.17 (dt, J = 5.4, 1.7 Hz, 2H), 2.89 (t, J = 
7.4 Hz, 2H), 1.93 (s, 3H), 1.65-1.56 (m, 2H), 1.49-1.40 (m, 2H), 0.95 (t, J = 7.3 Hz, 3H); 
13C-NMR (100 MHz, CDCl3) δ 189.0, 159.8, 138.4, 137.3, 128.8, 127.3, 126.7, 113.9, 
100.5, 47.1, 32.2, 32.1, 28.3, 22.2, 15.2, 13.7; 
HRMS (ESI) m/z calcd for C18H25NOS (M+H)+ 304.1735; found 304.1747. 
 
 
NH
SBu
OPh
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Compound 21p 
S-Trityl (Z)-3-(benzylamino)but-2-enethioate 
 
Light yellow solid, 91 %; mp = 151.2-152.2 °C;  
1H-NMR (400 MHz, CDCl3) δ 9.51 (t, J = 6.7 Hz, 1H), 7.44-7.23 (m, 18H), 7.21-7.13 
(m, 2H), 5.08 (s, 1H), 4.34 (d, J = 6.7 Hz, 2H), 1.85 (s, 3H); 
13C-NMR (100 MHz, CDCl3) δ 185.8, 160.1, 145.1, 138.2, 130.0, 128.7, 127.6, 127.3, 
126.7, 126.6, 93.8, 69.1, 46.7, 18.9; 
HRMS (MALDI+) m/z calcd for C30H27NOS (M+H)+ 450.1892; found 450.1879. 
 
NH
S
OPh
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Compound 21q 
S-Butyl (Z)-3-(phenoxyamino)but-2-enethioate 
 
Colorless oil, 58 %;  
1H-NMR (400 MHz, CDCl3) δ 7.42-7.26 (m, 5H), 5.15 (s, 2H), 3.44 (s, 2H), 2.92 (t, J = 
7.3 Hz, 2H), 1.97 (s, 3H), 1.61-1.50 (m, 2H), 1.46-1.38 (m, 2H), 0.94 (t, J = 7.3 Hz, 3H); 
13C-NMR (100 MHz, CDCl3) δ 195.3, 151.8, 137.9, 128.3, 127.9, 127.6, 75.7, 50.3, 
31.4, 28.9, 21.9, 14.7, 13.5; 
HRMS (ESI) m/z calcd for C15H21NO2S (M+H)+ 280.1371; found 280.1381. 
NH
SBu
OOPh
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Compound 21r 
S-Phenyl (Z)-3-(benzylamino)but-2-enethioate 
 
NH
S
OPh
  227 
 
Colorless oil, 76 %;  
1H-NMR (400 MHz, CDCl3) δ 9.71 (s, 1H), 7.59-7.50 (m, 2H), 7.47-7.22 (m, 8H), 5.09 
(s, 1H), 4.43 (d, J = 6.3 Hz, 2H), 1.97 (s, 3H); 
13C-NMR (100 MHz, CDCl3) δ 185.3, 161.0, 137.5, 135.2, 129.7, 128.8, 128.7, 127.6, 
126.9, 93.1, 47.1, 18.9; 
HRMS (ESI) m/z calcd for C18H25NOS (M+H)+ 284.1109; found 284.1101. 
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Compound 21t 
S-(4-Chlorophenyl) (Z)-3-(phenylamino)but-2-enethioate 
 
 
Light yellow solid, 72 %; mp = 75.1-76.9 °C;  
1H-NMR (400 MHz, CDCl3) δ 11.00 (s, 1H), 7.51-7.18 (m, 8H), 7.09 (d, J = 7.5 Hz, 
2H), 5.21 (s, 1H), 2.02 (s, 3H); 
13C-NMR (100 MHz, CDCl3) δ 185.4, 158.6, 138.2, 136.4, 135.2, 129.2, 129.1, 127.8, 
125.9, 124.7, 94.9, 19.8; 
HRMS (ESI) m/z calcd for C16H14ClNOS (M+H)+ 304.0563; found 304.0560. 
NH
S
OPh Cl
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Compound 21s 
S-(4-Chlorophenyl) (Z)-3-(benzylamino)but-2-enethioate 
 
White solid, 80 %; mp = 94.5-96.0 °C;  
1H-NMR (400 MHz, CDCl3) δ 9.66 (s, 1H), 7.48-7.20 (m, 9H), 5.06 (s, 1H), 4.43 (d, J = 
6.3 Hz, 2H), 1.97 (s, 3H); 
NH
S
OPh Cl
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13C-NMR (100 MHz, CDCl3) δ 184.4, 161.2, 137.3, 136.4, 135.0, 129.0, 128.8, 128.2, 
127.7, 126.9, 93.0, 47.1, 18.9; 
HRMS (ESI+) m/z calcd for C17H16ClNOS (M+H)+ 318.0719; found 318.0724. 
 
 
 
D. Syntheses of Indole Derivatives via Nenitzescu Reaction 
A solution of 21 (0.3 mmol) and 1,4-benzoquinone (0.33 mmol) was added to 0.6 
mL dry CH3NO2. The solution was stirred at 25 °C for 24 h. The solvent was removed 
under vacuum and the residue was purified by flash chromatography (10 % - 30 % 
EtOAc in hexanes) to give the desired product.  
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Compound 22a 
S-Butyl 1-benzyl-5-hydroxy-2-methyl-1H-indole-3-carbothioate 
 
Light yellow solid, 75 %; mp = 150.6-151.3 °C;  
1H-NMR (400 MHz, CDCl3) δ 7.88 (d, J = 2.4 Hz, 1H), 7.35-7.26 (m, 3H), 7.10 (d, J = 
8.7 Hz, 1H), 7.04-6.95 (m, 2H), 6.80 (dd, J = 8.7, 2.4 Hz, 1H), 5.31 (s, 2H), 5.28 (s, 1H), 
3.14 (t, J = 7.3 Hz, 2H), 2.73 (s, 3H), 1.76-1.65 (m, 2H), 1.55-1.43 (m, 2H), 0.98 (t, J = 
7.3 Hz, 3H); 
13C-NMR (100 MHz, CDCl3) δ 186.7, 151.6, 143.9, 136.0, 131.6, 128.9, 127.7, 126.3, 
125.9, 113.5, 111.7, 110.5, 106.8, 46.6, 31.9, 28.2, 22.1, 13.6, 12.9; 
HRMS (MALDI+) m/z calcd for C21H23NO2S (M+H)+ 354.1522; found 354.1538. 
1H NMR 
 
N
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13C NMR 
 
 
DEPT135 
 
 
1H-1H COSY 
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1H-13C HSQC 
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NOESY (Strong NOEs are labeled A-D) 
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Compound 22b 
S-Phenyl 1-benzyl-5-hydroxy-2-methyl-1H-indole-3-carbothioate 
 
White solid, 68 %; mp = 176.6-177.5 °C;  
1H-NMR (400 MHz, CDCl3) δ 7.88 (d, J = 2.4 Hz, 1H), 7.65-7.57 (m, 2H), 7.51-7.45 
(m, 3H), 7.40-7.26 (m, 3H), 7.16 (d, J = 8.7 Hz, 1H), 7.06-6.98 (m, 2H), 6.82 (dd, J = 
8.8, 2.4 Hz, 1H), 5.36 (s, 2H), 4.72 (s, 1H), 2.74 (s, 3H); 
N CH3
SBu
O
HO
HH
H
H
H
H
H
A
A
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13C-NMR (100 MHz, CDCl3) δ 184.2, 151.6, 144.9, 135.8, 135.4, 131.7, 129.1, 129.0, 
129.0, 128.2, 127.8, 126.3, 125.9, 112.6, 111.8, 110.7, 106.9, 46.7, 12.9; 
HRMS (MALDI+) m/z calcd for C23H19NO2S (M+Li)+ 380.1297; found 380.1278. 
 
 
 
 
Compound 22c 
S-Butyl 5-hydroxy-2-methyl-1-phenyl-1H-indole-3-carbothioate 
 
N
Ph
SBu
O
HO
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Light yellow solid, 53 %; mp = 180.2-181.9 °C;  
1H-NMR (400 MHz, CDCl3) δ 7.86 (d, J = 2.3 Hz, 1H), 7.63-7.51 (m, 3H), 7.36-7.27 
(m, 2H), 6.88 (d, J = 8.7 Hz, 1H), 6.76 (dd, J = 8.7, 2.4 Hz, 1H), 5.04 (s, 1H), 3.16 (t, J = 
7.3 Hz, 2H), 2.60 (s, 3H), 1.80-1.67 (m, 2H), 1.56-1.48 (m, 2H), 0.99 (t, J = 7.3 Hz, 3H); 
13C-NMR (100 MHz, CDCl3) δ 186.6, 151.8, 144.1, 136.3, 133.0, 129.7, 128.9, 128.2, 
126.1, 113.9, 111.8, 111.4, 106.5, 32.0, 28.2, 22.1, 14.1, 13.6; 
HRMS (MALDI+) m/z calcd for C20H21NO2S (M+H)+ 340.1371; found 340.1366. 
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E. Intermediate Formation in HOAt-mediated Reactions 
Method A for the synthesis of β-enamino esters was used in the absence of amine 
nucleophile. The crude product was purified by flash chromatography (CH2Cl2 to 5 % 
EtOAc in CH2Cl2) to give compound 23.  
 
Compound 23 
3-((3H-[1,2,3]Triazolo[4,5-b]pyridin-3-yl)oxy)cyclohex-2-en-1-one 
 
White solid, 65 %;  mp = 108.1-109.0 °C; 
1H-NMR (400 MHz, CDCl3) δ 8.75 (dd, J = 4.5, 1.4 Hz, 1H), 8.45 (dd, J = 8.4, 1.4 Hz, 
1H), 7.49 (dd, J = 8.4, 4.5 Hz, 1H), 4.90 (s, 1H), 2.89 (t, J = 6.3, 2H), 2.43 (dd, J = 7.4, 
6.0 Hz, 2H), 2.25-2.17 (m, 2H); 
13C-NMR (100 MHz, CDCl3) δ 13C NMR (101 MHz, CDCl3) δ 197.8, 176.5, 152.2, 
139.6, 134.7, 129.7, 121.3, 105.6, 36.5, 25.5, 20.7; 
HRMS (ESI+) m/z calcd for C11H10N4O2 (M+H)+ 231.0882; found 231.0883. 
O
O N N
N
N
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23 (23 mg, 0.1 mmol) was mixed with benzyl amine (22 uL, 0.2 mmol) in CHCl3 
at room temperature. The resulting solution was stirred at room temperature for 18h. The 
solvent was removed and the product was purified by flash chromatography (3 - 6 % 
MeOH in CH2Cl2) to give compound 24. 
Compound 24 
3-(Benzylamino)cyclohex-2-en-1-one 
 
Light yellow oil, 71 %;  
O
NH
Bn
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1H-NMR (400 MHz, CDCl3) δ 7.43-7.26 (m, 5H), 5.23 (s, 1H), 4.75 (s, 1H), 4.25 (d, J = 
5.2 Hz, 2H), 2.44-2.30 (m, 4H), 2.05-1.97 (m, 2H); 
13C-NMR (100 MHz, CDCl3) δ 197.3, 163.6, 136.7, 128.9, 128.0, 127.8, 97.7, 47.3, 
36.4, 29.6, 21.9; 
HRMS (ESI+) m/z calcd for C13H15NO (M+H)+ 202.1232; found 202.1239. 
 
 
 
F. Syntheses of β-Enamino Amides 
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Method A was used for the synthesis of β-enamino amides and the crude product was 
purified by flash chromatography (3 - 6 % MeOH in CH2Cl2). Characterization data for 
compounds 25a and 25b are consistent with previous reported data. 12,13 
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APPENDIX D  
EXPERIMENTAL PROCEDURES FOR CHAPTER IV 
 
A. Nondenaturing PAGE 
General procedure: α-Antithrombin was purchased from Haematologic 
Technologies Inc. and diluted with pH 7.4 Tris-HCl buffer containing 50 mM tris, 50 
mM NaCl, 1 mM EDTA.  20 mM stock solutions of the target compounds in DMSO 
were used in all the gel experiments.  
0.25 mg / mL α-Antithrombin was incubated with 200 fold the target compounds 
or controls at 50 °C for 1 h. The solutions were put on ice to quench the oligomerization 
after incubation.  Aliquots of the solutions were taken and analyzed by 8 % (w/v) 
acrylamide nondenaturing PAGE to evaluate the extent of oligomerization.14 Silver stain 
was performed according to a literature procedure to visualize the results.15 
 
Β .  α-Antithrombin Oligomerizartion Kinetics Determined By Nondenaturing 
PAGE 
Kinetics of a-antithrombin oligomerization was followed by nondenaturing 
PAGE according to the literature procedure except that silver staining was used to 
visualize the protein.16,17 Since silver staining method generally has a limited linear 
dynamic range, silver staining for a-antithrombin at various sample loading was 
performed to calibrate the band intensity relative to the amount of protein (Figure S1). 
The linear range was determined to be between 0 µg and 0.75 µg for protein loading on 
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gel. The protein loading in the kinetics studies was kept in this range to make sure the 
linear correlation between the amount of monomer and band intensity after silver 
staining. 
 
 
 
 
Figure S1. a Band intensity of α-antithrombin monomer at different protein loading on 
nondenaturing PAGE; b Determination of the linear dynamic range for silver staining. 
 
1 2 3 4 5 6 7 8
0.13
antithrombin 
loading on gel (µg) 0.25 0.50 0.75 0.88 1.00 1.13 1.25
antithrombin 
monomer
a
y = 1E+06x - 9185.4 
R² = 0.99559 
0 
200000 
400000 
600000 
800000 
1000000 
1200000 
0 0.2 0.4 0.6 0.8 1 1.2 1.4 
ba
nd
 in
te
ns
ity
 
sample loading (ug) 
b 
  244 
General procedure: 0.25 mg / mL α-Antithrombin was incubated with 200 fold 
DDD-1as’f at 50 °C for 3 h. Aliquots of the solutions were taken and cold quenched on 
ice in every 10 mins in the first hour and then in every 30 min afterwards. The relative 
amount of residual monomer was analyzed by 8 % (w/v) acrylamide nondenaturing 
PAGE. The intensities of the a-antithrombin monomer bands were measured and fitted 
to a second order kinetics model to determine the rate constant in terms of the loss of 
monomer. A representative example for DDD-1as’f was shown in Figure S2. 
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Figure S2. a Loss of monomeric α-antithrombin measured by nondenaturing PAGE; b 
Fitting into a second order kinetics model. 
 
C. Thrombin Activity Assay 
0.25 mg / mL a-Antithrombin was incubated with 200 fold DDD-1as’f or DDD-
1asf at 50 °C for 3 -5 h. Aliquots of the solutions were taken at indicated time and 
quenched on ice to stop oligomerization. The antithrombin solutions at different degrees 
of oligomerization were then incubated with 4 nM thrombin (purchased from 
Haematologic Technologies Inc.) in 20 mM Tris-HCl buffer containing 150 mM NaCl, 
2.5 mM CaCl2, 0.1 % PEG8000, 0.02 % Tween80 at pH = 7.4 in the presence of 10 nM 
heparin. After incubation of 5 min at room temperature, chromogenic substrate 
Spectrozyme TH (purchased from American diagnostic inc.) was added. The residual 
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enzyme activity was determined from the initial rate of increase in absorbance at 405 nm 
with a plate reader.18   
 
D. Electron Microscopy 
0.25 mg / mL α-Antithrombin was incubated with or without 200 fold DDD-1as’f 
at 50 °C for 1 h. The solutions were put on ice to quench the oligomerization after 
incubation.  The solution was diluted to a concentration of 0.05 mg / mL in pH 7.4 Tris-
HCl buffer containing 50 mM tris, 50 mM NaCl, 1 mM EDTA for use in the EM 
experiments. Specimens were prepared using an aqueous solution of 1% wt/vol uranyl 
acetate (pH 4.25). Uranyl acetate has been shown to fix the structure of protein 
molecules within 10 ms and prior to blotting the buffer off.19 Therefore it can be 
reasonably assumed that the preparation reflects the situation in solution. Specimens 
were observed in a Jeol 1200 EX TEM operated at an accelerating voltage of 100 kV. 
Images were captured at calibrated magnifications using an optically coupled 3 k slow 
scanCCD camera (model 15C, SIA, Duluth, GA) and Maxim DL imaging software. 
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APPENDIX E  
EXPERIMENTAL PROCEDURES FOR CHAPTER V 
A. Synthesis of Cyclic Peptides  
General Procedures	  
Coupling Method I 
Boc or Cbz protected amino acid (Pg-AA-OH, 2.0 mmol, 1.0 equiv.) was added 
to a solution of HOAt (408 mg, 3.0 mmol, 1.5 equiv.) and NMM (220 µL, 2.0 mmol, 1.0 
equiv.) in DCM (3.0 mL) at 0 oC under N2. The resulting mixture was stirred at 0 oC for 
10 min and then methyl anthranilate (906 mg, 6.0 mmol, 3.0 equiv.) was added, 
followed by the addition of EDCHCl (575 mg, 3.0 mmol, 1.5 equiv.) in one portion. 
The reaction mixture was allowed to warm to room temperature over 1 h and was stirred 
at room temperature for 6 h. 30 mL DCM was added to dilute the solution and the 
organic phase was washed with 0.2 M HCl aqueous solution (30 mL × 5). The organic 
phase was further washed with brine (10 mL), saturated NaHCO3 solution (20 mL × 2) 
and brine (10 mL), dried over MgSO4 and filtered. The solvent was removed under 
vacuum to give the crude material. The crude material was used in the next step without 
further purification. An analytically pure sample was prepared by crystallization from 
DCM/hexanes. 
 
Coupling Method II 
EDCHCl (287 mg, 1.5 mmol, 1.5 equiv.) was added to a mixture of Boc or Cbz 
protected amino acid (Pg-AA-OH, 1.0 mmol, 1.0 equiv.), N-terminus deprotected linear 
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peptide (1.0 mmol, 1.0 equiv.), HOBt (203 mg, 1.5 mmol, 1.5 equiv.) and DIPEA (175 
µL, 1.0 mmol, 1.0 equiv.) in DCM (10.0 mL) at 0 oC under N2. The reaction mixture was 
stirred at 0 oC for 10 min and was allowed to warm to room temperature. After overnight 
reaction at room temperature, 40 mL DCM was added to dilute the solution and the 
organic phase was washed with 0.1 M HCl aqueous solution (30 mL × 2). The organic 
phase was further washed with brine (10 mL), saturated NaHCO3 solution (30 mL × 2) 
and brine (10 mL), dried over MgSO4 and filtered. The solvent was removed under 
vacuum to give the crude material. The crude material was used in the next step without 
further purification. An analytically pure sample can be prepared by crystallization from 
DCM/hexanes. 
 
Boc Deprotection Procedure I 
Boc protected intermediate (1.0 mmol) was dissolved in DCM (5 mL) at 0 oC, 
and the mixture was stirred at 0 oC for 10 min. TFA (5 mL) was added in one portion 
and the reaction mixture was stirred for 30 min at room temperature. Toluene (30 mL) 
was added and the solution was concentrated. Residual TFA was azeotroped 3 times 
with toluene (3 × 30 mL) to give the crude product. Saturated NaHCO3 (20 mL) was 
added and the aqueous layer was extracted with DCM (30 mL). The organic layer was 
further washed with saturated NaHCO3 (20 mL × 2) and brine (10 mL), dried over 
MgSO4 and filtered. The solvent was removed under vacuum to give the crude material. 
The crude material was used in the next step without further purification. 
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Boc Deprotection Procedure II 
4 M HCl in dioxane (5 mL) was added to Boc protected intermediate (1.0 mmol) 
at 0 oC, and the mixture was stirred at room temperature for 30 min. Toluene (20 mL) 
was added and the solution was concentrated. Residual dioxane was azeotroped 3 times 
with toluene (3 × 20 mL) and then dried under high vacuum for 3 h to give the HCl salt 
of the Boc deprotected product.  
 
tBu Deprotection Procedure 
tBu protected cyclic peptides (0.08 mmol) was dissolved in 1:1 TFA/DCM 
containing 5 % (v/v) triethylsilane (TES) (0.8 mL) at 0 oC, and the mixture was stirred at 
0 oC for 10 min. The reaction mixture was stirred for an additional 60 min at room 
temperature. Toluene (2 mL) was added and the solution was concentrated. Residual 
TFA was azeotroped 3 times with toluene (3 × 2 mL) to give the crude product. The 
crude product was purified with flash chromatography (4 – 8 % MeOH in DCM 
containing 0.1 % AcOH) to give the pure product. 
 
Cbz Deprotection Procedure 
To a solution of Cbz protected substrate in methanol (0.1 M) under nitrogen was 
added 10 wt % Pd/C (0.05 equiv. Pd). The reaction was placed under an atmosphere of 
hydrogen (1 atm, balloon) for 12 h. After the reaction finished, the flask was purged with 
N2. The reaction mixture was filtered over a Celite pad and concentrated to afford the 
product. The product was used in the next step without further purification. 
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Bn Deprotection Procedure 
To a solution of Cbz protected substrate in methanol (0.05 M) under nitrogen 
was added 10 wt % Pd/C (0.15 equiv. Pd). The reaction was placed under an atmosphere 
of hydrogen (1 atm, balloon) for 24 h. After the reaction finished, the flask was purged 
with N2. The reaction mixture was filtered over a Celite pad and concentrated to afford 
the product. The product was purified with flash chromatography (4 – 8 % MeOH in 
CH2Cl2) to give the pure product. 
 
Hydrolysis of Methyl Ester 
The linear tetrapeptide (0.2 mmol) was added to 2.7 mL THF and the resulting 
suspension was stirred at room temperature for 10 min. A 0.3 M aqueous solution of 
LiOH (1.3 mL, 0.4 mmol, 2.0 equiv.) was added and the resulting mixture was stirred at 
room temperature for 2h. The mixture was concentrated to remove most THF and 0.1 M 
HCl solution (10 mL) was added. The white solid was filtered, washed with 0.1 M HCl 
and then water and dried under vacuum to give the product.   
 
Procedure for Cyclization  
The deprotected linear peptide (0.2 mmol, 1.0 equiv.) was dissolved in 
DMF/DCM (1:1 mixture) to give a 2 mM final concentration. HOAt (81.6 mg, 0.6 
mmol, 3.0 equiv.) and NMM (88 µL, 0.8 mmol, 4.0 equiv.) were added to the solution, 
followed by EDCHCl (114.6 mg, 0.6 mmol, 3.0 equiv.). The resulting mixture was 
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stirred at room temperature under N2 for 48 h and then concentrated in vacuum to give 
the crude mixture. The crude product was purified with flash chromatography (3 – 7 % 
MeOH in DCM) to give the pure product.   
 
Boc Approach to Products 1 
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Scheme S1. Boc approach to products 1 
 
General Procedures for Boc Approach in Solution 
Methyl anthranilate was coupled to the first Boc protected amino acid with 
“Coupling Method I”. The Boc protection group was deprotected with procedure 
described in “Boc Deprotection Procedure I” and the resulting material was coupled with 
the second Boc protected amino acid with “Coupling Method II”. The tripeptide 
intermediate was deprotected with “Boc Deprotection Procedure I” and coupled with the 
third Boc amino acid with “Coupling Method II” to give the protected tetrapeptide 
intermediate. The methyl ester of this intermediate was hydrolyzed with the procedure 
“Hydrolysis of Methyl Ester” and the N- terminus Boc group was removed with “Boc 
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cyclo-DAla-DAla-LPhe-Anth (DDL-1aaf), 44 %
cyclo-DGlu'-DAla-LPhe-Anth (DDL-1e'af), 35 % 
cyclo-LVal-LSer'-LTyr'-Anth  (LLL-1vs'y'), 45 %
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cyclo-LVal-LSer-LTyr-Anth (LLL-1vsy), 87 %
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Deprotection Procedure II”. The linear tetrapeptide was cyclized with “Procedure for 
Cyclization” to give the cyclic peptide product. If necessary, the cyclic peptide product 
was deprotected with “Bn Deprotection Procedure” or “tBu Deprotection Procedure” to 
give the final deprotected product. 
 
(3S,6S,9S)-3-Benzyl-6,9-dimethyl-3,4,6,7,9,10-hexahydro-1H-
benzo[k][1,4,7,10]tetraazacyclotridecine-2,5,8,11-tetraone (LLL-1aaf) 
 
White solid, 41 % over three steps; mp > 270 °C;  
1H-NMR (400 MHz, DMSO-d6) δ 9.67 (s, 1H), 8.84 (d, J = 7.0 Hz, 1H), 8.58 (d, J = 5.0 
Hz, 1H), 8.27 (d, J = 7.9 Hz, 1H), 7.57-7.40 (m, 2H), 7.34-7.11 (m, 7H), 4.42-4.33 (m, 
1H), 4.19-4.10 (m, 1H), 3.95-3.88 (m, 1H), 3.28-3.35 (m, 1H), 3.03 (dd, J = 13.9, 9.7 
Hz, 1H), 1.33 (d, J = 7.4 Hz, 3H), 1.09 (d, J = 6.8 Hz, 3H); 
13C-NMR (101 MHz, DMSO-d6) δ 172.7, 172.1, 169.8, 169.5, 139.2, 137.1, 131.4, 
129.7, 128.5, 127.5, 126.5, 125.6, 123.1, 121.0, 56.1, 53.6, 48.7, 34.4, 18.1, 16.1; 
HRMS (ESI+) m/z calcd for C22H24N4O4Na (M+Na)+ 431.1695; found 431.1679. 
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(3S,6R,9S)-3-Benzyl-6,9-dimethyl-3,4,6,7,9,10-hexahydro-1H-
benzo[k][1,4,7,10]tetraazacyclotridecine-2,5,8,11-tetraone (LDL-1aaf) 
 
White solid, 48 % over three steps; mp > 270 °C;  
1H-NMR (400 MHz, DMSO-d6) δ 9.45 (s, 1H), 8.96 (d, J = 7.2 Hz, 1H), 8.66 (d, J = 7.7 
Hz, 1H), 8.08 (d, J = 8.0 Hz, 1H), 7.93 (d, J = 8.8 Hz, 1H), 7.52-7.36 (m, 2H), 7.33-7.23 
(m, 4H), 7.23-7.08 (m, 2H), 4.59-4.32 (m, 2H), 4.23-4.15 (m, 1H), 3.16 (dd, J = 14.0, 5.1 
Hz, 1H), 2.91 (dd, J = 14.0, 9.5 Hz, 1H), 1.29 (d, J = 6.9 Hz, 3H), 1.06 (d, J = 6.8 Hz, 
3H); 
13C-NMR (101 MHz, DMSO-d6) δ 172.0, 171.5, 170.0, 169.0, 138.5, 135.7, 130.8, 
129.6, 128.5, 127.4, 127.3, 126.7, 123.8, 121.8, 55.9, 49.9, 48.4, 36.0, 17.0, 15.4; 
HRMS (ESI+) m/z calcd for C22H24N4O4Li (M+Li)+ 415.1958; found 415.1948. 
 
1H NMR 
NH
O N
H
Ph
O
HN
O
H
N
O
  259 
 
 
13C NMR 
 
 
DEPT135 
  260 
 
  
  261 
1H-1H COSY 
 
1H-13C HSQC 
  262 
 
 
NOESY 
  263 
 
  
  264 
 
(3S,6S,9R)-3-Benzyl-6,9-dimethyl-3,4,6,7,9,10-hexahydro-1H-
benzo[k][1,4,7,10]tetraazacyclotridecine-2,5,8,11-tetraone (DLL-1aaf) 
 
White solid, 55 % over three steps; mp > 270 °C;  
1H-NMR (400 MHz, DMSO-d6) δ 9.45 (s, 1H), 9.15 (d, J = 7.7 Hz, 1H), 8.48 (d, J = 7.9 
Hz, 1H), 8.16 (d, J = 8.1 Hz, 1H), 7.71 (d, J = 8.9 Hz, 1H), 7.51-7.36 (m, 2H), 7.33-7.11 
(m, 6H), 4.43-4.23 (m, 3H), 3.23 (dd, J = 13.7, 4.5 Hz, 1H), 2.98 (dd, J = 13.8, 10.2 Hz, 
1H), 1.26 (d, J = 6.9 Hz, 3H), 1.15 (d, J = 7.2 Hz, 3H); 
13C-NMR (101 MHz, DMSO-d6) δ 172.3, 171.0, 169.9, 168.9, 138.3, 135.8, 131.0, 
129.6, 128.6, 127.6, 127.3, 126.8, 123.8, 121.3, 56.1, 50.5, 49.4, 36.4, 17.5, 15.4; 
HRMS (ESI+) m/z calcd for C22H24N4O4Na (M+Na)+ 431.1695; found 431.1682. 
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(3S,6R,9R)-3-Benzyl-6,9-dimethyl-3,4,6,7,9,10-hexahydro-1H-
benzo[k][1,4,7,10]tetraazacyclotridecine-2,5,8,11-tetraone (DDL-1aaf) 
 
White solid, 44 % over three steps; mp > 270 °C;  
1H-NMR (400 MHz, DMSO-d6) δ 9.53 (s, 1H), 9.10 (d, J = 5.6 Hz, 1H), 8.45 (d, J = 5.2 
Hz, 1H), 8.28 (d, J = 8.1 Hz, 1H), 7.60-7.39 (m, 3H), 7.36-7.11 (m, 6H), 4.55-4.48 (m, 
1H), 4.26-4.19 (m, 1H), 4.05-3.99 (m, 1H), 3.04 (d, J = 7.4 Hz, 2H), 1.34 (d, J = 7.4 Hz, 
3H), 1.05 (d, J = 6.6 Hz, 3H); 
13C-NMR (101 MHz, DMSO-d6) δ 172.7, 172.5, 170.4, 169.5, 138.1, 136.4, 131.2, 
129.4, 128.7, 127.3, 126.9, 126.3, 123.4, 120.5, 58.6, 53.5, 47.9, 36.7, 17.4, 16.1; 
HRMS (ESI+) m/z calcd for C22H24N4O4Na (M+Na)+ 431.1695; found 431.1716. 
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tert-Butyl 3-((3S,6R,9R)-3-Benzyl-6-methyl-2,5,8,11-tetraoxo-2,3,4,5,6,7,8,9,10,11-
decahydro-1H-benzo[k][1,4,7,10]tetraazacyclotridecin-9-yl)propanoate (DDL-1e’af) 
 
 
 
White solid, 35 % over three steps; mp > 270 °C, color change observed at above 230 
°C;  
1H-NMR (400 MHz, DMSO-d6) δ 9.47 (s, 1H), 9.06 (d, J = 5.8 Hz, 1H), 8.44 (d, J = 5.6 
Hz, 1H), 8.27 (d, J = 8.1 Hz, 1H), 7.67 (d, J = 8.8 Hz, 1H), 7.53 (dd, J = 7.6, 1.2 Hz, 
1H), 7.47 (t, J = 7.8 Hz, 1H), 7.35-7.24 (m, 4H), 7.24-7.19 (m, 1H), 7.17 (t, J = 7.5 Hz, 
1H), 4.60-4.41 (m, 1H), 4.29-4.19 (m, 1H), 4.04-3.95 (m, 1H), 3.04 (d, J = 7.4 Hz, 2H), 
2.46-2.32 (m, 2H), 1.99-1.83 (m, 2H), 1.43 (s, 9H), 1.05 (d, J = 6.7 Hz, 3H); 
13C-NMR (101 MHz, DMSO-d6) δ 172.4, 172.0, 171.4, 170.4, 169.7, 138.1, 136.4, 
131.2, 129.4, 128.7, 127.5, 126.9, 126.4, 123.4, 120.5, 80.3, 58.5, 57.3, 47.9, 36.7, 31.9, 
28.2, 25.5, 17.4; 
HRMS (ESI-) m/z calcd for C28H33N4O6 (M-H)- 521.2400; found 521.2422. 
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3-((3S,6R,9R)-3-Benzyl-6-methyl-2,5,8,11-tetraoxo-2,3,4,5,6,7,8,9,10,11-decahydro-
1H-benzo[k][1,4,7,10]tetraazacyclotridecin-9-yl)propanoic acid (DDL-1eaf) 
 
White solid, 87 %; mp > 270 °C;  
1H-NMR (400 MHz, DMSO-d6) δ 9.48 (s, 1H), 9.07 (d, J = 5.7 Hz, 1H), 8.55 (d, J = 5.1 
Hz, 1H), 8.27 (d, J = 8.2 Hz, 1H), 7.69 (d, J = 8.8 Hz, 1H), 7.56-7.41 (m, 2H), 7.37-7.10 
(m, 7H), 4.58-4.48 (m, 1H), 4.29-4.22 (m, 1H), 4.05-3.96 (m, 1H), 3.04 (d, J = 7.4 Hz, 
2H), 2.46-2.38 (m, 2H), 2.03-1.78 (m, 2H), 1.05 (d, J = 6.6 Hz, 3H); 
13C-NMR (101 MHz, DMSO-d6) δ 174.5, 172.4, 171.5, 170.5, 169.7, 138.1, 136.4, 
131.2, 129.4, 128.7, 127.4, 126.9, 126.4, 123.4, 120.5, 58.5, 57.5, 47.9, 36.7, 31.1, 25.5, 
17.4; 
HRMS (ESI-) m/z calcd for C24H25N4O6 (M-H)- 465.1774; found 465.1786. 
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(3S,6S,9S)-3-(4-(Benzyloxy)benzyl)-6-((benzyloxy)methyl)-9-isopropyl-3,4,6,7,9,10-
hexahydro-1H-benzo[k][1,4,7,10]tetraazacyclotridecine-2,5,8,11-tetraone (LLL-1vs’y’) 
 
 
 
White solid, 45 % over three steps; mp > 270 °C;  
1H-NMR (400 MHz, DMSO-d6) δ 9.51 (s, 1H), 9.06 (d, J = 6.8 Hz, 1H), 8.36-8.28 (m, 
2H), 7.54-7.47 (m, 2H), 7.47-7.25 (m, 10H), 7.25-7.11 (m, 2H), 7.07 (d, J = 8.5 Hz, 2H), 
6.71 (d, J = 8.5 Hz, 2H), 4.98 (s, 2H), 4.69-4.60 (m, 1H), 4.57-4.46 (m, 2H), 4.03-3.88 
(m, 1H), 3.67-3.58 (m, 2H), 3.36 (dd, J = 9.2, 5.8 Hz, 1H), 3.24-3.15 (m, 1H), 2.98 (dd, J 
= 14.1, 10.1 Hz, 1H), 2.05-1.97 (m, 1H), 1.05 (d, J = 6.6 Hz, 3H), 0.92 (d, J = 6.7 Hz, 
3H); 
13C-NMR (101 MHz, DMSO-d6) δ 171.2, 170.5, 170.4, 169.4, 157.1, 138.5, 137.7, 
136.9, 131.4, 131.3, 130.9, 128.8, 128.6, 128.2, 128.0, 127.9, 127.8, 127.7, 126.0, 123.1, 
121.0, 114.8, 72.7, 69.6, 69.4, 64.4, 57.0, 52.3, 33.2, 28.6, 20.6, 19.4;  
HRMS (ESI-) m/z calcd for C38H39N4O6 (M-H)- 647.2870; found 647.2850. 
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 (3S,6S,9S)-3-(4-Hydroxybenzyl)-6-(hydroxymethyl)-9-isopropyl-3,4,6,7,9,10-
hexahydro-1H-benzo[k][1,4,7,10]tetraazacyclotridecine-2,5,8,11-tetraone (LLL-1vsy) 
 
White solid, 87 %; mp > 270 °C, color change observed at above 193 °C;  
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1H-NMR (400 MHz, DMSO-d6) δ 9.43 (s, 1H), 9.11 (s, 1H), 8.86 (d, J = 7.1 Hz, 1H), 
8.42 (d, J = 6.0 Hz, 1H), 8.25 (d, J = 8.4 Hz, 1H), 7.53-7.45 (m, 2H), 7.21-7.08 (m, 2H), 
7.02 (d, J = 8.4 Hz, 2H), 6.63 (d, J = 8.5 Hz, 2H), 4.96 (t, J = 5.3 Hz, 1H), 4.41-4.33 (m, 
1H), 3.98-3.91 (m, 1H), 3.65 (dd, J = 8.8, 6.3 Hz, 1H), 3.61-3.47 (m, 2H), 3.17 (dd, J = 
14.0, 4.4 Hz, 1H), 2.91 (dd, J = 14.0, 9.5 Hz, 1H), 2.05-1.92 (m, 1H), 1.04 (d, J = 6.6 Hz, 
3H), 0.93 (d, J = 6.7 Hz, 3H); 
13C-NMR (101 MHz, DMSO-d6) δ 171.2, 171.1, 170.2, 169.6, 156.0, 136.7, 131.2, 
130.9, 129.3, 127.7, 126.4, 123.2, 121.2, 115.3, 64.4, 61.2, 57.0, 55.2, 33.7, 28.6, 20.6, 
19.5; 
HRMS (ESI-) m/z calcd for C24H27N4O6 (M-H)- 467.1931; found 467.1919. 
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(3R,6R,9R)-6-((Benzyloxy)methyl)-9-(4-(tert-butoxy)benzyl)-3-isopropyl-3,4,6,7,9,10-
hexahydro-1H-benzo[k][1,4,7,10]tetraazacyclotridecine-2,5,8,11-tetraone (DDD-1y’s’v) 
 
 
 
White solid, 31 % over three steps; mp > 270 °C;  
1H-NMR (400 MHz, DMSO-d6) δ 9.40 (s, 1H), 8.83 (d, J = 7.3 Hz, 1H), 8.59 (d, J = 5.4 
Hz, 1H), 8.17 (d, J = 8.1 Hz, 1H), 7.54 (d, J = 9.5 Hz, 1H), 7.50-7.44 (m, 1H), 7.36-7.26 
(m, 6H), 7.21-7.11 (m, 3H), 6.89 (d, J = 8.4 Hz, 2H), 4.67 (td, J = 9.2, 6.0 Hz, 1H), 4.54 
(d, J = 12.0 Hz, 1H), 4.48 (d, J = 12.0 Hz, 1H), 4.18-4.09 (m, 1H), 3.69 (t, J = 7.2 Hz, 
1H), 3.63 (t, J = 9.3 Hz, 1H), 3.43 (dd, J = 9.4, 6.0 Hz, 1H), 3.06-2.93 (m, 2H), 2.68-2.59 
(m, 1H), 1.29 (s, 9H), 0.98 (d, J = 6.7 Hz, 3H), 0.79 (d, J = 6.8 Hz, 3H); 
13C-NMR (101 MHz, DMSO-d6) δ 171.3, 170.1, 170.0, 169.2, 154.1, 138.3, 136.8, 
132.1, 131.3, 129.9, 128.6, 128.0, 127.9, 127.2, 126.1, 123.9, 123.2, 121.6, 78.1, 72.6, 
69.2, 59.7, 59.4, 53.1, 35.3, 29.0, 27.9, 21.3, 19.0; 
HRMS (ESI+) m/z calcd for C35H42N4O6Na (M+Na)+ 637.3002; found 637.2988. 
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Scheme S2. Cbz approach to products 1 
 
General Procedures For Cbz Approach in Solution 
Methyl anthranilate was coupled to the first Cbz protected amino acid with 
“Coupling Method I”. The Cbz protection group was deprotected with “Cbz 
Deprotection Procedure” and the resulting material was coupled with the second Cbz 
protected amino acid with “Coupling Method II”. The tripeptide intermediate was 
deprotected with “Cbz Deprotection Procedure” and coupled with the third Cbz amino 
acid with “Coupling Method II” to give the protected tetrapeptide intermediate. The 
methyl ester of this intermediate was hydrolyzed with the procedure “Hydrolysis of 
Methyl Ester” and the N- terminus Cbz group was removed with “Cbz Deprotection 
Procedure”. The linear tetrapeptide was cyclized with “Procedure for Cyclization” to 
give the cyclic peptide product. If necessary, the cyclic peptide product was deprotected 
with “tBu Deprotection Procedure” to give the final deprotected product. 
 
cyclo-LPhe-DAla-LPhe-Anth (LDL-1faf), 45 %
cyclo-DPhe-LAla-LGlu'-Anth (DLL-1fae'), 42 %
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Methyl (R)-2-(2-(((benzyloxy)carbonyl)amino)-5-(tert-butoxy)-5-
oxopentanamido)benzoate (D-3g’) 
 
White solid, 82 %; mp = 78.8-79.8 °C;  
1H-NMR (400 MHz, CDCl3) δ 11.58 (s, 1H), 8.71 (d, J = 8.4 Hz, 1H), 8.05 (dd, J = 8.0, 
1.5 Hz, 1H), 7.64-7.47 (m, 1H), 7.43-7.30 (m, 5H), 7.20-7.03 (m, 1H), 5.80 (d, J = 6.2 
Hz, 1H), 5.28-5.10 (m, 2H), 4.49-4.38 (m, 1H), 3.91 (s, 3H), 2.50-2.19 (m, 3H), 2.19-
1.99 (m, 1H), 1.45 (s, 9H); 
13C-NMR (101 MHz, CDCl3) δ 172.3, 170.2, 168.4, 156.1, 140.8, 136.3, 134.5, 130.8, 
128.4, 128.0, 128.0, 122.9, 120.4, 115.5, 80.9, 67.1, 56.2, 52.3, 31.7, 28.0, 27.6; 
HRMS (ESI+) m/z calcd for C25H31N2O7 (M+H)+ 471.2131; found 471.2145. 
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(3S,6R,9S)-3,9-Dibenzyl-6-methyl-3,4,6,7,9,10-hexahydro-1H-
benzo[k][1,4,7,10]tetraazacyclotridecine-2,5,8,11-tetraone (LDL-1faf) 
  301 
 
White solid, 45 % over four steps, starting from Boc-deprotected L-2f; mp > 270 °C;  
1H-NMR (400 MHz, DMSO-d6) δ 9.39 (s, 1H), 9.02 (d, J = 7.5 Hz, 1H), 8.69 (d, J = 7.1 
Hz, 1H), 8.06 (d, J = 8.2 Hz, 1H), 7.90 (d, J = 8.8 Hz, 1H), 7.49-7.37 (m, 1H), 7.37-7.17 
(m, 10H), 7.17-7.06 (m, 2H), 4.53-4.48 (m, 2H), 4.29-4.25 (m, 1H), 3.19-3.12 (m, 2H), 
3.08-2.90 (m, 2H), 1.06 (d, J = 6.8 Hz, 3H); 
13C-NMR (101 MHz, DMSO-d6) δ 172.0, 170.8, 170.0, 169.2, 139.0, 138.5, 135.7, 
130.9, 129.7, 129.6, 128.6, 128.5, 127.5, 127.1, 126.7, 126.7, 123.8, 121.9, 56.1, 56.0, 
48.4, 36.0, 34.9, 17.0; 
HRMS (ESI+) m/z calcd for C28H28N4O4Na (M+Na)+ 507.2008; found 507.2027. 
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1H-1H COSY 
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tert-Butyl 3-((3S,6S,9R)-9-benzyl-6-methyl-2,5,8,11-tetraoxo-2,3,4,5,6,7,8,9,10,11-
decahydro-1H-benzo[k][1,4,7,10]tetraazacyclotridecin-3-yl)propanoate (DLL-fae’) 
 
White solid, 42 % over three steps; mp > 270 °C, color change observed at above 215 
°C;  
1H-NMR (400 MHz, DMSO-d6) δ 9.39 (s, 1H), 9.26 (d, J = 7.9 Hz, 1H), 8.58 (d, J = 7.4 
Hz, 1H), 8.12 (d, J = 8.2 Hz, 1H), 7.69 (d, J = 9.2 Hz, 1H), 7.49-7.40 (m, 1H), 7.37-7.18 
(m, 5H), 7.18-7.08 (m, 2H), 4.52-4.42 (m, 1H), 4.41-4.32 (m, 1H), 4.16-4.08 (m, 1H), 
3.15 (dd, J = 13.8, 5.4 Hz, 1H), 3.00 (dd, J = 13.8, 9.7 Hz, 1H), 2.29 (t, J = 7.5 Hz, 2H), 
2.15-2.05 (m, 1H), 1.91-1.77 (m, 1H), 1.41 (s, 9H), 1.29 (d, J = 7.2 Hz, 3H); 
13C-NMR (101 MHz, DMSO-d6) δ 172.4, 172.0, 170.1, 170.1, 169.3, 138.9, 135.8, 
131.1, 129.7, 128.7, 127.1, 127.0, 126.7, 123.7, 121.3, 80.2, 55.6, 54.1, 50.5, 34.8, 31.7, 
28.2, 26.2, 17.6; 
HRMS (ESI-) m/z calcd for C28H33N4O6 (M-H)- 521.2400; found 521.2411. 
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3-((3S,6S,9R)-9-Benzyl-6-methyl-2,5,8,11-tetraoxo-2,3,4,5,6,7,8,9,10,11-decahydro-
1H-benzo[k][1,4,7,10]tetraazacyclotridecin-3-yl)propanoic acid (DLL-fae) 
 
White solid, 81 %; mp > 270 °C;  
NH
O N
H
O
HN
O
H
N
O
COOH
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1H-NMR (400 MHz, DMSO-d6) δ 9.37 (s, 1H), 9.26 (d, J = 8.0 Hz, 1H), 8.59 (d, J = 7.3 
Hz, 1H), 8.11 (d, J = 8.1 Hz, 1H), 7.71 (d, J = 9.1 Hz, 1H), 7.50-7.39 (m, 1H), 7.37-7.05 
(m, 7H), 4.54-4.32 (m, 2H), 4.19-4.06 (m, 1H), 3.14 (dd, J = 13.8, 5.4 Hz, 1H), 2.99 (dd, 
J = 13.8, 9.6 Hz, 1H), 2.30 (t, J = 7.6 Hz, 2H), 2.15-2.08 (m, 1H), 1.90-1.79 (m, 1H), 
1.29 (d, J = 7.3 Hz, 3H); 
13C-NMR (101 MHz, DMSO-d6) δ 174.3, 172.4, 170.2, 170.1, 169.2, 138.9, 135.8, 
131.1, 129.7, 128.7, 127.1, 127.0, 126.7, 123.8, 121.3, 55.6, 54.2, 50.6, 34.8, 30.8, 26.2, 
17.5; 
HRMS (ESI-) m/z calcd for C24H25N4O6 (M-H)- 465.1774; found 465.1781. 
 
1H NMR 
 
 
13C NMR 
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Fmoc solid phase approach to products 1 
 
 
 
 
 
 
 
COOMe
NH2
(ii) NaI/EtOAc
(i) Fmoc-AA-OH
EDC, HOAt, NMM, CH2Cl2
COOH
NH
O
R3
NHFmoc
L-4f
71 %
2-chlorotrityl resin
DIPEA, DCM
NH
O NHFmoc
O
O
Ph
Fmoc SPPS
0.7 meq/g
NH
O N
H
O
O
O H
N
O
NH2
20 % HFIP in DCM
HFIP = hexafluoro-2-propanol
Ph
NH
O N
H
O
OH
O H
N
O
NH2
Ph
89 % yield
 > 90 % pure by 1H NMR
  315 
 
Scheme S3. Fmoc solid phase approach to products 1. 
 
General Procedures for Fmoc Approach on Solid Phase 
Synthesis Of Dipeptide Intermediate 
Fmoc-Phe-OH (775 mg, 2.0 mmol, 1.0 equiv.) was added to a solution of HOAt 
(408 mg, 3.0 mmol, 1.5 equiv.) and NMM (220 µL, 2.0 mmol, 1.0 equiv.) in DCM (3.0 
mL) at 0 oC under N2. The resulting mixture was stirred at 0 oC for 10 min and then 
methyl anthranilate (906 mg, 6.0 mmol, 3.0 equiv.) was added, followed by the addition 
of EDCHCl (575 mg, 3.0 mmol, 1.5 equiv.) in one portion. The reaction mixture was 
allowed to warm to room temperature over 1 h and was stirred at room temperature for 2 
h. 30 mL DCM was added to dilute the solution and the organic phase was washed with 
0.2 M HCl aqueous solution (30 mL × 5). The organic phase was further washed with 
brine (10 mL), saturated NaHCO3 solution (20 mL × 2) and brine (10 mL), dried over 
MgSO4 and filtered. The solvent was removed under vacuum to give the crude material. 
The crude material was dissolved in EtOAc (10 mL) and LiI (1.07 g, 8.0 mmol, 4.0 
equiv.) was added. The mixture was stirred at 80 oC for 18 h and then it was cooled 
down to room temperature. 0.2 M HCl (20 mL) was added and the mixture was extracted 
with EtOAc (30 mL × 3). The organic phase was washed with brine (10 mL), dried over 
MgSO4, filtered and the solvent was removed under vacuum to give the crude product. 
The crude product was purified by flash chromatography (30% EtOAc in DCM to 100 % 
EtOAc) to give the desired product L-4f as a white solid.  
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(S)-2-(2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-phenylpropanamido)benzoic 
acid (L-4f) 
 
White solid, 71 %; mp = 175.5-176.4 °C;  
1H-NMR (400 MHz, DMSO-d6) δ 11.71 (s, 1H), 8.62 (d, J = 8.4 Hz, 1H), 8.11 (d, J = 
8.0 Hz, 1H), 8.02 (dd, J = 7.9, 1.4 Hz, 1H), 7.88-7.83 (m, 2H), 7.68-7.57 (m, 3H), 7.42-
7.11 (m, 10H), 4.43-4.08 (m, 4H), 3.30 (dd, J = 13.8, 4.2 Hz, 1H), 2.96 (dd, J = 13.6 Hz, 
10.7 Hz, 1H); 
13C-NMR (101 MHz, DMSO-d6) δ 171.0, 169.8, 156.6, 144.2, 141.1, 140.9, 138.6, 
134.6, 131.6, 129.6, 128.7, 128.1, 127.5, 126.8, 125.8, 123.4, 120.5, 120.2, 117.1, 66.5, 
58.6, 47.1, 37.1; 
HRMS (ESI-) m/z calcd for C31H25N2O5 (M-H)- 505.1763; found 505.1781. 
 
1H NMR 
 
COOH
NH
O NHFmoc
Ph
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13C NMR 
 
 
Loading of Dipeptide onto 2-Cl-Trityl Resin 
Cl-Trt resin (200 mg, 1.4 meq/g) was shaken with anhydrous DCM (4 mL) in a 
fritted syringe for 30 min. Then the DCM was removed and a mixture of L-4f (71 mg, 
0.14 mmol) and DIPEA (98 µL, 0.56 mmol) in DCM (2 mL) was added into the syringe 
and the mixture was shaken at room temperature for 2h. The remaining reactive site was 
blocked with MeOH/DIPEA (9:1 v/v) for 30 min and the beads were washed with DCM 
3 times, MeOH and then DMF 3 times.  
 
Coupling With Amino Acids And Fmoc Deprotection 
Fmoc protection groups were deprotected by treating the bead with 20 % 
piperidine in DMF for 1 min, followed by the second treatment with 20 % piperidine in 
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DMF for 15 minutes. The beads were washed with DMF 6 times after the second 
treatment.  
Coupling reactions with amino acids were carried out with 3 equiv. of Fmoc 
amino acid, 3 equiv. of HBTU, 3 equiv. of HOBt, 6 equiv. of DIPEA in DMF for 1 h at 
room temperature. The beads were washed with DMF 6 times after the coupling reaction 
and a few beads were subjected to Kaiser test to confirm the completion of the coupling 
reaction.  
 
Cleavage From Solid Support 
After the last Fmoc deprotection step, the resin was washed with DMF 6 times, 
MeOH 3 times and DCM 3 times. The linear peptide was cleaved off the bead by 
treating the beads with HFIP/DCM (1:4 v/v) for 30 min at room temperature. After 
filteration, the solvents were removed under vacuum and the crude material was dried 
under high vacuum to give the linear peptide. The crude material was analyzed by HPLC 
and 1H NMR for its purity.  
 
2-((S)-2-((S)-2-((S)-2-Aminopropanamido)propanamido)-3-phenylpropanamido)benzoic 
acid (LLL-aaf linear peptide, crude material) 
 
White solid, 89 %;  
NH
COOH
O N
H
O H
N
O
NH2
Ph
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1H-NMR (400 MHz, MeOH-d4) δ 8.50 (dd, J = 8.3, 0.9 Hz, 1H), 8.05 (dd, J = 7.8, 1.6 
Hz, 1H), 7.43-7.35 (m, 1H), 7.32-7.23 (m, 4H), 7.23-7.17 (m, 1H), 7.08 (td, J = 7.8, 1.1 
Hz, 1H), 4.72-4.65 (m, 1H), 4.42 (q, J = 7.1 Hz, 1H), 3.95 (q, J = 7.0 Hz, 1H), 3.41-3.34 
(m, 1H), 3.16-3.08 (m, 1H), 1.46 (d, J = 7.0 Hz, 3H), 1.33 (d, J = 7.1 Hz, 3H). 
13C-NMR (101 MHz, DMSO-d6) δ 172.0, 170.6, 170.0, 169.8, 140.5, 138.6, 131.5, 
130.8, 129.5, 128.5, 126.7, 124.7, 122.2, 118.8, 56.5, 50.4, 49.3, 37.4, 18.0, 17.1; 
HRMS (ESI+) m/z calcd for C22H27N4O5 (M+H)+ 427.1981; found 427.1999. 
1H NMR 
 
 
13C NMR 
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B. NMR Structure Determination and Analysis 
NMR measurements for cyclic peptides 1 were carried out in DMSO-d6 with a 
sample concentration of ~20 mM. NOESY spectra were taken using a mixing time of 
400 ms for compounds LLL-1aaf, LDL-1aaf, DLL-1aaf, DDL-1aaf, DDL-1e’af, DDL-
1eaf, LLL-1vsy, DLL-1fae’, DLL-1fae, LDL-1faf. ROESY spectra were taken using a 
mixture time of 200 ms for compounds LLL-1vs’y’ and DDD-1y’s’v. There was no 
evidence of cis-amide bonds due to the absence of Cα-Cα or Cα-Cβ couplings across 
residues.  
The observed NOE measurements were summarized in the following tables for 
1aaf. s: strong, 1.8 Å ≤ H-H distance ≤ 2.7 Å; m: medium, 1.8 Å ≤ H-H distance ≤ 3.5 Å; 
w: weak, 1.8 Å ≤ H-H distance ≤ 5.0 Å.20,21 
  
  321 
 
Table S1. Observed NOE measurements. 
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DLL-1aaf 
 
 
DDL-1aaf 
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NMR structure calculation in DMSO was carried out using the Conformational 
Searches in MacroModel with distance checks (MacroModel, version 10.0, Schrödinger, 
LLC, New York, NY). Monte Carlo Multiple Minimum method were used to sample the 
cyclic peptide conformations. 10000 structures were sampled and minimized with 
OPLS_2005 force field in dielectric constant 46.7 with a convergence criteria 0.05 
kJ/mol over 2000 iterations. Distance constraints from the previous tables were applied 
during the conformational sampling to eliminate the conformations with distance 
violations. Duplicate structures base on heavy-atom superposition (RMSD < 0.02 Å) 
were discarded. The unique conformations within 5 kJ/mol of the global minimum were 
collected and clustered based on heavy atoms of the macrocyclic scaffold without the 
Phe side-chain. The clustered conformations were shown in Figure S4. 
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Figure S4. Conformational clusters of 1aaf with NMR constraints. 
  
LLL DLL
LDL DDL
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C. H/D Exchange of the Amide NH 
H/D exchange experiments were explored in CDCl3/CD3OD. A sample of cyclic 
peptide 1 was prepared in 450 µL CDCl3 and 50 µL of CD3OD was added (4 mM final 
cyclic peptide concentration). The mixture was mixed for 1 min and 1H NMR of the 
sample was recorded 3, 5, 7, 10, 15, 20, 25, 30 min after the addition of CD3OD. The 
fact that all the amide protons showed significant reduction (> 75 %) in their intensity 30 
min after CD3OD addition indicated that there was no strong intramolecular hydrogen-
bond interaction within any diastereomer of the cyclic peptide under the conditions 
tested.22,23 The half-lifes of the H/D exchange reactions were summarized in Table S2. 
 
Table S2. H/D exchange half-life t1/2 (min). 
 
 
NH1 NH2 NH3 NH4 
LLL-1aaf < 5  15  < 5  < 5  
DLL-1aaf < 5 12  < 5 < 5 
LDL-1aaf < 5  two peaks overlapped* < 5 
DDL-1aaf < 5 < 5 < 5 < 5 
 
* For the overlapped peak, the peak intensity decreased to 19 % of the original intensity 
after 30 min. 
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D. Temperature Dependence of the Amide NH Chemical Shifts 
A ~10 mM solution of 1 in DMSO-d6 was prepared. 1H NMR measurements 
were made in the range 303 – 353 K. The first measurement was made at 303 K and the 
rest of 1H NMRs were acquired at 10 K intervals. All the spectra obtained were 
referenced to the solvent peak and the ppm change of the amide NH peaks was 
monitored. The change in chemical shift was plotted versus the change in temperature 
and the data was fitted to a linear equation to give the temperature-dependent coefficient 
(Δδ/ΔΚ) of the NH proton of interest. The temperature coefficient data in Table S3 
indicated that most of the amide protons were shielded from the solvent in the cyclic 
peptide system.24,25  
 
Table S3. Temperature coefficient data of amide NHs. 
 
 
NH1 NH2 NH3 NH4 
LLL-1aaf -1.7 - -4.5 -2.7 
DLL-1aaf -4.2 -1.6 -4.9 -2.7 
LDL-1aaf -3.7 -3.8 -6.2 -3.7 
DDL-1aaf -2.3 - -6.8 -3.4 
 
 
E. QikProp Calculation 
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QikProp 3.5 from Schrödinger (2012)26 was used to evaluate pharmaceutically 
relevant properties for compounds listed below. 
 
 
 
F. Stability Analysis of Cyclic Peptide 
 
General Procedure for the pH Stability Assay 
A stock solution of cyclic peptide LLL-1aaf (66 mM) and triphenylphosphine 
oxide (TPPO, internal standard, 100 mM) in DMSO was prepared and stored at 25 °C. 9 
µL of the DMSO stock solution was dissolved in aqueous solutions with different pH 
(pH 7.4, PBS buffer; pH 12, 10 mM NaOH; pH 2, 10 mM HCl; all solutions contain 20 
% MeOH) to give a 400 µM working solution. The solution was filtered through a 0.2 
µm membrane filter and analyzed by reversed phase HPLC (see general methods) at 
intervals (retention time t LLL-1aaf  = 15.1 min, tTPPO = 17.9 min). The peak areas of LLL-
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1aaf from rp-HPLC were measured and normalized against peak areas of TPPO and 
plotted against incubation time. The data points were fitted to first order kinetics to give 
the rate constant and half-life t1/2 of the decomposition reaction.  
 
General Procedure for the Protease Stability Assay 
A stock solution of cyclic peptide LLL-1aaf (66 mM) and TPPO (100 mM) in 
DMSO was prepared and stored at 25 °C. A similar stock solution containing 66 mM 
linear LLL-aaf peptide and 100 mM TPPO was prepared in DMSO as a control. A 0.2 
unit / µL stock solution of pronase from Streptomyces griseus was prepared in PBS 
buffer and further diluted to 0.4 unit / mL with PBS buffer containing 20 % MeOH. 4.5 
µL of cyclic peptide or linear peptide stock solution was added to 1.5 mL pronase 
solution and then filtered through a 0.2 µm membrane filter and the resulting solution 
was analyzed by rp-HPLC (see general methods) at intervals. The peak areas of LLL-
1aaf or LLL-aaf from rp-HPLC were measured and normalized against peak areas of 
TPPO and plotted against incubation time. Under the experimental condition, no 
decomposition of LLL-1aaf was observed even after 12 h, while for the control linear 
peptide LLL-aaf the half-life of decomposition was about 1.5 h.   
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